Nuffield
Health
Annual Report and Financial Statements 2024
Nuffield Health Annual Report 2024
Contents
**1**
- Building a healthier nation is at the heart of everything we do.
Contents
**Strategic report**
Charity profile
Chair’s statement Chief Executive Officer’s statement Chief Finance Officer’s statement Strategy at a glance
Strategy in action
Strategic ambition 1: provide the best care and support you can get, anywhere Strategic ambition 2: deliver the best possible customer and patient experience Strategic ambition 3: be the best place to work in health and wellbeing in the UK Strategic ambition 4: be at least as efficient and productive as our competitors Strategic ambition 5: multiply our social impact and sustainability
|**2**
2
4
5
8
11
14
16
17
18
19|Streamlined Energy and Carbon Reporting
23
Climate-related Financial Disclosures
25
Risk management
31
Stakeholder engagement
35
Section 172 statement
37
**Trustees’ report**
**39**
Chair’s Trustees’ statement
40
Our Board of Trustees
41
Our Executive Committee
42
Structure, governance and management
43
Committee reports
Board Quality and Safety Committee
45
Finance and Investment Committee
45
Board Audit and Risk Committee
45
Trustees’ Nominations Committee
45|Executive Remuneration and Succession
46
Committee
Trustees’ Remuneration Committee
46
Trustees’ review of our objectives
47
Trustees’ responsibilities for the financial
47
statements
**Independent auditor’s report**
**48**
Independent auditor’s report to the Charity
49
Members and Trustees of Nuffield Health
**Financial statements**
**51**
Financial statements
52|
|---|---|---|
With Clinical Governance Leads at every hospital, data-led decisions are driving quality improvements. **Read more p14**
Our social impact programmes are reaching more people than ever in local communities. **Read more p19**
By getting the basics right, we’re driving energy efficiencies across our estate. **Read more p21**
Nuffield Health Annual Report 2024
Charity profile
**2**
We are the UK’s largest healthcare charity and our purpose is to build a healthier nation.
Who we are
We deliver outstanding clinical and wellbeing services and free rehabilitation programmes that address unmet health needs and reach those living on lower resources or in underserved communities, and collaborate on research to improve health outcomes.
*Social Value is the £ value of the wider impact on society that is generated through an activity. This can be through Programmes For All or as an ‘over and above’ component of a trading service. Read our Social Impact report for more detail. ** Excludes Nuffield Health at St Bartholomew’s Hospital, which is yet to undergo Care Quality Commission assessment.
Hospitals
Diagnostics
Physiotherapy
GP services
Pathology
Hospitals Sterile Services Units (HSSU)
the services **+** we offer
Fitness and wellbeing Personal training
Social impact programmes
Workplace wellbeing Health assessments Wellbeing clinics
240 UK sites
where & how **= +** we offer them
36 110 86
Hospitals Fitness and wellbeing centres Corporate fitness and wellbeing sites HSSU sites Research and development facility
7 1
£126m
social value*
99,707
beneficiaries reached through our free social impact programmes
41,219
people who benefited from our social impact programmes are living with lower resources
the value we create
386,000
fitness and wellbeing members
297,000 hospital episodes 100%
of our hospitals rated Good or Outstanding by national regulators**
Nuffield Health Annual Report 2024
Charity profile
**3**
## Our services
## H E A LT H
## Hospitals
Consultant-led treatment, delivering the highest standards of care to patients referred from the NHS, private medical insurers, and self-pay
## Diagnostics
Wide range of scans and imaging, giving immediate insight into a person’s health, and assisting in early diagnosis of disease
## Physiotherapy
Treatments to heal and prevent injuries. We combine physiotherapy with fitness and mental health, for long-term benefits
## GP services
Access to private GP services, offering people flexibility to fit appointments around busy schedules, including during the evening
## Pathology
Laboratory blood science, blood transfusion and microbiology services, tailored to requirements, to aid diagnosis
## Hospitals Sterile Services Units
Seven purpose-built sites, delivering decontamination and sterilisation services for reusable medical equipment
## W E L L B E I N G
Fitness and wellbeing Industry-leading personal trainers (PT) and gyms equipped with the latest technology, fitness classes and swimming pools
## Personal training
CIMSPA-accredited personal trainers deliver tailored fitness plans and specialise in rehabilitating long-term health conditions
## Social impact programmes
Unique, free community programmes, addressing unmet health needs, delivered by our expert PTs and Rehabilitation Specialists
## Workplace wellbeing
A range of connected services to meet employee health and wellbeing needs, delivered through onsite clinics and gyms
## Health assessments
In-person and online comprehensive health checks, covering concerns such as diabetes, heart health, cancer risk and emotional wellbeing
## Wellbeing clinics
Situated within our fitness and wellbeing centres, offering a range of clinical experts from physiotherapists to physiologists
**----- Start of picture text -----**
Strategic report
**----- End of picture text -----**
**----- Start of picture text -----**
Financial statements
**----- End of picture text -----**
Chair’s statement
**4**
**----- Start of picture text -----**
Nuffield Health Annual Report 2024
**----- End of picture text -----**
## A message from our Chair
Dr Natalie-Jane Macdonald MBE Chair
## **“ Throughout the year, we’ve continued to deliver outstanding services and outcomes for all those we served.”**
2024 will go down as a year of transition as we said goodbye to Steve Gray, and welcomed Alex Perry to the role of Chief Executive Officer (CEO). Steve led Nuffield Health through an eventful period in the history of not only our charity but also the healthcare industry – and the country as a whole – and for this we’re indebted to him.
Alex has extensive leadership experience, having worked in executive roles across Bupa, the UK’s largest healthcare insurer, for the last 16 years. He brings a new perspective to the role of CEO, and is well positioned to capitalise on the achievements of the past, while improving performance to deliver on our purpose even more.
The year marked a change in the political landscape with the formation of a new Government, which saw a shift in national priorities. The independent investigation into the NHS in England, led by Lord Darzi, assessed patient access, quality of care, and overall performance, signalling a new era of transparency around the pressures facing our public services.
The Independent Healthcare Providers Network (IHPN) has done a great job in enabling independent healthcare providers to work collaboratively in supporting the NHS, and I think this will have a positive impact on patients and waiting lists in the months and years to come.
As a non-fundraising charity with considerable capital costs, it’s critical that we achieve a surplus through our paid-for services, which can then be reinvested into our people, our services, our social impact activity, and the environments in which we operate. Therefore, financial sustainability has been our key priority throughout the year and enabled us to invest in strategic partnerships with ICON radiation-therapy services and GE HealthCare diagnostic imaging, both great examples of the organisation looking forward and taking important steps to improve our patient services.
A sharp emphasis on productivity and scalability has been maintained in everything we do. Going forward, we need to continue the focus on being efficient and profitable, in order to increase our ability to invest in our free services, such as our acclaimed Joint Pain Programme, and delivering vital support to people living with unmet health needs.
Over the last seven years, Nuffield Health has led the way in measuring the benefits we bring to communities, using our Social Return on Investment framework, and we can be proud of the remarkable social value we have delivered. However, there’s no doubt that the national need for greater access to health and wellbeing services will continue to grow, as will the imperative to address health inequalities.
Reflecting on 2024, it’s certainly been a year of change for all of us, in different ways. I took on the temporary role of Executive Chair during the transitional period, as we awaited the arrival of our new CEO. It gave me a valuable opportunity to look at things from a different perspective.
As always, I’ve enjoyed spending time with our people, who are the beating heart of Nuffield Health. I’m always impressed by their tenacity, enthusiasm and willingness to adapt. I know Alex’s fresh approach is already resonating as he travels around the organisation and gets to know the teams that make Nuffield Health the special place that it is.
Throughout the year, we’ve continued to deliver
outstanding services and outcomes. We’ve seen increased stakeholder engagement, and formed strong partnerships, working closely with like-minded organisations on major healthcare needs. My thanks go to everyone, at every level of the Charity, for their hard work during 2024.
Our Board of Trustees approved this Annual Report and Financial Statements, including the Strategic Report on 26 June 2025, and I commend it to our members.
Dr Natalie-Jane Macdonald MBE
Chair
**----- Start of picture text -----**
Strategic report
**----- End of picture text -----**
Nuffield Health Annual Report 2024
Chief Executive Officer’s statement
**5**
- A message from our Chief Executive Officer
I was delighted to be appointed CEO of Nuffield Health in September last year. This is an organisation I’ve long admired, because of its purpose to build a healthier nation, and its history of providing great care and support to its customers. Nuffield Health has been improving the lives of people across the UK for more than 65 years, and I’m excited to be given this opportunity to build on this heritage. I strongly believe we can take Nuffield Health to new heights in the coming years.
Successful organisations are dependent on the engagement and skill of their people. So, one of the first things on my agenda when I joined Nuffield Health was to get out and meet people from every corner of the organisation, to find out their views on how we can realise our full potential.
My first impression is that our people at all levels are passionate about what they do and dedicated to the organisation and what we stand for. Throughout my visits, I’ve been met with smiles, kindness and, above all, a genuine sense of pride as people have updated me on their commitment to caring for our patients, members, and beneficiaries.
**“ We’ve adopted five bold new ambitions for Nuffield Health to help set new horizons for us and guide the contributions of our people across the organisation.”**
2024 saw some big steps forward in our social impact delivery. Our dedicated programmes delivered £126 million in social value, a big increase on the prior year (2023 – £100 million). Designed to support those living with lower resources, our programmes tackle unmet healthcare needs by using movement as a fundamental part of preventing, treating, and managing long-term conditions.
Nearly 100,000 individuals benefited from our free programmes during the year, including 12,318 on our flagship Joint Pain Programme alone. The direct support given to people is making a difference to their lives and, in many instances, is life-changing. As we look forward our aim is to multiply our social impact, and we are developing plans to do this over the next five years.
In March 2025, Wes Streeting, Secretary of State for Health and Social Care, announced the Government’s partnership with Nuffield Health to enable more than 4,000 NHS workers to access our free Joint Pain Programme. The announcement came as over 198,000 working days were missed by NHS staff in 2023 due to arthritis and painful joints, and waiting lists continued to rise. We are pleased to be able to offer support to the NHS in getting people back to work, so they in turn can support the health of the nation.
There was an improved financial performance in 2024 (see Chief Finance Officer’s statement on page 8). Demand for our hospital services continued to grow, with a notable rise in NHS work, and our fitness and wellbeing membership rose to 386,000, with the public continuing to prioritise their health. Productivity and efficiency need to improve to enable us to invest more in our services and sites, and this has been a major focus for me since joining.
**Our five ambitions**
**for Nuffield Health**
1
**Provide the best care and support you can get, anywhere**
2
**Deliver the best possible customer and patient experience**
3
**Be the best place to work in health and wellbeing in the UK**
**Be at least as efficient and productive as our competitors**
4
5
**Multiply our social impact and sustainability**
Nuffield Health Annual Report 2024
Chief Executive Officer’s statement
**6**
Signa Voyager MRI system from GE HealthCare installed at Brentwood Hospital, delivering superior image quality to support faster diagnostics and treatment for patients
Our successful free Joint Pain Programme is delivered in all of our fitness and wellbeing centres across the UK, helping over 12,700 people in 2024
## **“ I strongly believe we can take Nuffield Health to new heights in the coming years.”**
At the end of the year, we agreed a major 20-year, estimated £200-million partnership with GE HealthCare, a market leader in diagnostic imaging that embeds sustainable principles into its design processes. Our partnership will see over 770 new pieces of equipment delivered to all our hospitals and will mean that we will have the latest AI-enabled technology to help diagnose our patients. We have also agreed in principle a partnership with ICON Group to jointly develop some new cancer treatment centres in some of our major hospital sites. This will enable us to deliver a much-enhanced service to our cancer patients.
## Healthcare has a significant impact on the
environment, contributing to greenhouse gas emissions and resource depletion, and we recognise the importance of acting now to protect our future. Over the year, we made meaningful strides in our sustainability agenda, maintaining a 41.8% reduction in carbon emissions, against our 2022 carbon baseline.
We continued to undertake research projects to discover new opportunities, share best practice with the sector and drive behaviour change among our people. Initiatives such as reusable medical equipment and evolving our patient dining experience further embed sustainability into our operations (see page 22 for more on our projects).
Since I’ve joined, we’ve adopted five bold new ambitions for Nuffield Health to help set new horizons for us and guide the contributions of our people across the
organisation. We will build on our reputation for delivering high quality health and wellbeing services; deliver the best customer experience; focus on productivity and efficiency; multiply our social impact and sustainability; and build a workplace where everyone can truly thrive.
To help us drive forward our ambitions, we’ve
strengthened our leadership team and I’ve welcomed a number of talented people to the Executive Committee, with a range of experience and complementary skills (see page 42). I’m confident they will help us deliver our plans and ensure that Nuffield Health has an even bigger impact on the future health and wellbeing of the nation.
Winner of Most Effective Contribution to Integrated Health and Care for the Greater Manchester Major Trauma Enhanced Rehabilitation Service, delivered by Nuffield Health in partnership with Manchester University FT, the Northern Care Alliance, the University of Manchester and the University of Salford
The support of our people will be critical to achieving
our ambitions, and I’m committed to maintaining a fair and equitable workplace. The Executive Committee will continue to champion a culture of openness, where people can build fulfilling careers, and where speaking up is encouraged and acted upon.
In closing, I must thank everyone across the Charity for their hard work throughout a demanding year. I would also like to express my appreciation for the warm welcome given to me at all levels. In particular, my thanks go to our Chair, Natalie-Jane, and the Trustees for their support in helping me hit the ground running.
I am very much looking forward to the coming year.
Alex Perry, Chief Executive Officer
Nuffield Health Annual Report 2024
Chief Executive Officer’s statement
**7**
**1**
## Getting to know our people
A top priority for new CEO Alex Perry was to visit sites and meet our people across the Charity, listening to their views and understanding their roles.
1. Hereford Hospital
2. Barbican Fitness & Wellbeing Centre
3. Guildford Hospital
4 . Nuffield Health at St Bartholomew’s Hospital
5. Plymouth Fitness & Wellbeing Centre
6. Crawley Fitness & Wellbeing Centre
7. Tees Hospital
**3**
**4**
**5**
**“ I’ve been met with smiles, kindness and, above all, a genuine sense of pride.”** Alex Perry, CEO
**7**
**6**
**2**
Nuffield Health Annual Report 2024
Chief Finance Officer statement
**8**
## A message from our Chief Finance Officer
##
Matthew Lynn Chief Finance Officer
## **“ 2024 was an important milestone on our journey to sustainable improvement.”**
* The full calculation of adjusted EBITDA can be found within the key financial indicators on page 9
Since the pandemic, Nuffield Health has continued to focus on building financial resilience and performance. Despite the challenges posed by the energy crisis of 2022/23 and ongoing global economic uncertainty, we have remained focused on building financial strength and stability. This focus reflects our unwavering commitment to our charitable purpose and positions us to grow, innovate, and make an even greater impact in the years ahead.
Our financial strategy is clear: to deliver increased profitability so we can reinvest more into our built estate, services, systems, people and social purpose. We also continued to invest in our infrastructure, including the rollout of new diagnostic imaging equipment through our estimated £200-million partnership with GE HealthCare, and enhancements to our fitness and wellbeing centres.
2024 represents a stepping stone in our sustained improvement journey. We are seeing year-on-year gains in our financial position, and we are confident that we are on the right path. Our trading activity continues on an upward trajectory, delivering results in terms of adjusted EBITDA* and cash, and we have secured an extension to our additional loan facility, enhancing our financial stability.
## **Our financial year**
The Group entered 2024 with a focus on building upon the successful financial improvement measures implemented in the previous year. Despite the challenging external environment, the Group remained committed to supporting our beneficiaries and their health. We delivered a strong financial performance with adjusted EBITDA increasing from £78.4 million in 2023 to £91.9 million in 2024. The improved adjusted EBITDA and reduced finance costs resulted in an improved deficit after tax of £36.4 million (2023 – £64.0 million).
In 2024, the UK economy experienced modest growth, with GDP increasing by approximately 0.7%. This growth was influenced by several key factors, including a decline in inflation rates due to lower wholesale energy prices and slower increases in food and goods prices. Additionally, consumer spending saw a slight uptick, contributing positively to economic activity. However, the lingering effects of the 2023 technical recession continued to pose challenges, alongside high interest rates, which remained relatively elevated throughout the year. Despite these hurdles, the economy showed signs of recovery during 2024, setting the stage for potentially stronger growth in 2025.
The pressure of lengthy waiting times in the NHS continued to drive increased activity in our healthcare settings, with a notable rise in NHS work volumes. Demand from selfpaying patients remained steady, while the number of patients using private medical insurers (PMIs) to meet their healthcare needs continued to grow.
Demand for our healthcare services continued its upward trajectory, with the number of episodes of hospital care delivered increasing by 2.4% in 2024. Our fitness memberships closed in 2024 with 11,000 members more than 2023, at 386,000 members, demonstrating our commitment to delivering excellent wellbeing services, as the public continued to prioritise maintaining and monitoring their health through our fitness and wellbeing centres and health assessment facilities.
The Group saw high levels of activity in our corporate fitness sites, as employees spent more time in the office. The Charity now operates 86 corporate fitness and wellbeing sites and, with additional service lines, our total corporate locations exceed 100 sites. These remain an important channel to improve the reach of the Charity, aiding the delivery of our charitable purpose.
Nuffield Health Annual Report 2024
Chief Finance Officer statement
**9**
As a result of the demand for our services, Group turnover rose by 7%, to £1,453.1 million. Hospital turnover increased by £63 million, with PMI and NHS revenue being significant areas of growth. This increase included revenue growth in both hospital diagnostic services, which grew by 10.3%, and income from episodes of hospital care, which grew by 5.9% over the year. Wellbeing and other trading revenue increased by £32.0 million in 2024, driven by the significant positive impact of our consumer fitness membership base. Health assessment activity also improved in 2024, following a focus on recruitment that drove capacity and resulted in a 15.1% increase in this revenue stream.
Rising activity brought increasing costs, both from the work itself and the people delivering it. The Group continued to focus on reducing costs by driving efficiency across our sites and improving our structures for the future, placing more staff in beneficiary-facing roles and delivering a leaner support centre model. As a result, the efficiencies made in the year enabled us to invest in a meaningful and conscious way.
In 2024 we enacted a Group-wide pay review, providing enhanced increases for those on lower wages, while maintaining our Nuffield Health Living Wage at 5% above the statutory minimum.
## **Steps taken to improve our efficiency**
In 2024, we focused on making the Charity more efficient. This process involved teams across the whole organisation, and included work to reduce the cost of delivering our services, both in terms of people cost and the cost of goods and services. The objective of this work was to generate additional funds for investment in our assets, systems and people, in order to make the organisation more sustainable for the long term. As part of this, we restructured teams in both central functions and more broadly, resulting in a number of redundancies.
The cost savings have enabled the Charity to relaunch a proactive programme of investment aimed at keeping our estate both competitive and sustainable. At the heart of our capital investment strategy is a steadfast commitment to enhancing patient safety and delivering exceptional care.
**Group turnover £1,453.1m** (2023 – £1,358.1m) **Adjusted EBITDA* £91.9m** (2023 – £78.4m) **Adjusted EBITDA*** as percentage of Group turnover
**6.3%** (2023 – 5.8%)
## **Deficit after tax £(36.4)m** (2023 – £(64.0)m)
**Capital expenditure £67.6m** (2023 – £53.6m)
## **Net debt**
**£473.2m** (2023 – £478.2m)
* Adjusted EBITDA is calculated as total operating deficit £14.7 million (2023 – £17.7 million), with adjusting items £15.2 million (2023 – £16.9 million), depreciation and amortisation £91.4 million (2023 – £79.2 million), added back.
**----- Start of picture text -----**
Strategic report
**----- End of picture text -----**
## **Investment in our assets**
sustainability strategic ambition, they reduce operating costs, which in turn frees up funds for further investment.
In line with this vision, Nuffield Health continued to invest in the beneficiary experience, with our omnichannel programme for a much improved service to patients and customers, and ordering 308 top-of-the-range spin bikes, arriving in 2025, to deliver motivating workouts for our fitness and wellbeing centre members.
Through careful cost management and ongoing focus on operational efficiencies, the Group achieved an adjusted EBITDA of £91.9 million for the financial year (2023 – £78.4 million). This represented an adjusted EBITDA margin of 6.3% (2023 – 5.8%). The full calculation of adjusted EBITDA can be found within the key performance indicators on page 13.
As part of our commitment to reduce our environmental impact and carbon emissions, we delivered initiatives in our four key areas: property and operations, procurement, people and greener healthcare. Investment continued in energy-efficiency projects, including reducing heat loss through lagging and installing LED lighting. Our procurement team focused on sourcing reusable items to replace the need for single-use where appropriate, for example, introducing reusable tourniquets, resulting in a considerable reduction in volume. And in our Hospital Sterile Services Units (HSSU) we upgraded to a new fleet of fuel-efficient, HVO-ready vehicles.
Interest costs on our bank borrowings rose to £23.9 million (2023 – £20.9 million) in the year, being directly impacted by the Bank of England rate rises. Net interest payable and similar income is £21.7 million compared to £46.3 million in 2023 and includes a fair value gain on the third-party loan of £13.7 million (2023 – £9.3 million loss), resulting in an improved net deficit of £36.4 million (2023 – £64.0 million).
## **Net debt and liquidity**
Net debt was £473.2 million at the end of 2024, a reduction of £5.0 million against 2023’s position of £478.2 million. This was primarily due to a £7.3 million reduction in the usage of the banking facilities, a £15.6 million favourable revaluation on the third-party loan and an increase in finance leases
Behaviour change has been key in driving down energy use and improving our recycling rates, and our people campaigns ran throughout the year, engaging and educating our teams. These and other actions not only support our
Nuffield Health Annual Report 2024
Chief Finance Officer statement
**10**
of £17.9 million. Further information can be found in note 29 on page 80. The Group’s net cash position was £7.7 million overdrawn at the year end (2023: £1.0 million overdrawn). The overdrawn position reflects the Group’s use of its overdraft facility as part of its overall approach to managing short-term liquidity within the wider borrowing arrangements. The Group aims to use the majority of cash generated from activities to invest in services and improve the quality of our offering to patients and members, furthering the charitable objective to improve the health of the nation. This is carefully balanced with management of the debt facilities to ensure adequate cash headroom, providing stability and financial resilience for the future.
## **Movement in funds**
Total net expenditure, including adjusting items, reduced the Group’s funds by £36.4 million (2023 – £64.0 million). Other movements included an actuarial gain on defined benefit retirement schemes of £15.0 million (2023 – £0.9 million loss), and a gain on the revaluation of land and buildings of £4.4 million, following the market valuation enacted at year end 2023. The Group’s total funds have a surplus position of £1,064.2 million (2023 – £1,081.2 million), reflecting the value of the land and buildings on the Group’s balance sheet. The revaluation surplus can only be realised upon disposal of the related assets.
The general fund remains in a deficit position of £155.0 million (2023 – £132.7 million). The Trustees are committed to returning to a surplus position within the general fund. Actions introduced by the Trustees to eliminate the general fund deficit include an aspirational plan to deliver increased profitability so we can reinvest more into our built estate, systems, services and people, building strategic partnerships to improve Nuffield Health’s offering in key clinical areas to support revenue growth. This is underpinned by a significant focus on reducing operating costs to ensure flow through to net surplus. The Trustees have approved forecasts on this basis.
Total restricted funds of £0.8 million (2023 – £0.8 million), permanent endowments of £0.1 million (2023 – £0.1 million) and a post-retirement reserve of £19.0 million (2023 – £38.1 million) are included in the Group’s reserves.
## **Turnover and adjusted EBITDA 2019-2024**
**----- Start of picture text -----**
Turnover Adjusted EBITDA
£m £m
1,500 100
1,200 80
900 60
600 40
300 20
0 0
2019 2020 2021 2022 2023 2024
Hospitals Wellbeing Adjusted EBITDA
**----- End of picture text -----**
The Trustees scrutinise the financial sustainability of the Group through regular reviews of cash forecast and budgets. The Group aims to use the majority of surplus cash to invest in operational assets and infrastructure to improve the quality of its activities for public benefit. There is no expectation that free reserves will be created at this stage.
## **Going concern**
## Assessment period
The Trustees have assessed the Group’s ability to continue as a going concern for a period of 18 months from the date of approval of the financial statements. This assessment covers operational activity and challenges up to the end of the financial year following the approval of the financial statements, and includes a view beyond the repayment of the £30 million additional facility in August 2026.
## Governance and oversight
The assessment process involved rigorous governance and oversight, including multiple layers of review and
## **Capital expenditure and net debt 2019-2024**
**----- Start of picture text -----**
Expenditure Net debt
£m £m
100 500
80 400
60 300
40 200
20 100
0 0
2019 2020 2021 2022 2023 2024
Capital expenditure Net debt
**----- End of picture text -----**
challenge by management as well as a review by the Board Audit and Risk Committee (BARC) members. Assumptions and sensitivity scenarios were thoroughly checked and challenged to ensure robustness.
## Key assumptions
Management has considered several key assumptions and sensitivities in their assessment. A detailed forecast has been prepared using actual results for Q1 2025 and modelling the remainder of the current financial year, primarily using the Board-approved budget, adjusted for material items in the remainder of 2025 that will have a confirmed impact on the approved budget, such as the receipt of a COVID-19 business interruption claim due from insurers. The forecast includes assumptions such as revenue drivers for both activity and price, cost drivers such as salary increases, inflationary increases for propertyrelated and other costs, as well as assumptions for utilities based on our energy broker’s latest estimates. These adjustments, where applicable, also impact 2026.
Events after the end of the reporting period Subsequent to the year end, the Group disposed of Parkside IHL Scanning LLP to Icon. In June 2025 the Group secured an extension of the £30 million portion of the loan facility until August 2026, which is expected to be fully repaid on 31 August 2026. See note 35 on page 82.
## Uncertainties and sensitivities
Management has modelled a range of sensitivity scenarios to assess the potential impact on the Group’s financial position. These scenarios include fluctuations in NHS activity and associated revenue, volatility in energy prices affecting operational costs, changes in membership levels, and variations in self-pay activity. The total adverse impact modelled across 2025 and 2026 amounts to a potential reduction in EBITDA of £26.5 million.
In response to these risks, management has identified a number of mitigations that could be implemented if required. These include discretionary cost controls, operational efficiency measures, financing options to enhance liquidity, and the ability to rephase or defer nonessential expenditure. While these mitigations are not reflected in the sensitised case, they remain available to support the Group’s financial resilience if needed.
It has been calculated that EBITDA would need to fall by 14.8% from the sensitised forecast to result in a breach of covenant compliance. Based on this analysis, management considers the going concern basis of accounting to be appropriate, with no material uncertainties identified.
## Conclusion
Based on the assessment and the sensitivity analysis performed, the Trustees have a reasonable expectation that the Group has adequate resources to continue in operational existence for at least 18 months from the date of approval of the financial statements. Therefore, the financial statements have been prepared on a going concern basis.
Matthew Lynn, Chief Finance Officer
Nuffield Health Annual Report 2024
Strategy at a glance **11**
## Our strategy
## **Our PURPOSE**
To build a healthier nation, we advance, promote and maintain health and healthcare of all descriptions, and prevent, relieve and cure sickness and ill health of any kind, all for the public benefit.
## **reinforces our VISION**
To help individuals achieve, maintain and recover to the level of health and wellbeing that they aspire to, by being a trusted provider and partner.
**----- Start of picture text -----**
to fulfil our strategic
AMBITIONS
1 2 3 4 5
Provide the best Deliver the best Be the best place Be at least as Multiply our
care and support possible customer to work in health efficient and social impact and
you can get, and patient and wellbeing productive as our sustainability
anywhere experience in the UK competitors
**----- End of picture text -----**
**R Responsive E Ethical** We listen, communicate We demonstrate our and act in an open, commitment to individuals, straightforward way our communities, society and the environment
**A Aspirational** We inspire individual and collective health and wellbeing
> **true to our C Connected** We work together as one Nuffield Health to deliver **VALUES** the best experience to our patients, customers and colleagues
Nuffield Health Annual Report 2024
Strategy at a glance
**12**
**----- Start of picture text -----**
Our strategic ambitions explained
1 2 3 4 5
Provide the best Deliver the best Be the best place Be at least as Multiply our
care and support possible customer to work in health efficient and social impact and
you can get, and patient and wellbeing productive as our sustainability
anywhere experience in the UK competitors
We’re committed to ensuring we provide The overall end-to-end experience is Being the best place to work in the health As a trading charity, we do not have to pay By expanding our free social impact
the best quality care and support to our fundamental to building trust with our and wellbeing industry will ensure we shareholders or dividends. Our surplus programmes across more sites, and
patients and customers, by investing in customers and patients. This comes from recruit and retain people of calibre, funds are invested back into our services, partnering with external bodies to
our people, processes, technology, and empowering our people to understand allowing us to develop the healthcare including sustainability and social impact extend our reach, we will increase our
facilities. and anticipate their needs. providers of the future. programmes. support, and impact more individuals and
communities living with lower resources.
We strive to deliver world-class care We want to ensure all our patients We deliver an outstanding environment By ensuring that financial health is at the
across all our health and wellbeing and customers enjoy a world-leading for our people by investing in excellent forefront of our planning, we will continue We’re committed to becoming carbon net
facilities, supporting individuals and experience when they visit any of our learning and development opportunities; to deliver and grow our services, while zero. By reducing harmful emissions and
communities to manage their health and hospitals and fitness and wellbeing looking after their health and wellbeing; maximising efficiency and productivity in introducing greener practices into our
wellbeing positively, and with confidence, centres, treating everyone with respect showing commitment to pay equity; and order to reinvest in community outreach day-to-day operations and supply chain,
so that they can live life to the fullest. and ensuring they feel welcomed, ensuring we are a diverse and inclusive and free rehabilitation programmes. we aim to fulfil our sustainability goals
comfortable, and listened to. place to work. at pace.
Read more p14 Read more p16 Read more p17 Read more p18 Read more p19
**----- End of picture text -----**
Nuffield Health Annual Report 2024
Strategy at a glance
**13**
## 2024 key performance indicators
Our key performance indicators (KPIs) comprise a number of financial and non-financial metrics that enable us to evaluate our performance.
£126m*
**Social value**
The growth of our social **£126m 2024** impact activity has increased £100m 2023 our social value in 2024. We calculate this by measuring £72m 2022 the impact of a service on four beneficiary areas * Social value for 2024 was – health improvement for calculated using the same method an individual, change in as was used in 2023 and 2022. wellbeing of family or carers, cost savings to health and social care, and the change in productivity of the economy. **Carbon reduction in** 41.8%*%* **Scope 1, 2 and 3, against 2022 baseline** We maintained a reduction **187k** (tCO2e) **2024** in carbon emissions in 2024 185k (tCO2e)* 2023 against our 2022 baseline. * 321k (tCO2e) 2022 Due to a slight increase in energy usage driven by an uplift in activity and improved data collection with the addition of fugitive * FY2022 and FY2023 Scope 3 gases, emissions rose by emissions have been restated to 1.1% compared to 2023. account for updated DEFRA spend emission factors and an improved calculation methodology.
41.8%*%*
297k
**Hospital episodes**
Demand for our healthcare **297k 2024** services rose, with the 290k 2023 number of episodes of hospital care delivered 223k 2022 increasing to 297,000. The pressure of lengthy waiting times in the NHS continued to drive increased activity, with a notable rise in NHS work volumes. Demand from self-paying patients remained steady.
386k
**Fitness and wellbeing members**
Our 2024 fitness **386k 2024** memberships increased by 375k 2023 11,000 members compared 365k 2022 to 2023, demonstrating our commitment to delivering excellent wellbeing services, as the public continued to prioritise maintaining and monitoring their health through our fitness and wellbeing centres, across the UK.
£91.9m*
**Adjusted EBITDA***
|**2024**
**£91.9m**|Through improved
turnover,careful cost|
|---|---|
|£78.4m
2023|management and ongoing|
|£70.4m
2022|focus on operational
efciencies, the Group|
||achieved an adjusted|
|* Adjusted EBITDA is calculated as
total operating deficit £14.7 million
(2023 – £17.7 million), with adjusting
items £15.2 million (2023 – £16.9
million), depreciation and|EBITDA of £91.9 million
for the fnancial year
(2023 – £78.4 million). This
represented an adjusted|
|amortisation £91.4 million (2023
– £79.2 million), added back.|EBITDA margin of 6.3%
(2023 – 5.8%).|
|**Median**
1.1%|**gender pay gap**|
|**2024**
**1.1%**
-1.2%2023|Our 2024 median gender
pay gap is now 1.1%,
compared to -1.2% last|
|0.24% 2022|year. This continues to be
signifcantly below the|
||national pay gap of 13.1%,|
||(Ofce for National|
||Statistics, April 2024).|
m £1,453.1
**Group turnover**
Demand for our services **£1,453.1m 2024** continued its upward £1,358.1m 2023 trajectory, resulting in Group turnover rising by 7%, to £1,237.6m 2022 £1,453.1 million in 2024. Hospitals turnover improved by £63 million and a £31.8 million improvement was seen in our fitness and wellbeing centres and other trading revenue.
£36.4m
**Deficit after tax**
Deficit after tax was £36.4m at the end of 2024, reflecting a year-on-year improvement in adjusted EBITDA*, increased depreciation and amortisation as the Group continues to invest in our estate and services, and a reduced finance costs resulting from the fair value gain of its third-party loan.
**2024 £(36.4)m** 2023 £(64.0)m 2022 £(62.6)m
Nuffield Health Annual Report 2024
Strategy in action
**14**
At Nuffield Health, quality is at the heart of everything we do. By supporting our patients, members and beneficiaries with the best care we can, we will help them manage their health and wellbeing, and live life to the full.
**----- Start of picture text -----**
S T R AT E G I C A M B I T I O N
**----- End of picture text -----**
**Quality assurance** Nuffield Health’s quality assurance is built on a framework of safety, effectiveness, and experience. We use data-driven standards to assess and improve healthcare across all sites, devolving operational responsibility locally, while maintaining national consistency. In 2024, we enhanced Radar, our Quality Management System, with the introduction of a clinical audit module. This information, alongside other data collected in Radar, populates our Primary and Secondary Care quality dashboards. Radar further enhanced the organisational visibility of Patient Safety Incidents (PSIs), allowing us to conduct more precise thematic analysis across specialty areas, leading **1** to deeper insights and improved responses. Incidents, near misses and complaints analysis now play a pivotal role in identifying patient safety trends, contributing to a more Provide the best data-driven approach to quality improvement. care and support The utilisation and visibility of data within our hospital sites was improved, you can get, with the launch of site-specific quality dashboards, which enabled analysis anywhere of trends and focus areas, and
## **Governance**
Clinical governance is fundamental to our quality assurance model, ensuring that our healthcare services deliver the highest standards of care, effectively, safely, and efficiently.
## **SAFETY**
At Nuffield Health, clinical governance is embedded through structured oversight involving committees at executive, functional, and site level to ensure we’re continually monitoring and improving the quality of patient care and support. The structure emphasises accountability, transparency, and a culture of learning.
Meeting the highest possible standards by avoiding harm, upholding professional standards and acting responsibly
Over the past year, we made significant strides in implementing the Patient Safety Incident Response Framework (PSIRF) to strengthen our approach to patient safety. The framework was successfully launched within Primary Care (see page 15) and we’re continuing to embed this across the organisation.
Radar further enhanced the organisational visibility of Patient Safety Incidents (PSIs), allowing us to conduct more precise thematic analysis across specialty areas, leading to deeper insights and improved responses. Incidents, near misses and complaints analysis now play a pivotal role in identifying patient safety trends, contributing to a more data-driven approach to quality improvement.
## **EFFECTIVENESS**
Being a trusted partner to our patients, members and customers by giving them a positive and reassuring experience
Governance processes are always
evolving, with the Patient Safety Improvement Forum providing a dedicated platform for safety incident reviews, thematic analysis, and strategic decision-making. Weekly Adverse Event Forums identify emerging trends.
The utilisation and visibility of data within our hospital sites was improved, with the launch of site-specific quality dashboards, which enabled analysis of trends and focus areas, and contributed to the creation of local quality improvement action plans.
## **EXPERIENCE**
Overall, our efforts to embed PSIRF into our organisational framework have led to measurable improvements in patient safety, and strengthened staff empowerment.
Providing evidence-based health and wellbeing expertise and services that lead to excellent outcomes
**----- Start of picture text -----**
C A S E S T U DY
**----- End of picture text -----**
# **Data-led improvements**
Our commitment to quality assurance and data-led improvement continues to be underpinned by the effective use of quality dashboards. These provide critical oversight to the Executive Committee, enabling informed decision-making and guiding the prioritisation of quality improvement initiatives.
Stephanie Horner, Clinical Governance Lead at Guildford Hospital, shares how the team has actively engaged with the dashboard data to drive service improvements, at a local level.
“We utilise the dashboards to communicate our quality metrics and performance to our team, as well as demonstrating improvement in our quality indicators over time. By benchmarking our outcomes against the wider organisation, we can identify opportunities for quality improvement.”
Nuffield Health Annual Report 2024
**15**
## **Patient Safety Partners**
Experience is central to our quality assurance framework, and this includes listening to the views and experiences of our patients, their families and their carers.
Following the launch of the NHS Patient Safety Strategy, one recommendation was the introduction of Patient Safety Partners (PSP), to support and contribute to an organisation’s governance and management processes for patient safety.
At the beginning of 2024, we appointed Bill Savage as our first PSP and he has proven to be an invaluable resource in advocating for our patients and their families. With a background in both the airline industry and the clergy, he has helped enhance our safety practices and compassionate engagement when responding to patient safety incidents.
Bill acts as the ‘patient voice’ on our Board Quality and Safety Committee. He supports our Quality Lead for Patient Safety and Clinical Effectiveness in reviewing all Patient Safety Incident Investigations to ensure affected parties understand the procedures and findings, as well as piloting our new approach to patient forums, with the emphasis on safety.
It is our intention to expand our team of PSPs, and eventually have one in each Nuffield Health region.
**“ I’m proud to be a patient voice on the Board Quality and Safety Committee and to support the Quality Lead for Patient Safety and Clinical Effectiveness in reviewing incident investigations. Our aim is to ensure these are clear and meaningful to those affected. I’m also excited to help pilot our new, safetyfocused approach to patient forums, creating spaces where listening and learning truly drive improvement.”**
Bill Savage, Patient Safety Partner
## **Accreditations and achievements**
External verification of our quality assurance standards reinforces confidence in our expertise and the provision of care we offer our patients across the organisation. It drives us to constantly improve our practices, and is a source of great pride.
In 2024, hospitals in England and Wales providing oncology services maintained Macmillan Quality Environment Mark accreditation; whilst the National Joint Registry (NJR) rated 34 hospitals ‘Gold’ Quality Data Provider. Fifteen sites offering gastrointestinal endoscopy services received Joint Advisory Group (JAG) accreditation, with our physiotherapy and health assessment service lines awarded ISO 9001.
During the year, the Health Innovation Network (HIN) awarded Nuffield Health an Early Adopter Badge for our approach to the mobilisation of the Patient Safety Incident Response Framework (PSIRF) across Primary Care services.
HIN is the innovation arm of NHS England and supports the adoption and spread of innovation at pace and scale, to improve health outcomes. The Early Adopter Badge award recognised Nuffield Health’s commitment to, and successful implementation of, the new framework across our GP, physiotherapy, and health assessment services. HIN said the badge recognised the Charity’s willingness to ‘explore, learn and test’ PSIRF principles.
Macmillan Quality Environment Mark: Accreditation held at all our hospitals providing oncology services
NJR: Our 34 hospitals in England and Wales rated ‘Gold’ Quality Data Provider
JAG: Accreditation achieved by 15 of our
gastrointestinal endoscopy services, recognising high quality
ISO 9001: Accreditation achieved by physiotherapy and health assessment services lines.
**100% of our hospitals rated overall as Good or Outstanding by national regulators***
*Excluding Nuffield Health at St Bartholomew’s Hospital, which opened in May 2022 and is yet to undergo Care Quality Commission (CQC) assessment
Nuffield Health Annual Report 2024
Strategy in action
**16** our beneficiaries to receive the best experience possible. S T R AT E G I C A M B I T I O N **Access to services at your fingertips** Our customer services team introduced WhatsApp as a way to connect with our patients, making it easier for them to access the support they need, whenever they need it, from anywhere. We’re offering our customers different ways to access our physiotherapy service, by using WhatsApp to handle the simple questions efficiently, freeing up phone lines for more complex issues. The feedback has been extremely **Bookings made easy** positive, with customers enjoying We know our customers expect the quick, professional and clear easy, self-service options to book responses. We’ll be looking to expand what they want, when they want, so our use of WhatsApp across other investing in booking flexibility and service lines. customer experience is essential. The launch of our online booking platform, in 2024, is making it easy for corporate customers to book their health assessments. Initial data showed around Deliver the best three-quarters of bookings had switched to online and over 50% of possible customer appointments were booked before 9am, so convenience is key. Not only is online booking enabling us and patient to facilitate more appointments, reducing waiting time, the feedback **[2]** experience is extremely positive. The first thing we hear is “It’s easy!” – which is exactly what we’re aiming for.
From our expertise to ease of access, the latest technology and quality care, we aim for all our beneficiaries to receive the best experience possible.
## **More than just great coffee**
To elevate our customer experience, we consider every part of our offering, including the all-important cup of coffee. It’s been over a year since we partnered with Change Please Coffee and the results are heartwarming. Served at all of our fitness and wellbeing centres, this is more than just great coffee for our members.
100% of the profits Change Please make support individuals experiencing homelessness, including barista training at our sites. So not only are we providing excellent coffee to our members, but we’ve directly supported 3,500 hours of training through the Change Please programme, helping people to start a new chapter in life.
**Leading-edge diagnostics partnership**
Our 20-year, £200-million partnership with market leader GE HealthCare (GEHC) will deliver over 770 pieces of diagnostic imaging equipment to our hospitals, and significantly advance our ability to diagnose patients, and support those waiting for these services.
We’ve access to the latest technology and equipment, ensuring we deliver leading-edge diagnostics at pace, reducing patient wait time and improving diagnosis, providing a better patient experience. GEHC share our commitment to sustainability. Their major equipment comes with a sustainability passport detailing their limited use of rare materials, recyclability, and reduced energy consumption. For example, 84% of their MRI magnet is recyclable, and during its 25-year lifespan they can continually refurbish the rest of the device, recycling the plastic surround.
Nuffield Health Annual Report 2024
Strategy in action
**17** We champion the physical, mental and financial wellbeing of our people and want to create an environment where they can thrive and take pride in their work. S T R AT E G I C A M B I T I O N **Gender pay gap** Our median gender pay gap is now 1.1% and this continues to be significantly better than the national pay gap (which stood at 13.1% in April 2024, according to figures from the Office for National Statistics). Our mean gender pay gap has increased to 4.5%, from 2.2% in 2023. As in previous years, this is driven **Investing in our leaders** primarily by the hourly pay rate **Diversity and inclusion** Our leadership development differentials in our upper quartile, We’re on a continuous journey to initiatives are key to ensuring our where our most senior roles sit. develop an inclusive workplace, leaders are equipped to create a where everyone feels they belong. positive, inclusive and productive Although both our gender pay gaps We can only achieve this by listening environment for their teams, both are below the national average, we to and learning from the diverse now and in the future. will continue to guide and support experiences of our people. our managers, providing ongoing During the year, we launched several coaching and oversight to ensure The employee forum represents new initiatives. Our Leadership thoughtful and effective people people from across the Charity and Induction programme provides a decisions. enables open conversation directly consistent and impactful onboarding with the Executive Committee. It’s experience for new leaders, fostering a a way of gaining valuable insight, sense of community and connection listening to the employee voice and across the Charity. addressing challenges as well as 1.1% sharing success stories. We’re equipping leaders with Median gender pay gap 2024 Be the best place practical skills, such as leading with Alongside this, our diversity wellbeing in mind; recruitment networks founded and owned by our to work in health and selection; and courageous people, provide an opportunity to Gender conversations, through our share experiences, address inclusion pay gap Leadership Fundamentals training. needs and shape the action that will and wellbeing report For the year ending April 2024 drive change across the Charity. Our In addition, we introduced a Women networks include the Pride Network; **[3]** in the UK in Leadership programme, which Muslim Network; Black Employee aims to empower and support them Network; and Women’s Network. to lead with confidence and impact.
Alongside this, our diversity networks founded and owned by our people, provide an opportunity to share experiences, address inclusion needs and shape the action that will drive change across the Charity. Our networks include the Pride Network; Muslim Network; Black Employee Network; and Women’s Network.
**----- Start of picture text -----**
Gender
pay gap
report
For the year ending April 2024
Read the full report here
**----- End of picture text -----**
**The power of apprenticeship**
In 2024, we invested £2.4 million in the development of our people through our apprenticeship offering. There are more than 100 programmes available to our people and over 450 employees started an apprenticeship.
Around 100 learners started our new Data Literacy apprenticeship, with many reporting a saving of over 2.5 hours a week thanks to the skills they gained, and delivering cost-saving innovations to the Charity.
It takes dedication and determination to complete an apprenticeship, and this was recognised when Rebecca Mayor, our Leadership and Learning Associate (pictured above) was awarded the Lifetime Apprentice of the Year, for completing her level 5 Learning and Development course.
Nuffield Health Annual Report 2024
Strategy in action
**18** We’re focused on being at least as efficient and productive as our competitors. This will allow us to maximise the profit and cash generated from our services, and invest in our S T R AT E G I C A M B I T I O N estate, our systems, our people, and our unique free social impact activity. To deliver this, we’re engaged in programmes of work across the organisation which include: **Procurement efficiencies** Our procurement team play a vital role in supporting the Charity’s growing activity. Through a carefully managed and sustainable network of suppliers with strong, wellestablished relationships, we ensure consistent access to essential resources and equipment needed to deliver high-quality care and services. This approach also drives efficiency **Supporting the nation’s health** across the organisation. **Assuring long-term financial** As the UK’s largest healthcare Charity, **stability Digitisation and** we remain committed to supporting The Group’s trading performance the NHS and addressing the challenge **Standardisation** in the first five months of 2025 **automation** of long waiting lists. We are prioritising A new Standardisation Framework, exceeded expectations, with all areas consultant engagement and referral led by our Chief Medical Officer and contributing strongly to this position. optimisation in order to expand NHS Chief Clinical and Quality Officer, Hospital activity and revenue remain Nuffield Health launched its online consultant capacity across our hospital network. was launched during the year. The strong, particularly in private medical booking service in 2023, allowing people framework spans clinical and noninsurance, NHS, and diagnostics. to make outpatient appointments directly Through the year we’ve embarked on clinical disciplines, and underpins Additionally, in February 2025, with consultants, and our final four hospitals a number of initiatives in support of our commitment to deliver safe, high the Group’s fitness and wellbeing went live, with the service, this year, ensuring a building a healthier nation, including quality patient care through efficient, centres delivered its highest ever consistent digital experience across our estate. opening up more NHS e-Referral standardised practices across the membership revenue. Alongside this, our First Available Appointment Service slots to increase the number organisation. Strong partnerships with initiative enables patients, to book the right of Nuffield Health appointments clinicians and suppliers will maximise EBITDA levels exceeded budget and consultant and get quicker appointments available to NHS patients. value, and we are determined to our 2025 results are already showing regardless of hospital location. Be at least as ensure that variation reduction will be an improved margin compared By documenting and sharing best at the core of everything we do. to the previous year. Direct costs Improving accessibility means patients are practice, and optimum training and were kept under control in the early finding it much easier to book appointments, efficient and staffing models, we have increased months of 2025, as we moved to a and 75% of all Health Assessment bookings are theatre utilisation. In addition, we’ve leaner support centre model and now made online (see page 16). opened up more consultant diaries more efficient ways of working. productive as for online booking, which has proved We are continuing to explore further to be an enabler for greater patient opportunities for automation and digitalisation, **[4]** our competitors access to our hospital services. including our business services.
Improving accessibility means patients are finding it much easier to book appointments, and 75% of all Health Assessment bookings are now made online (see page 16).
Nuffield Health Annual Report 2024
Strategy in action
**19** In our mission to tackle health inequalities, we’re increasing the number of beneficiaries we can support through our free programmes. Working with external partners, we’re S T R AT E G I C A M B I T I O N developing new initiatives and removing the barriers to exercise. **Academic partnerships** Our academic partnerships are fundamental to how we design, evaluate and scale our free programmes, ensuring they are Healthy robust and capable of delivering community long-term health benefits for both in action individuals and society. Social Impact report 2024 We’ve joined forces with the Faculty of Read our Social Impact report here Sport and Exercise Medicine to break down barriers and make it easier for people with long-term conditions **Making an impact** (LTC) to exercise and access As the UK’s largest healthcare movement as a form of treatment. charity, we reinvest every penny into improving the nation’s health. In In 2024, we launched a new multi2024, our social impact programmes year research partnership with **99,707** continued to reach underserved **beneficiaries reached** Manchester Metropolitan University communities, breaking down barriers **in 2024** focused on strengthening the to access, and delivering £126 million evidence base for movement as in social value (2023 – £100 million), a treatment for LTC. Together, we **WITH** as verified by Frontier Economics. are developing a new innovative movement-based programme, Our free programmes are designed aimed at catering for the growing **41** % to tackle unmet health needs by using burden of multimorbidity in society. movement as a fundamental part of **41,219 living with lower resources*** preventing, treating, and managing Multiply our long-term conditions. **AND** social impact and In 2024, we delivered our lifechanging Joint Pain Programme, to over 12,300 participants (see page **£126** m **[5]** sustainability 20), enabling those living with lower **delivered in social value** Unlocking the resources to access our fitness and ‘miracle cure’ A white paper on wellbeing centres at no cost. *CACI Acorn classification is used to
Our academic partnerships are fundamental to how we design, evaluate and scale our free programmes, ensuring they are robust and capable of delivering long-term health benefits for both individuals and society.
We’ve joined forces with the Faculty of Sport and Exercise Medicine to break down barriers and make it easier for people with long-term conditions (LTC) to exercise and access movement as a form of treatment.
In 2024, we launched a new multiyear research partnership with Manchester Metropolitan University focused on strengthening the evidence base for movement as a treatment for LTC. Together, we are developing a new innovative movement-based programme, aimed at catering for the growing burden of multimorbidity in society.
*CACI Acorn classification is used to define individuals who live with financial constraints.
A white paper on movement for health
**Driving change in health policy**
In 2024, our profile as a trusted and influential voice in health policy continued to grow. Our expertise in research, data, and delivering excellent health outcomes has helped us to shape national conversations – whether around improving population health, reducing health inequalities, or supporting economic growth by helping people stay healthy and in work.
Our white paper (below left) with Manchester Metropolitan University, campaigned for embedding movement into the management of long-term conditions. It was referenced in Parliament, and the Government expressed interest in the outcomes of our research partnership.
As we continue our thought leadership in this space, Nuffield Health is becoming an established voice on how movement-based interventions can play a vital role in the future of healthcare.
Download the full paper here
Nuffield Health Annual Report 2024
Strategy in action
**20**
## **Scaling our Joint Pain Programme**
Our largest and longest-running Programme For All, Joint Pain, is run across all 110 of our fitness and wellbeing centres and is free to access.
Chronic joint pain causes misery to many thousands of people and musculoskeletal (MSK) conditions are estimated to cost the NHS around £5 billion a year to treat.
The programme is run by our Rehabilitation Specialists and comprises an initial 12 weeks of supervised, low-impact exercise, together with emotional wellbeing support and education. The aim is that participants emerge with the tools to self-manage their condition. This is followed by a further 12 weeks of unsupervised support, with free access to the fitness and wellbeing centre.
The programme has supported 12,318 people in 2024. The clinical outcomes have been impressive, with wider positive outcomes in terms of Social Return on Investment (SROI). And for many, it has been life-changing.
## 35%
improvement in joint pain
37%
improvement in joint function
47%
reduction in sick days
## **Groundbreaking research in cancer care**
In 2024, we completed the STAMINA trial, the largest clinical trial of its kind, focused on the effects of a structured exercise intervention for men living with prostate cancer undergoing androgen deprivation therapy.
This landmark study is set to publish results later this year and will provide vital, high-quality evidence on the role of movement in improving the health, wellbeing, and independence of men during cancer treatment.
700
patients across 40 NHS sites took part in the trial, providing crucial data that could pave the way to integrating exercise into routine cancer care
29%
reduction in GP appointments
28% improvement in stiffness
26%
improvement in anxiety
**Community blood pressure champions** Hypertension (high blood pressure) is a condition that may have no symptoms, yet its consequences can be serious. In 2023, we launched a pilot initiative in collaboration with Manchester University NHS Foundation Trust to offer free blood pressure checks to the public.
Working with NHS community health services provider, Manchester Local Care Organisation, 51 members of the local area were recruited to be ‘community champions’ and trained to carry out blood pressure checks. 1,409 people had their blood pressure taken, with 444 needing to take steps to improve their blood pressure rating.
**----- Start of picture text -----**
Take Heart
A community-led blood pressure programme
Download the full report here
**----- End of picture text -----**
Nuffield Health Annual Report 2024
Strategy in action
**21**
## Greener today for a healthier tomorrow
We’re focused on creating a sustainable environment, and that means changing the way we do things. We’re working hard to minimise carbon emissions, from our procurement decisions, to making small, daily changes which add up to make a big impact.
## **Reporting frameworks and benchmarks**
**PROPERTY AND OPERATIONS** Investing in our infrastructure and getting the basics right to drive efficiencies across our estate.
## **PEOPLE**
Driving behavioural change and equipping our people with the knowledge and skills to help us reduce emissions.
## **PROCUREMENT**
Working with our suppliers to understand their carbon footprint and ensure their practices are aligned to ours.
## **GREENER SURGERY**
Focusing on care pathways and delivery models to reduce our environmental impact, while maintaining quality.
## **Reducing single-use items**
Reducing our reliance on singleuse products and sourcing reusable alternatives has been a priority throughout the year.
One million plastic shoe covers, used at our fitness and wellbeing centres’ swimming pools, were removed, with no impact to our services. We received positive feedback from our members, who welcomed this green initiative.
In our hospitals we identified that we were using over 400,000 single-use tourniquets per year, that were not able to be recycled. Working with our supply chain, we sourced a reusable tourniquet that can be used up to 10,000 times, reducing waste and the use of raw materials.
After successfully trialling the tourniquets at several of our hospitals across the UK, we implemented a national rollout. The response from our teams has been fantastic and all hospitals have switched to the reusable version where possible.
## **Embedding sustainable behaviour**
With over 18,000 employees, it’s key that we engage, inspire and educate our people to drive our sustainability initiatives. In 2024 we continued to embed behaviour change with #SwitchOff, our energy campaign.
Focusing on embedding energy-saving practices at a local site level, the campaign includes nighttime closure checklists, explaining what can be safely turned off at night, from treadmills to theatre equipment, set point guides for heating and cooling and quick wins that can be part of daily routines. Importantly, every site has access to a sustainability dashboard where monthly electricity and gas consumption can be tracked. This enables our people to see the impact of the changes they are making.
By raising awareness and encouraging behaviour change, we can effectively reduce unnecessary energy consumption.
Nuffield Health Annual Report 2024
Strategy in action
**22**
## **Reducing medical gas leakage**
Following on from the removal of desflurane in 2023, we continued to focus on reducing the use of medical gases that are extremely harmful to the environment.
Nitrous oxide anaesthetic gas is a more potent greenhouse gas than carbon dioxide and remains in the atmosphere for over 100 years. Typically, it’s housed in external storage sheds and piped into theatres. This is extremely inefficient; we measured its use at our Bristol Hospital and found that 80% was lost to leakage. We took the decision to decommission external storage and manifolds, and instead install canisters on trollies in theatres, resulting in a reduction equivalent to 370 tonnes of CO2 in 2024. We managed to complete this project at all 36 hospitals within the year.
The key to our success was collaboration, with valuable input from consultants, theatre teams, procurement and building management.
370 tCO e 2 reduction in 2024 due to the change in nitrous oxide delivery system
**----- Start of picture text -----**
Menu
**----- End of picture text -----**
## **Evolving our patient dining experience**
Autumn 2024 saw the start of our journey to evolve our patient menus to reduce our meat content to 10% of our menu and our carbon impact by 30%, over the next two years. By incorporating sustainable ingredients, plant-based alternatives and reducing meat consumption, we’ll offer a healthier and more sustainable menu to our patients, without restricting choice or compromising nutritional value.
Our autumn/winter menu trialled the first iteration of our greener menu and was well received by patients. Working with our supplier, Sodexo, and behavioural science experts Greener By Default, we’ll continue to evolve our menu during 2025.
## **Making benefits greener**
The introduction of our new Electric Car Salary Sacrifice Scheme, in 2024, provides a fantastic opportunity for our employees to access a wide range of brand-new or nearly-new electric vehicles, helping to make a more environmentallyfriendly choice for their next car.
The scheme not only helps our people to reduce their impact on the environment but can have potential tax and National Insurance savings.
This initiative supports our strategic ambition to multiply sustainability and provides an opportunity for our people to be a part of our journey towards a greener future.
In 2025, we’ll be looking to introduce further greener employee benefits designed to encourage sustainable practices, reduce environmental impact, and appeal to environmentally conscious employees.
## **Theatre ventilation trial**
We’re always looking for new ideas to reduce our environmental impact. Our latest project is researching the effects of turning off theatre ventilation at night, when not in use, on carbon emissions and energy usage.
With theatres being the most energy-intensive part of the hospital, there is a huge opportunity to reduce our consumption, resulting in lower emissions and cost savings.
Monitoring equipment was fitted in the theatres at our York Hospital, to enable us to see exactly what energy the air handling units were using 24 hours a day. We tracked consumption over the last year and are currently analysing the data.
The results will be published shortly to share our learnings across the healthcare sector.
Nuffield Health Annual Report 2024
Strategy in action: SECR
**23**
## Streamlined Energy and Carbon Reporting
This report summarises Nuffield Health’s energy usage, associated emissions, energy efficiency actions and energy performance under the government policy SECR. This is implemented by the Companies (Directors’ Report) and Limited Liability Partnerships (Energy and Carbon Report) Regulations 2018.
e Our operations have an intensity metric of 5.670 tCO2 per FTE for this reporting year. This represents an increase in the operational carbon intensity of 3.94% from last year ending December 2023 (see Table 3).
The tables right show the consumption and associated emissions for financial years ending December 2024 and December 2023 for all operations.
The report includes the methodologies utilised for all calculations related to the elements reported under energy and carbon. Under the legislation, we must disclose our energy consumption, emissions, intensity metrics and all energy-efficiency improvements implemented for all UK operations.
We’ve disclosed mandatory UK consumption and emissions data. Total consumption and location-based emissions are reported in Tables 1 and 2 (right).
Nuffield Health is a UK-incorporated charity. An operational boundary has been applied for the purposes of the reporting. A total of 0.47% of consumption data used for SECR has been estimated to achieve 100% data coverage.
**Scope 1** consumption and emissions include direct combustion of natural gas, and fuels utilised for transportation operations, for example, company vehicle fleets.
## **Reporting year: January 2024 – December 2024**
Nuffield Health’s Scope 1 direct and Scope 3 indirect emissions (combustion of natural gas and transportation fuels) for this reporting year are 45,311.61 tCO2e, resulting from the direct combustion of 234,012,827 kWh of fuel. This represents a carbon increase of 7.17% from last year ending December 2023 (see Table 2).
**Scope 2** consumption and emissions cover indirect emissions related to the consumption of purchased electricity in day-to-day business operations.
Scope 2 indirect emissions (purchased electricity) for this reporting year are 23,183.04 tCO2e, resulting from the consumption of 111,968,328 kWh of electricity purchased and consumed in day-to-day business operations. This represents a carbon increase of 1.34% from last year ending December 2023 (see Table 2).
**Scope 3** consumption and emissions cover emissions resulting from sources not directly owned by Nuffield Health, ie grey fleet business travel undertaken in employee-owned vehicles only.
## **Table 1. Nuffield Health total energy consumption (kWh)**
**----- Start of picture text -----**
FY2024 consumption (kWh) FY2023 consumption (kWh)
Utility and scope UK UK
Scope 1 total 232,558,864 222,656,415
Natural gas (Scope 1) 229,228,129 219,450,528
Transportation (Scope 1) 3,330,735 3,205,887
Scope 2 total 111,968,328 110,479,270
Grid-supplied electricity (Scope 2) 111,968,328 110,479,270
Scope 3 total 1,453,963 1,507,571
Transportation (Scope 3) 1,453,963 1,507,571
TOTAL 345,981,155 334,643,256
**----- End of picture text -----**
## **Table 2. Nuffield Health location-based emissions (tCO2e)****
**----- Start of picture text -----**
FY2024 emissions (tCO2e) FY2023 emissions (tCO2e)
Utility and scope UK UK
Scope 1 total 44,987.55 41,940.20
Natural gas (Scope 1) 41,925.82 40,143.85
Medical gas (Scope 1 – other fuels) 705.30 1,075.33
Fugitive gas (Scope 1 – other fuels) 1,567.27 N/A*
Transportation (Scope 1) 789.16 721.02
Scope 2 total 23,183.04 22,877.42
Grid-supplied electricity (Scope 2) 23,183.04 22,877.42
Scope 3 total 324.06 339.06
Transportation (Scope 3) 324.06 339.06
TOTAL 68,494.65 65,156.68
*N/A in FY2024, Nuffield Health has also provided fugitive gas loss from air conditioners and refrigerants in weight as a data-improvement measure compared to FY2023 and
FY2022 baseline year. **The reported Scope 1, 2 and 3 emissions have been rounded to two decimal places. Any year-on-year comparison calculations have been conducted using
complete unrounded figures.
Table 3. Group UK emissions intensity metric***
Location-based (tCO2e) Market-based (tCO2e)
Intensity metrics FY2024 FY2023 FY2024 FY2023
Total full-time equivalent (FTE) 12,080 11,944 12,080 11,944
All scopes tCO2e per FTE 5.67 5.45 4.00 3.70
Year-on-year percentage change (tCO2e) +3.94% +8.26%
**----- End of picture text -----**
***The reported Scope 1, 2 and 3 emissions and associated intensity metrics have been rounded to two decimal places. Any year-on-year comparison calculations have been conducted using complete unrounded figures.
Nuffield Health Annual Report 2024
Strategy in action: SECR
**24**
## **Year-on-year changes**
Overall, there has been an increase of 7.23% in natural gas, refrigerants and other fuels emissions when compared to FY2023. Natural gas kWh increased by 4.44%, and medical gas emissions decreased by 34.41%, due to changes in our nitrous oxide delivery system (see page 22). However, the major increase is due to an addition of fugitive gas emissions in the FY2024 data improvement measure.
Fugitive gas emissions refers to emissions of certain greenhouse gases, from sources including air-conditioners and refrigeration. In FY2024, fugitive gas emissions have been captured for the first time since baseline year to provide a more accurate representation of our Scope 1 direct emissions.
Electricity emissions have increased by 1.34% when compared to FY2023. This increase is due to increased business activity on sites, with more hospital procedures and membership growth in Nuffield Health’s fitness and wellbeing centres.
Overall transport emissions increased by 5.01%. Scope 1, HSSU fleet and company car kWh increased by 3.89% and Scope 3 (grey fleet) kWh decreased by 3.56%. This overall rise is also due to increased business activity.
Our overall intensity metric has increased by 3.94% due to increased emissions, whereas the FTE metric only increased by 1.14%.
## **Energy efficiency narrative**
We’re committed to year-on-year improvements in our operational energy efficiency. A register of energy efficiency measures has been compiled, with a view to implementing these measures in the next five years.
## Measures undertaken in FY2024
## Expansion of core energy team
We hired three Regional Energy Managers. These managers oversaw energy-related initiatives and optimisations across all fitness and wellbeing sites. By carrying out audits when visiting sites, opportunities were quickly recognised and actions implemented to optimise energy usage.
## Driving energy efficiency through everyday practice
We continued to prioritise optimisation of Building Management Systems (BMS). With a focus on plant room efficiency, extra support at sites for Building Services Engineers and ensuring operating toolkits are followed, awareness of energy savings opportunities and best practice has increased.
Through precise monitoring and control of heating, ventilation, and air conditioning (HVAC) systems, settings have been able to be adjusted according to occupancy patterns and external weather conditions to reduce energy wastage.
Our lagging programme has continued and effectively reduces heat loss during the transportation of water, minimising the need for constant heating or cooling. The optimised systems require less energy to maintain desired temperatures.
LED lighting installation has continued across the estate. Transitioning to LED lighting results in reductions in energy consumption.
We also have Combined Heat and Power (CHP) installation at the Oxford Hospital site. This ensures our efforts towards efficient process of capturing and utilising the heat that is a by-product of the electricity generation process.
## #SwitchOff internal employee campaign
We delivered a behaviour change #SwitchOff campaign to keep employees engaged in energy-saving practices. The campaign focused on embedding small changes at a local site level. By raising awareness and promoting behavioural changes among our people, we effectively reduced unnecessary energy consumption.
## Measures to be addressed in FY2025
## Continuation of enhanced energy team
After a successful first year, the three Regional Energy Managers will move their focus to the hospital sites. These managers will oversee energy-related initiatives and optimisations, ensuring consistent and effective energymanagement practices. Working with Building Services Engineers, they will support site teams to identify further opportunities for energy reduction.
## Photovoltaics trial
We plan to trial the installation of photovoltaics (PV) at selected sites. This initiative aims to generate electricity, providing the site with its own supply, which will then reduce dependency on the grid. A scoping project is underway, with the aim of installing PV at both hospitals and fitness and wellbeing centres in 2025.
## Theatre ventilation “off at night” project
We initiated a trial project at York Hospital in 2024 focused on turning off air-handling units (AHUs) during night-time hours. As the most energy-intensive part of the hospitals, this project looked at the impact of turning off AHUs safely at night, with the ability to turn back on at speed, should it be required. Monitoring equipment was installed to measure energy usage and data tracked across the year. A research report with results will be published in 2025 and we will look to roll this out across our hospitals.
## LED lighting installation
We will continue to replace lighting with energy-efficient LED lighting systems on a site-by-site basis. By transitioning to LED lighting, we anticipate significant reductions in energy consumption while maintaining optimal lighting quality.
## **Reporting methodology**
This report (including the Scope 1, 2 and 3 kWh consumption and CO2e emissions data) has been developed and calculated using the GHG Protocol – A Corporate Accounting and Reporting Standard (World Resources Institute and World Business Council for Sustainable Development, 2004); Greenhouse Gas Protocol – Scope 2 Guidance (World Resources Institute, 2015); ISO 14064-1 and ISO 14064-2 (ISO, 2018; ISO, 2019); Environmental Reporting Guidelines: Including Streamlined Energy and Carbon Reporting Guidance (HM Government, 2019).
Government Emissions Factor Database 2024 version 1.0.1
has been used, utilising the published kWh gross calorific value (CV) and kgCO2e emissions factors relevant for the reporting period 1 January 2024 – 31 December 2024. Estimations were undertaken to cover missing billing periods for properties directly invoiced to Nuffield Health. These were calculated on a kWh/day pro-rata basis at the meter level.
All estimations equated to 0.47% of reported consumption.
For all landlord properties where Nuffield Health is indirectly responsible for utilities and only the cost of utilities was available, the consumption of the electricity and gas supply was calculated using an average between Ofgem’s 2024 Q1 – Q4 cost (£) per kWh figures.
Market-based emissions were calculated using REGObacked electricity contracts and an emission factor of 0kgCO2e/kWh was applied. For landlord sites where the electricity meter was not REGO-backed, a residual UK Government-published emission factor was applied. e Intensity metrics have been calculated using total tCO2 figures and the selected performance indicator agreed with Nuffield Health for the relevant report period.
Nuffield Health Annual Report 2024
Strategy in action: CFD report
**25**
## Climate-related Financial Disclosures
The Companies (Strategic report) (Climate-related Financial Disclosure) Regulations 2022 require publicly quoted and large private companies to integrate climate disclosures into their annual reports. Nuffield Health (“the Charity”) is a charity, limited by guarantee without share capital, incorporated in the UK and registered in England and Wales, and is captured by this regulation.
Nuffield Health has disclosed in accordance with all eight requirements of the Climate-related Financial Disclosure regulations. We have fulfilled the reporting requirements of Climate-related Financial Disclosures (CFD) by basing the report on the integration of climate-related risks and opportunities into our processes and operations across four key areas: Governance, Risk Management, Strategy, and Metrics and Targets.
## **GOVERNANCE**
Climate-related risks are overseen through the same risk governance structure outlined in our risk management section on page 32, ensuring alignment with our broader approach to Principle Risk management and executive accountability.
## B OA R D A U D I T A N D R I S K C O M M I T T E E ( B A R C )
## E X E C U T I V E R I S K C O M M I T T E E ( E R C )
## B OA R D O F T R U S T E E S
The Executive Risk Committee (ERC), attended by senior executives, monitors and reports on climate-related risks and mitigation efforts. It assigns executive responsibility for integrating climate considerations into decision-making.
Our Board of Trustees, made up of nine members are both directors and Trustees of the Charity. The Trustees delegate day-to-day executive authority to the Group Chief Executive Officer (CEO).
BARC is made up of representatives of the Trustees, external auditors, as well as the Executive Committee and provides the Board of Trustees with assurances in key areas, including risk management.
The Board of Trustees sets strategy, ensures sufficient financial, human and physical resources, monitors performance, oversees risk management, and defines the Group’s values.They are responsible for identifying and managing climate-related risks and opportunities as part of strategic decision-making. Climate risks and opportunities are a standing item at quarterly Board meetings, supported by the CEO and Executive Committee, to whom day-to-day authority is delegated.
The ERC sets the Charity’s risk tolerance for climate-related exposure and drives mitigation and adaptation measures, including operational changes, investment in resilience, and policy adjustments.
The Committee provides the Board of Trustees with
assurance in key areas of risk management (including
climate-related risks), offering a comprehensive overview of the ongoing efforts and initiatives in risk management. BARC signs off on the annual update of material climatechange risks and opportunities.
## S O C I A L I M PAC T A N D S U STA I N A B I L I T Y F O R U M ( S I S F O R U M )
## E X E C U T I V E C O M M I T T E E
The SIS Forum comprises directors responsible for risk and finance, property and procurement, communications and marketing, trading, operations, quality, and people.
The Board relies on insights from committees and forums throughout the year to ensure climate risks, opportunities, and progress are considered in leadership decisions. Recognising the importance of climate issues, the Board participated in a dedicated competency session last financial year, followed by a refresher in December 2024. This included updates on climate risks and opportunities within the risk register.
The Executive Committee, made up of senior leaders
including the CEO and CFO, oversees the Charity’s operations and delivery of key performance indicators across carbon reduction, energy, suppliers, waste, and recycling.
It drives the Charity’s sustainability strategy and ensures it is embedded across the organisation. Meeting monthly, the Forum discusses social impact and environmental sustainability across four key areas: people, procurement, property and operations, and greener surgery.
The Committee ensures climate and sustainability are embedded into strategy, investment decisions, and organisational priorities. The CFO leads on climate oversight within the Committee, which reviews and approves the climate risk register before it is submitted to the Board of Trustees for final approval.
The SIS team includes owners of climate-related risks and reports monthly to the Executive Committee and is informed by the Social Impact and Sustainability operational business review and healthy environment working group.
The Board brings a range of sustainability expertise, including the CFO, who completed the Cambridge Institute for Sustainability’s Business and Climate Change: Towards Net Zero Emissions course.
Nuffield Health Annual Report 2024
Strategy in action: CFD report
**26**
## **RISK MANAGEMENT**
The Board of Trustees assumes overall responsibility for Nuffield Health’s risk management framework, delegating this duty through committees dedicated to risk oversight.
In December 2024, during the biannual review of the corporate risk register, climate change was reassessed and continues to be identified as an emerging risk, following its initial identification in June 2023. While it is not considered a high risk in the near term, the potential long-term impacts of climate change are becoming increasingly recognised.
SIS Forum is responsible for the annual climate change risk and opportunity identification and assessment conducted through climate scenario analysis, to identify, assess and manage vulnerabilities and opportunities.
## **Identify**
With support from our ESG consultancy, Inspired PLC, we conduct an annual climate scenario analysis to identify climate-related risks. This includes assessment of both physical risks – acute (e.g. wildfires, flooding, heatwaves) and chronic (e.g. sea level rise, rising temperatures, water stress) – and transition risks linked to the shift to a low-carbon economy. Transition risks are assessed at the Charity level, while physical risks are evaluated on a site-by-site basis. Analysis is conducted across three future warming scenarios and time horizons, as outlined in Table 3.
## **Assess**
Findings from our climate scenario analysis were presented at a climate risk management workshop in November 2024, attended by SIS Forum and Risk committee members. The workshop included updated climate training to support the reassessment of climate-related risks and opportunities using the rating methodology outlined in Table 1.
Our classification approach (Tables 1 and 2) builds on the Charity’s existing risk management framework, with enhancements to account for the long-term nature of climate-related risks. In 2024, we introduced climate opportunity ratings using the same framework. Rather than
## **Table 1: Risk and opportunity impact rating methodology**
**----- Start of picture text -----**
Risk score Description of risk impact Description of opportunity impact Opportunity score
**----- End of picture text -----**
|**Risk score**
**Description of risk impact**
**Description of opportunity impact**
**Opportunity score**|**Risk score**
**Description of risk impact**
**Description of opportunity impact**
**Opportunity score**|**Risk score**
**Description of risk impact**
**Description of opportunity impact**
**Opportunity score**|**Risk score**
**Description of risk impact**
**Description of opportunity impact**
**Opportunity score**|
|---|---|---|---|
|||||
|GREEN – low risk|Minimal or negligible negative
impact on our operations or
ability to achieve objectives|No impact or minor contribution to
the delivery of Charity Plan
objectives|RED – low opportunity|
|AMBER – Medium Risk|Indicates a potential for moderate
delay in achieving objectives or
moderate negative impact|Some support to the delivery of
Charity Plan objectives|AMBER – medium opportunity|
|RED – high risk|Signifies a significant or severe
negative impact|Major contribution made to
achieving Charity Plan objectives|GREEN – high opportunity|
## **Table 2: Risk and opportunity likelihood rating methodology**
|**Risk likelihood**||||
|---|---|---|---|
|Descriptor|GREEN|AMBER|RED|
|Probability|Less than 9% within the timeframe|10-49% within the timeframe|More than 50% within the
timeframe|
|**Opportunity likelihood**||||
|Descriptor|RED|AMBER|GREEN|
|Probability|Less than 9% within the timeframe|10-49% within the timeframe|More than 50% within the
timeframe|
endorsed by BARC and ratified by the Executive Committee in December 2024. Tables 4–6 outline these and the associated management actions. In FY2024, we conducted financial modelling to assess both actual and potential financial impacts of physical risks, transition risks, and opportunities. These insights informed our management approach and will be reviewed annually.
applying 1–5 scores, we adopted a RAG rating system –green (low risk/high opportunity), amber (medium), and red (high risk/low opportunity) – based on likelihood and impact criteria. The final rating is primarily driven by likelihood, as this is more within our control. Climate risks and opportunities rated red or green are deemed material to Nuffield Health and detailed in Tables 4-6. We also began assessing climate-related risks in our supply chain, focusing on our top 10 suppliers by spend. Instead of individual scores, we evaluated each supplier’s vulnerability and risk management practices as part of our broader value chain assessment.
Decisions are guided by a RAG rating system, where red risks trigger enhanced actions and frequent reviews, amber risks are managed through regular monitoring, and green risks are monitored periodically. All climate-related risks and opportunities are embedded within our risk management system, Radar, and are reviewed biannually as part of the corporate risk process.
## **Manage**
Climate-related risks are managed by designated risk owners through a hierarchy of governance committees. The Board Audit and Risk Committee (BARC) and senior leaders provide objective oversight to the Executive Committee, enabling effective Board scrutiny. Material climate-related risks and opportunities were
We are also updating our business continuity framework to include climate-related disaster scenarios at each site. The revised plans will be issued in FY2025, aligned to our Charity risks and opportunities recommended by the CFD.
Nuffield Health Annual Report 2024
Strategy in action: CFD report
**27**
## **STRATEGY**
## Our approach
Climate scenario analysis was carried out across 10 strategically selected sites, covering fitness and wellbeing centres, hospitals, and offices across the UK to ensure broad representation.
Building on previous analysis, we began assessing climate risks across our value chain in 2024. We engaged with 81% of tier 1 suppliers (those who provide over £1 million of goods and services annually) on their Scope 1, 2, and 3 emissions. Supplier engagement rose by 36% between 2023 and 2024. This analysis helped us better understand how supplier vulnerability contributes to our overall climate risk exposure. We plan to expand engagement with key supply chain stakeholders in the next financial year.
Our scenario analysis used established models, including Intergovernmental Panel on Climate Change (IPCC) Representative Concentration Pathways (RCPs), Climada natural catastrophe damage model, Coordinated Regional Downscaling Experiment (CORDEX), regional climate projections, Integrated Assessment Models (IAM), and Shared Socioeconomic Pathways (SSPs). The analysis considered three distinct time horizons, as outlined in Table 3.
We’re implementing strategies to mitigate climate-related risks and capitalise on opportunities presented by a lowcarbon future, ensuring our long-term sustainability in a below 2ºC global warming scenario.
We’re building resilience and contributing to a more sustainable future and have invested in climate-related capital expenditures as part of our energy efficiency plan (see pages 22-24). We’ve worked closely with other teams to ensure all functions consider climate change in their day-to-day activities; this includes our procurement team, where sustainability is a key consideration for suppliers, holding a weighting of 30% on their purchasing decision.
## **Table 3: Warming scenarios and time horizons used in the climate scenario analysis**
## S C E N A R I O WA R M I N G PAT H WAY S
## **Below 2ºC (“proactive”) scenario**
Organisations are committing to the Paris Agreement and setting net-zero targets by 2050. Governments are expected to implement systematic policies, while investment in low-carbon technology drives innovation in reducing energy consumption and emissions. Consumer demand for sustainable products is pushing markets toward low-carbon alternatives. Fortunately, the likelihood of reaching many climate tipping points is low, contributing to a more predictable climate outlook, which enables Nuffield Health’s low-carbon strategy to play out effectively while optimising its opportunities (Table 6). Nuffield Health’s business model and strategy are resilient to a “proactive” scenario through our commitment to renewable energy sources in facilities, the implementation of energy-efficient technologies, and the integration of sustainable practices in our service offerings, ensuring we meet consumer demand for environmentally responsible solutions while supporting greener healthcare.
## **Between 2-3ºC (“reactive”) scenario**
Agreements from COP29 are in place, but government policies are uncoordinated, providing companies with limited time to comply. Industry leaders are setting net-zero targets, but investment in low-emission technology is staggered. Several climate tipping points are reached, leading to an unpredictable climate with severe physical risks, causing supply chain disruptions. Nuffield Health is mitigating these disruptions through engagement throughout the value chain to ensure we are resilient within our direct and upstream value chain. Our business model and strategy demonstrate resilience in the “reactive” scenario by prioritising sustainable practices and fostering collaboration throughout our value chain. For example, we invest in renewable energy sources for our facilities and establish partnerships with suppliers committed to sustainable operations, helping us mitigate supply chain disruptions and enhance our adaptability to climate-induced challenges.
## **Above 3ºC (“inactive”) scenario**
The most destructive, longer-term climate change risks lie within this scenario, which Nuffield Health carefully monitors annually and has begun preparing for through climate-inclusive business continuity plans. Climate inaction persists as both industries and governments maintain a “business as usual” approach. Few companies set net-zero targets, and untested and ineffective low-emission technology hampers progress. Numerous climate tipping points are reached, contributing to a volatile atmosphere. Businesses grapple with adapting to physical climate risks without access to green financing. Our business model and strategy demonstrate resilience to the “inactive” scenario through the implementation of robust climate-inclusive business continuity plans, investing in sustainable infrastructure, and prioritising employee wellbeing, ensuring our facilities can adapt to physical climate risks while fostering community health initiatives that emphasise awareness and action on climate change.
## T I M E H O R I ZO N S
## **Short term (2024-2028):**
## **Medium term (2029-2038):**
## **Long term (2039-2053):**
The effects of climate change are anticipated to become more noticeable, particularly in terms of reactive and inactive scenarios for physical risks. Transition risks will intensify in this period, requiring governmental responses to tackle evolving challenges.
In this timeframe, we gain insights into imminent climate change implications, guiding decisions for enhanced resilience. We anticipate strict
The most substantial threat arises from physical risks, especially in reactive and inactive scenarios. Businesses need comprehensive preparation to navigate and manage the resulting outcomes in these situations. This timeframe is consistent with the UK Government’s net-zero pledge by 2050 and Nuffield Health’s long-term target to be net zero (90% reduction, 10% offset) across Scopes 1, 2, and 3 by 2040.
enforcement of transition risks as we move towards a low-carbon economy.
Nuffield Health Annual Report 2024
Strategy in action: CFD report
**28**
## **Table 4: A table showing the material climate-related transition risks that could impact Nuffield Health**
Based on the risks and opportunities identified through the climate scenario analysis, four transition risks, one physical (acute) risk and one climate-related opportunity were identified as material.
An annual review of all identified risks and opportunities was carried out, which led to the declassification of three material risks (wildfires, mandates on and regulation of existing products and services, and increased cost of raw materials); and two material opportunities (technology and changing customer behaviour, and reputation).
In FY2023, increased cost of energy and raw materials was assessed as one combined risk; in FY2024, however, this was assessed as two separate risks (increased cost of energy and increased cost of raw materials). Our understanding of the specific impacts on our business have matured leading to a revaluation of our FY2023 assessment, which has led to the declassification of some previously disclosed risks and opportunities.
|**Climate risk category**|**Description of climate-related risk**
**Risk description**
**Mitigation controls**
Carbon pricing
Carbon pricing may raise operating and compliance costs by putting
a price on emissions. Suppliers could pass on their own increased
costs, driving up procurement spend. The greatest financial impact is
expected in the medium term under a reactive scenario, where faster
decarbonisation may be needed to reduce exposure to carbon taxes.
Nuffield Health is aiming to achieve net zero by 2030 for Scope 1 and 2
emissions and by 2040 for Scope 3 emissions
Energy meters are in place across all sites to monitor usage and identify anomalies
Management of third-party supplier relationships by procurement includes
contract negotiation focusing on ensuring suppliers have the right social,
environmental and economic credentials.
Related metrics and targets:Scope 1, 2 and 3.
Increased cost of energy
As carbon pricing is applied to gas and oil imports, energy costs are
likely to rise. While renewable electricity offers more stable pricing, it
is generally more expensive. Increased demand for renewables may
also drive prices higher. Rising energy costs could increase Nuffield
Health’s operating expenses and potentially limit its ability to deliver
the full range of services or invest in strategic priorities. Additionally,
if customers face reduced disposable income, revenue from self-pay
treatments may decline.
Commodity hedging for energy, gas and electricity is in place.
Energy meters are in place across all sites to monitor usage and identify
anomalies and maximise cost efficiency (eg restricted operating times for
saunas and steam rooms)
Energy-efficient technology has been installed to reduce wastage of energy,
including Building Management Systems (BMS). In addition, we have engaged in
behaviour change initiatives with staff, such as #SwitchOff, to encourage
responsible energy usage at sites
Reports for individual sites that are breaching the night base load for water
and electricity use are produced to highlight use over a defined level.
Related metrics and targets:Scope 1, 2 and 3 emissions.
Substitute existing
products and services
with lower-emissions
alternatives
There is a risk that Nuffield Health may not invest, adapt, or innovate
quickly enough to meet the growing demand for lower-emission
services from beneficiaries and B2B clients. Failing to respond could
mean missing opportunities to expand services, improve outcomes,
extend charitable reach, and stay ahead of competitors. As customer
preferences shift toward more environmentally friendly options,
there may be increased costs linked to developing and delivering
lower-emission alternatives. Existing assets could also face early
retirement or write-offs, reducing their value for money.
We have a decarbonisation plan in progress, tailored to our operations
We have begun investing in developments to reduce our energy consumption
and emissions output. We will continue to do this in line with our net-zero
transition strategy
Management of third-party supplier relationships by procurement ensures
suppliers have the right social, environmental and economic credentials
36 hospitals have transitioned from transporting nitrous oxide to theatres
using a piped system to canisters on trolleys. This is to reduce the loss of gas
into the environment that occurs when using a piped system.
Related metrics and targets:Scope 1, 2 and 3 emissions and our recycling targets.
Costs to transition
to lower-emissions
technology
To reduce carbon emissions, Nuffield Health will need to invest in
lower-emissions technologies, leading to short-term cost increases.
New practices may require training and process changes, temporarily
reducing productivity. Long payback periods, early retirement of existing
tech, and limited access to renewable energy at landlord-supplied sites
may also impact progress toward Scope 1 and 2 net zero targets by
2030. Delayed action risks missed efficiency savings and rising future
costs. Financial impacts include capital investment, implementation
costs, and potential R&D spend on alternative technologies.
We have undertaken an analysis of a decarbonisation plan we will begin working
towards tailored to our business and sites. We have begun investing in
developments to reduce our energy consumption and emissions output.
We will continue to do this in line with our net-zero transition strategy
Management of third-party supplier relationships by procurement includes
contract negotiation with a focus on ensuring that suppliers have the right social,
environmental and economic credentials.
Related metrics and targets:Scope 3 emissions (Category 1 – Purchased Goods
and Services).|
|---|---|
|Policy & Legal
Short to medium term
(2024-2038)
<2°C
2-3°C|Carbon pricing|
|Market
Medium to long term
(2029-2053)
<2°C
2-3°C|Increased cost of energy|
|Technology
Short to medium term
(2024-2038)
<2°C
2-3°C|Substitute existing
products and services
with lower-emissions
alternatives|
|Technology
Short to medium term
(2024-2038)
<2°C
2-3°C|Costs to transition
to lower-emissions
technology|
Nuffield Health Annual Report 2024
Strategy in action: CFD report
**29**
## **Table 5: A table showing the material climate-related physical risks that could impact Nuffield Health**
**----- Start of picture text -----**
Climate risk category Description of climate-related risk Risk description Mitigation controls
Acute Flooding Flooding can damage sites, increase repair costs, cause closures, and disrupt services. Site assessments are undertaken annually for all sites to assess exposure risk with
Medium to long term (2029-2053) Stock losses, new flood-resilient building standards, and property damage raise capital findings analysed centrally
>3°C spend. Southeast UK faces the highest flood risk, which will be monitored. Disrupted Business continuity plans in place at each site in compliance with the Charity’s Business
transport can delay patients, staff, and services, while medicine losses may impact care Continuity Policy
and reputation. Financially, this may reduce revenue, increase workforce costs, and lead Next financial year, we will look to integrate climate change factors into our revised
to asset write-offs. Insurance premiums relating to weather-related catastrophe, Business Continuity Plans.
including flooding could rise 29% by 2040 without climate action. Related metrics and targets: Scope 1 and 2 emissions.
Table 6: A table showing climate-related opportunities that could impact Nuffield Health
Climate risk category Description of climate-related risk Risk description Mitigation controls
Energy source Renewable energy source Onsite energy generation can cut energy costs, lower direct emissions, and reduce exposure Solar energy is being explored across the property portfolio
Short – Medium Term (2024-2038) optimisation to fossil fuel price volatility and carbon pricing. It also enhances reputation and may deliver Half-hourly matching is to be explored to get more accurate energy consumption
<2°C financial gains through reduced operating spend. Heat pumps to be installed.
2-3°C Related metrics and targets: Scope 1 and 2 emissions.
**----- End of picture text -----**
## **METRICS AND TARGETS**
We recognise the importance of measuring and monitoring relevant metrics and targets to reduce our Greenhouse Gas (GHG) emissions and improve energy efficiency across our estate and value chain.
We have been calculating our Scope 1 (emissions that are directly produced from sources owned or controlled by Nuffield Health) and Scope 2 (indirect emissions associated with the generation of purchased energy) since 2020, in accordance with the SECR framework.
Additionally, we have been measuring our Scope 3 emissions (emissions resulting from sources not directly owned by us) since 2020. However, following our acquisition of Aspen Healthcare in 2021, we set our financial year from January to December 2022 (FY2022) as the baseline year for emissions reporting and tracking progress against targets.
We’ve established the following net-zero targets:
- Achieve net-zero Scope 1 and 2 (location-based) GHG emissions by 2030 and net-zero Scope 3 GHG emissions by 2040.
Our definition of net-zero aligns with the Science Based Targets initiative (SBTi), which specifies that net zero means a minimum of a 90% reduction in absolute emissions. Any remaining emissions will be offset through carbon removal strategies. Due to our charitable status, we cannot have our emission reduction targets validated by the SBTi.
Our target for achieving absolute net-zero Scope 1 and 2 emissions by 2030 is a near-term goal that aligns with the SBTi near-term target criteria. Scope 2 emissions will be tracked using a location-based approach, which means the purchase of renewable electricity will not be accounted for in achieving our target.
Additionally, we have set near-term Scope 3 targets which will be achieved in the next five to ten years:
- 52% of our suppliers by emissions covering Scope 3 Category 1 (Purchased Goods and Services), Category 2 (Capital Goods) and Category 4 (Upstream Transportation and Distribution) will have science-based targets by 2028
- reduce absolute Scope 3 – Category 3 (Fuel- and Energyrelated Activities) GHG emissions by 50% by 2033 from a 2022 base year
- reduce absolute Scope 3 – Category 7 (Employee Commuting emissions) GHG emissions by 50% by 2030 from a 2022 base year.
To meet our targets, we need to reduce Scope 1 and 2 (location-based) emissions by 11.25% annually, compared to the baseline, and reduce Scope 3 emissions by 5% annually against the baseline. Our FY2024 Scope 1 and 2 (location-based) emissions were 68,171 tCO2e, which is a 0.7% reduction compared to the FY2022 baseline year. In FY2024, Scope 3 emissions reached 118,677 tCO2e, marking a 53% reduction from the FY2022 baseline.
This year, we focused on supplier engagement and waste reduction, both of which contributed to lowering Scope 3 emissions. However, this shift in priority limited our ability to adopt the energy efficiency technologies needed to achieve our annual reduction targets for Scope 1 and 2 emissions. Additionally, we will review our net-zero targets during 2025 to ensure that there will be sufficient funds to achieve them.
Nuffield Health Annual Report 2024
Strategy in action: CFD report
**30**
## **CARBON EMISSIONS BREAKDOWN**
This is our fifth year of quantifying our full Scope 1, 2, and 3 GHG inventory. Nuffield Health is captured by the SECR framework, which requires organisations to disclose their energy use, carbon emissions, and measures taken to improve energy efficiency as part of their corporate reporting. Please see page 23 for our full SECR disclosure. We voluntarily calculate and report our Scope 3 GHG emissions inventory to ensure the Charity is accountable for its full GHG emissions impact.
Our total Scope 1, 2 (location-based) and 3 GHG emissions increased by 1.1% between FY2023 and FY2024. However, FY2024 emissions are still 41.8% lower than our FY2022 baseline emissions. While Scope 1 and 2 emissions rose from FY2023 to FY2024, Scope 3 emissions decreased by 1.1%. In fact, Scope 3 emissions have been reduced by 53% compared to the FY2022 baseline.
Our Scope 1 and 2 (location-based) GHG emissions increased by 5.2% from FY2023 to FY2024. The yearon-year increase was primarily driven by a 7.2% rise in Scope 1 emissions, which resulted from higher natural gas consumption and the inclusion of emissions associated with fugitive gas leakage for the first time. Scope 2 (locationbased) emissions increased by 1.3% between FY2023 and FY2024, and by 4.5% between the FY2022 baseline and FY2024. The increase in electricity consumption, and so Scope 2 (location-based) emissions, is due to higher business activity at sites with more hospital procedures and a growth in membership in our fitness and wellbeing centres.
Based on our FY2024 Scope 1 and 2 emissions, we’re not on track to achieve our near-term 2030 net-zero target, this will be reviewed during 2025.
The most significant source of Scope 3 emissions comes from purchased goods and services, which accounts for 32.1% of our total carbon footprint (location-based). In comparison to FY2023, emissions in this category have decreased by 8.0%. This reduction is attributed to updated DEFRA emissions factors and the inclusion of supplier-
## **Table 7: Nuffield Health FY2024 carbon balance sheet**
**----- Start of picture text -----**
Greenhouse Gas Emissions Inventory FY2023 and FY2022 (Baseline) Comparison
% of total Previous year Baseline year
emissions FY2023 FY2022 % Change
Intensity metrics FY2024 (tCO2e) (location-based) (tCO2e)* (tCO2e)* FY2022-FY2024
Scope 1 total 44,988 24.1 41,940 46,437 (3.1)
Natural gas 41,926 22.4 40,144 42,560 (1.5)
Transportation (excluding grey fleet) 789 0.4 721 958 (17.6)
Medical gases 705 0.4 1,075 2,918 (75.8)
Fugitive gas 1,567 0.8 N/A N/A 100
Scope 2 total (location-based) 23,183 12.4 22,877 22,191 4.5
–
Scope 2 total (market-based)** 3,057 1,897 3,892 (21.5)
Scope 3 total 118,677 63.5 119,991* 252,626* (53.0)
1. Purchased goods & services 59,925 32.1 65,125 195,476 (69.3)
2. Capital goods 18,495 9.9 16,445 18,801 (1.6)
3. Fuel and energy-related activities 14,763 7.9 14,307 15,444 (4.4)
4. Upstream transportation and
601 0.3 278 2,028 (70.4)
distribution
5. Waste generated in operations 306 0.2 379 623 (50.9)
6. Business travel 1,517 0.8 1,009 813 86.6
7. Employee commuting 23,070 12.3 22,448 19,441 18.7
Total emissions (location-based) 186,847 100 184,809 321,254 (41.8)
–
Total emissions (market-based) 166,722 163,828 302,955 (45.0)
All tCO2e (location-based) per FTE 15 15 29
**----- End of picture text -----**
* FY2022 and FY2023 Scope 3 emissions have been restated to account for updated DEFRA spend emission factors and an improved calculation methodology. ** Market-based emissions are reported in tCO2 only, and reflect the specific emissions associated with a REGO-backed electricity contract or a residual grid factor.
*** Nuffield Health’s FY2024 emissions are reported on a consolidation, operational control approach, as defined by the GHG Protocol.
specific factors for the first time. We plan to continue collaborating with our suppliers to gather emissions data and improve our Scope 3 accounting.
The second largest source of Scope 3 emissions is Category 7 (Employee Commuting), which represents 12.3% of overall emissions (location-based). Compared to FY2023, emissions in this category have increased by 2.8% due to a slight rise in the number of full-time equivalents (FTEs). The third most significant source of Scope 3 emissions is Category 2 (Capital Goods), which accounts for 9.9% of total emissions (location-based). FY2024 emissions have increased by 12.5% due to the purchase of more carbonintensive capital goods compared to FY2023.
According to the Greenhouse Gas Protocol corporate guidance, we only report on Scope 3 categories that are relevant to our operational structure and activities. Therefore, we do not report emissions for the following Scope 3 categories: 8 (Upstream Leased Assets), 9 (Downstream Transportation and Distribution), 10 (Processing of Sold Products), 11 (Use of Sold Products), 12 (End-of-Life Treatment of Sold Products), 13 (Downstream Leased Assets), 14 (Franchises), and 15 (Investments). Based on our FY2024 Scope 3 emissions, we are ahead of our Scope 3 2040 net-zero target trajectory.
## **Energy breakdown**
We are mandated by the SECR framework, which requires organisations to disclose their energy use, carbon emissions, and measures taken to improve energy efficiency as part of their corporate reporting. See breakdown on pages 23-24.
## **Future actions**
As we move forward, we will leverage the findings outlined in the CFD report to enhance our climate resilience and seize the opportunities presented by the low-carbon transition. This includes exploring the use of lower-emission sources of energy within our operations, aligning ourselves with the consumer shift towards sustainable healthcare options and treatments, and positioning ourselves as a market leader in the health and wellbeing industry that prioritises environmental responsibility.
Nuffield Health Annual Report 2024
Risk management
**31**
## Managing our risks
Risk management sits at the core of our operation as a charity and is critical for ensuring we deliver our purpose and meet all our stakeholders’ expectations.
## **Risk Management Framework (RMF)**
Nuffield Health operates a structured and integrated RMF to support the delivery of its strategy and charitable purpose. The framework ensures risks are consistently identified, assessed, managed, and monitored across all levels of the organisation. It is underpinned by the Risk Management Policy and supporting procedures, which were refreshed in 2024 to align with Nuffield Health’s evolving operating environment and governance structures.
During the year, Nuffield Health enhanced the framework by embedding Critical Risk Events (CREs) and CRE Drivers to sharpen focus on the key strategic and operational risks that could impact the achievement of its ambitions. The risk appetite methodology provides clear guidance on the level of risk Nuffield Health is prepared to accept, promoting consistent decision-making across the charity.
The RMF provides structured, multi-layered assurance over the identification, management, and monitoring of risks, enabling Nuffield Health to maintain oversight of key strategic and operational exposures, ensure alignment to risk appetite, and support continuous improvement through targeted internal audit and assurance activities.
## **Risk identification and prioritisation**
Risks are identified and assessed at site, functional, and strategic levels, focusing on those that could affect Nuffield Health’s five strategic ambitions. Operational risks are recorded on Radar, the central risk system, and aligned to Principal Risks. Critical Risk Events and Drivers are assessed
## R I S K M A N AG E M E N T F R A M E WO R K
**----- Start of picture text -----**
Site &
Function
Risks
**----- End of picture text -----**
Operational and departmental risks identified across our hospitals, gyms and central services
On Radar, categorised by Principle Risk and location (site or function)
Assessed using a 5x5 Consequence and Control matrix Can be used to inform assessment of the Critical Risk Event (CRE) drivers.
**----- Start of picture text -----**
Critical
Risk Event
Drivers
**----- End of picture text -----**
Specific risks or conditions that may cause a Critical Risk
Event to occur
Assessed using a 5x5 Consequence and Control matrix via a dedicated Teams channel
Can be used to inform and determine the overall risk appetite status of each Critical Risk Event and assessment of Principal Risks.
**----- Start of picture text -----**
Critical
Risk
Events
**----- End of picture text -----**
Significant risk events that would materially impact the delivery of our strategic objectives
Each CRE holds a risk appetite level proposed by the Executive Committee and approved at Board level Risk appetite assessed via a dedicated Teams channel Can be used to inform assessment of Principal Risks.
The most critical, strategic risks to the Charity Assessed using a 5x5 Consequence and Control matrix via a dedicated Teams channel Informed by the status of CREs against risk appetite and the risk score of each CRE drivers.
Principal Risks
Site/ Function Risk Owners
Exec and Senior Leadership Risk Owners
Exec and Senior Leadership Risk Owners
Exec Risk Owners
separately, to provide a forward-looking view. A 5x5 matrix evaluates impact across six consequence themes and control confidence, ensuring risk prioritisation and targeted action.
## **Risk controls and responses**
Each Principal Risk and Critical Risk Event has an assigned Executive Owner accountable for maintaining effective mitigating controls. Risk responses are designed to reduce the likelihood or impact of key risks, with control effectiveness assessed through a combination of firstline operational review, second-line oversight by senior leadership and governance committees, and independent assurance. During 2024, Nuffield Health delivered targeted improvement programmes, including strengthening financial controls, enhancing cyber-resilience capabilities, and refining clinical governance frameworks to support quality of care.
## **Audit and assurance**
Nuffield Health operates a ‘three lines of defence’ model to provide robust assurance over the effectiveness of risk management and internal controls. A key development in 2024 was the transition of third-line assurance from an external provider to Nuffield Health’s internal Risk and Assurance team, which now reports into the Board Audit and Risk Committee (BARC). This change continues to ensure independent assurance while strengthening deeper organisational knowledge, enhancing the relevance and quality of audit insights.
The Risk and Assurance team focuses on delivering assurance across the charity’s strategic and critical risk areas, using a structured, risk-based internal audit programme aligned to our Principal and Critical Risk Events. This approach supports the delivery of focused insights and targeted recommendations on key risk exposures.
Nuffield Health Annual Report 2024
Risk management
**32**
## R I S K G OV E R N A N C E S T R U C T U R E
## **Board of Governors**
The principle decision-making body of the Charity, collectively responsible for promoting the long-term success of the Charity for the benefit of all stakeholders
**Board Quality & Board Audit & Risk Safety Committee Committee (BARC) (BQSC)** Oversees risk Monitors clinical management and and health and mitigation safety governance Reviews internal Considers Clinical and external internal controls assurance and risk matters Monitors financial reported to BARC. reporting and controls.
## **CEO & Executive Committee**
Proposing and meeting financial and operational objectives, improving performance and managing and mitigating risk
**----- Start of picture text -----**
Executive Executive Risk Transformation Business &
Quality Committee & Investment Social Impact
& Safety (ERC) Committee Performance
Committee Reviews
**----- End of picture text -----**
Audit findings and recommendations from both external and internal assurance reviews are tracked, with progress reported quarterly to the Executive Risk Committee (ERC) and BARC. The transition to an in-house model in 2024 enabled improved agility, continuity, and alignment of assurance activities, particularly in areas such as financial control, cybersecurity, compliance, and clinical safety.
## **Principal Risks uncertainties**
Principal Risks represent the most critical strategic risks faced by Nuffield Health. They are assessed regularly by ERC and BARC, informed by the performance of Critical Risk Events and operational risks. Each Principal Risk has an assigned Executive Owner, mitigation plan, and defined risk appetite.
During the year, Principal Risks were reviewed and updated to reflect emerging themes including cyber threats, regulatory compliance, financial sustainability, and workforce challenges. Overall, the Principal Risk profile
remains broadly stable, with improvements noted in financial control, sustainability, and clinical safety following targeted interventions.
## **Governance, reporting and monitoring**
Risk governance is embedded across Nuffield Health through a clear structure of roles, responsibilities, and escalation pathways. Site and function risk reviews provide operational oversight, while ERC and BARC oversee strategic risk management. Oversight of clinical risk is specifically the responsibility of the Board Quality and Safety Committee (BQSC), which receives assurance on clinical safety and patient care, helping to avoid duplication with BARC’s broader oversight of strategic and non-clinical risk areas.
To prevent gaps or overlap between BQSC and BARC, assurance activities are planned and coordinated through the Executive Risk Committee, which provides a central point of review and escalation across all risk domains. Risk performance, including alignment to appetite, is reported quarterly to both BARC and BQSC as appropriate, supported by Radar dashboards. Training and awareness initiatives continued throughout 2024 to strengthen risk culture and ensure consistent application of the framework.
## P R I N C I PA L R I S K C H A R T
**----- Start of picture text -----**
10 2 4
12 5 6 7 8 1 3
9 11
Rare Unlikely Possible Likely Almost certain
L I K E L I H O O D
Further detail on the principal risks identified below are provided on pages 33-34
Ranked by likelihood Ranked by likelihood
1 Technology 6 Financial control
3 Physical assets 8 Financial performance and sustainability
2 Clinical safety and quality 11 Security of supply
4 Cybersecurity 9 Data privacy
5 Regulatory and compliance 10 Health and safety
7 Customers, competition and markets 12 People
Severe
Major
Moderate
Minor
I M PAC T
Insignificant
**----- End of picture text -----**
Nuffield Health Annual Report 2024
Risk management
**33**
## Principal Risks and uncertainties
12 of the Charity’s Principal Risks are presented here, with a summary of mitigations and forward plans. This does not comprise all our risks, and they are not in priority order. Additional currently unknown risks, or those deemed less material, may also have adverse effects.
|
|
|
|
|---|---|---|
|**33**
12 of the Charity’s Principal Risks are presented here, with a summary of mitigations and forward plans. This does not comprise all our risks, and they are not in priority order. Additional
currently unknown risks, or those deemed less material, may also have adverse effects.
Principal Risks and uncertainties|||
|**Principle risk**
**Key responses and controls**
**Forward plans**
Failure to design, build, operate, and maintain resilient key IT systems and
infrastructure, may result in loss of operating capabilities, fnancial impacts,
and damage to our reputation.
Failure to meet and enforce high clinical and regulatory standards and patient
expectations related to the care we provide may unfortunately result in illness,
injury or death of our customers, with potential regulatory or legal sanction,
and negative efects on our performance and reputation.
Failure to maintain our essential assets at the right level of quality and reliability
could result in the stopping, interruption or adjustment of the services we
can provide, and our attractiveness to consultants and customers, negatively
impacting our reputation and fnancial performance.
A cybersecurity incident can result in unauthorised access to, or misuse of,
our information systems, technology, or data. This could lead to leakage of
sensitive information, loss of our critical assets, impact on trade, regulatory
sanction and fnancial and reputational damage.
Failure to comply with legal and other requirements (such as anti-bribery,
competition law, charity law) in an increasingly litigious environment, may
result in fnes, criminal penalties for Nufeld Health or colleagues and litigation
that may lead to adverse fnancial, legal and reputational consequences.
Replacing outdated systems to ensure continued reliability
and performance
Applying secure-by-design principles to all technology projects
and services
Strengthening cyber defences through upgraded networks
and security tools.
Complete rollout of upgraded digital infrastructure across sites
Launch a dedicated team to monitor and respond to cyber
threats
Improve alignment between technology risks and wider
business needs.
Strengthened clinical governance and operating procedures
Ongoing clinical leadership and capability development
Independent reviews and continuous improvement processes.
Standardise clinical risk assessments across all sites
Roll out enhanced leadership induction and clinical training
framework through the Learning Foundation
Embed outcomes-based metrics in clinical governance.
Targeted capital investment in maintenance and compliance
Strengthened asset and estates governance
Strategic estate surveys supporting investment decisions.
Finalise rollout of asset management system by end of year
Use estate survey data to inform three-year investment plan
Develop climate risk-aligned estates strategy.
Multi-layered cyber defence and real-time threat monitoring
Ongoing colleague cyber awareness and training
Strengthened third-party assurance programme.
Strengthened compliance frameworks and regulatory alignment
Active horizon scanning and governance oversight
Ongoing colleague training on regulatory standards.
Expand third-party risk management tools and assessments
Update security incident playbooks and response protocols
Launch role-specific cyber training
Develop Security Operations Centre capability to enhance
cyber threat detection and response.
Launch integrated compliance register across functions
Refresh mandatory training content aligned to 2025 laws
Introduce quarterly risk and compliance reviews.
**N O R I S K M OV E M E N T**
**N O R I S K M OV E M E N T**
**N O R I S K M OV E M E N T**
**N O R I S K M OV E M E N T**
**R I S K D E C R E A S I N G**
1
4
5
3
2
**Technology**
**Cybersecurity**
**Regulatory and**
**compliance**
**Quality and**
**availability of**
**physical assets**
**Clinical safety**
**and quality**||report|
|Failure to design, build, operate, and maintain resilient key IT systems and
infrastructure, may result in loss of operating capabilities, fnancial impacts,
and damage to our reputation.
**N O R I S K M OV E M E N T**
1
**Technology**|Replacing outdated systems to ensure continued reliability
and performance
Applying secure-by-design principles to all technology projects
and services
Strengthening cyber defences through upgraded networks
and security tools.||
|||Trustees’ report
Independent auditor
Financial statements|
|Failure to meet and enforce high clinical and regulatory standards and patient
expectations related to the care we provide may unfortunately result in illness,
injury or death of our customers, with potential regulatory or legal sanction,
and negative efects on our performance and reputation.
**R I S K D E C R E A S I N G**
2
**Clinical safety**
**and quality**|Strengthened clinical governance and operating procedures
Ongoing clinical leadership and capability development
Independent reviews and continuous improvement processes.||
|Failure to maintain our essential assets at the right level of quality and reliability
could result in the stopping, interruption or adjustment of the services we
can provide, and our attractiveness to consultants and customers, negatively
impacting our reputation and fnancial performance.
**N O R I S K M OV E M E N T**
3
**Quality and**
**availability of**
**physical assets**|Targeted capital investment in maintenance and compliance
Strengthened asset and estates governance
Strategic estate surveys supporting investment decisions.||
|A cybersecurity incident can result in unauthorised access to, or misuse of,
our information systems, technology, or data. This could lead to leakage of
sensitive information, loss of our critical assets, impact on trade, regulatory
sanction and fnancial and reputational damage.
**N O R I S K M OV E M E N T**
4
**Cybersecurity**|Multi-layered cyber defence and real-time threat monitoring
Ongoing colleague cyber awareness and training
Strengthened third-party assurance programme.||
|Failure to comply with legal and other requirements (such as anti-bribery,
competition law, charity law) in an increasingly litigious environment, may
result in fnes, criminal penalties for Nufeld Health or colleagues and litigation
that may lead to adverse fnancial, legal and reputational consequences.
**N O R I S K M OV E M E N T**
5
**Regulatory and**
**compliance**|Strengthened compliance frameworks and regulatory alignment
Active horizon scanning and governance oversight
Ongoing colleague training on regulatory standards.||
Nuffield Health Annual Report 2024
|Nuffield HealthAnnual Repo
Risk management|Nuffield HealthAnnual Repo
Risk management|Nuffield HealthAnnual Repo
Risk management|Nuffield HealthAnnual Repo
Risk management|
|---|---|---|---|
|**34**
**Principle risk**
**Key responses and controls**
**Forward plans**||||
|Failure to adequately control the fnances of the Charity could result in
fnancial loss, fnancial misstatements and fnancial crime, negatively
impacting the reputation, confdence of lenders and fnancial sustainability
of the Charity.
**R I S K D E C R E A S I N G**
6
**Financial**
**control**|Embedded financial control and reporting frameworks
Regular financial reviews through executive oversight
Ongoing financial process training for our people.|Develop control maturity assessments for key finance areas
Expand training for non-finance managers
Continue system upgrades to improve reporting.||
|Failure to evolve our customer processes and value proposition and deliver
an efective, coherent and consistent strategy in response to a quickly evolving
customer, market and competitor landscape, and/or changes in market
conditions, may result in a negative impact on our market share and margins,
causing damage to our proftability and business performance.
**N O R I S K M OV E M E N T**
7
**Customers,**
**competition and**
**markets**|Evolving customer service propositions and insights
Investment in digital and in-person experience
Strengthened brand and marketing strategies.|Refresh brand strategy in 2025 to reflect hybrid model
Integrate customer feedback into service design cycles
Build omnichannel experience roadmap.||
|Our fnancial performance may be adversely afected by volatile
macroeconomic conditions such as infation, energy costs, customer payment
fuctuations, and tax exposures from changing laws or interpretations. If not
well managed, these factors may impact our ability to meet fnancial goals and
sustain the Charity’s fnancial health.
**R I S K D E C R E A S I N G**
8
**Financial**
**performance and**
**sustainability**|Delivery of cost efficiency and productivity initiatives
Enhanced commercial and operational performance oversight
Strengthened financial discipline across all business areas.|Drive margin improvement through targeted efficiency
measures
Align workforce planning to support sustainable service delivery
Strengthen forecasting, cost controls, and scenario planning.||
|Failure to comply with legal or regulatory requirements relating to data privacy
during our business activities results in reputational damage, fnes, or other
adverse consequences. These can include criminal penalties and consequential
litigation which may result in an adverse impact on our ability to do business.
**N E W R I S K**
9
**Data privacy**|Structured data governance and privacy frameworks
Enhanced monitoring, incident response, and best practice
alignment
Regular colleague training on data protection.|Review data breach trends and refine control environment
Launch maturity roadmap for data governance
Conduct independent UK GDPR compliance review.||
|Failure to meet workplace safety standards may sadly result in death or injury
to customers, colleagues or third parties, or cause operational disruption,
leading to fnancial, legal and reputational harm.
**N E W R I S K**
10
**Health and**
**safety**|Embedded site safety frameworks and critical risk audits
Strengthened incident response and investigation processes
Targeted training and competency development.|Conduct deep-dive safety reviews at high-risk sites
Launch refreshed safety and compliance training programme
Develop leading indicators to track site risk.||
|Disruption in our supply chain due to adverse macroeconomic conditions,
geopolitical events and/or loss of resilience with a key supplier network, may
result in Nufeld Health being unable to provide the services to fulfl customer
demand on time and at acceptable costs. This could result in customer
dissatisfaction, endangering of our staf, reputational impact, loss of market
share, loss of business and fnancial damage to the organisation.
**N E W R I S K**
11
**Security of**
**supply**|Strengthened supplier management and contingency planning
Ongoing supplier assurance and risk mitigation
Strategic partnerships to support supply chain resilience.|Expand supply chain mapping for critical dependencies
Pilot digital supplier risk monitoring tools
Strengthen escalation routes for supplier issues.||
|Failure to attract, retain and develop the required talent and capabilities,
and to embed our values in our culture, could impact on the delivery of our
purpose, quality and safety standards and business performance.
**N O R I S K M OV E M E N T**
12
**People**|Refreshed colleague engagement and wellbeing strategies
Strengthened leadership, talent, and culture frameworks
Investment in colleague development and recognition.|Roll out new people strategy to support retention
Build DE&I KPIs into executive reporting
Expand leadership training to mid-level managers.||
Nuffield Health Annual Report 2024
Stakeholder engagement
**35**
## Engaging with our stakeholders
Our impact and success wouldn’t be possible without the support and perspective of our stakeholders, and their insights contribute significantly to our development. Indeed, as we aim to deliver ever-more sustainable healthcare, we choose only to work alongside like-minded organisations who seek to learn and grow together.
|**35**
Our impact and success wouldn’t be possible without the support and perspective of our stakeholders, and their insights contribute significantly to our development. Indeed, as we aim
to deliver ever-more sustainable healthcare, we choose only to work alongside like-minded organisations who seek to learn and grow together.
Engaging with our stakeholders
**Stakeholder group**
**Why we engage**
**How we engage**
**Outcomes of engagement**
**Plans for 2025**
The dedication, skills, passion and support
of our people, at all levels, across the
Charity enable us to achieve our purpose
to build a healthier nation. They are the
beating heart of Nufeld Health.
We aim to provide outstanding levels
of healthcare and wellbeing services to
anyone who uses or touches our services
– our patients and members. It’s only by
giving a voice to the people who use our
services that we can continually improve
and develop.
We’re committed to being part of our
local communities, becoming more
accessible to people living with lower
resources, addressing health inequalities
and supporting unmet health needs. This
is central to our purpose to build a
healthier nation.
Regular CEO video and weekly email on areas of focus
for the organisation
Leadership and business briefngs
Peakon employee survey
Extranet and Viva Engage internal newsfeed
Healthy Work hub
Freedom to Speak Up Guardians
WeCARE values recognition scheme
Workday HR system.
Face-to-face through our people, at our hospitals,
medical centres, and ftness and wellbeing centres
Feedback from benefciaries
Customer satisfaction surveys
Patient forums
Our contact centre
Online booking systems
Our social media channels, digital, video, and our website
Leaders’ site visits.
Ofering free rehabilitation programmes, across all 110 of
our ftness and wellbeing centres
Delivering free community outreach initiatives, including
exercise sessions, health education and health checks
Delivering services in the local communities, such
as our Merton Libraries partnership and our free
blood pressure checks project.
The launch of our Employee Forum to ensure we’re the
best place to work in health and wellbeing in the UK
Networks supporting our Muslim, LGBTQIA+, black, and
disabled colleagues, and dedicated Neurodiversity and
Social Mobility networks
Gender and ethnicity pay gap reports
Proactive cost-of-living support and pay increases,
including paying above the Statutory Living Wage to all
eligible employees.
Increased membership in our fitness and wellbeing
centres
Increased hospital episodes
A greater understanding of our services that enables us
to develop and improve based on beneficiary feedback
Increased numbers of visits to our social media channels
year-on-year.
Delivered a social value of £126 million
(2023 – £100 million)
Supported 99,707 people through our social impact
activity, with 41,219 living with lower resources.
To deliver on our new strategic ambition
3 – to be the best place to work in health
and wellbeing in the UK – by investing in
training and development, providing
health and fnancial benefts and looking
for new opportunities, eg our electric
vehicle salary sacrifce scheme
Continue to build an environment that
advances equity, diversity and inclusion.
Enhance and develop technology to
meet the needs of our benefciaries
Invest in our facilities to ensure we ofer
the best possible customer experience.
Continue to extend our reach to more
people living with lower resources, in
underserved communities
Evolve our free rehabilitation
programme to cater for those with
long-term conditions
Pilot our free cancer activity programme.
**OUR PEOPLE**
**PATIENTS AND**
**MEMBERS**
**COMMUNITIES**|**35**
Our impact and success wouldn’t be possible without the support and perspective of our stakeholders, and their insights contribute significantly to our development. Indeed, as we aim
to deliver ever-more sustainable healthcare, we choose only to work alongside like-minded organisations who seek to learn and grow together.
Engaging with our stakeholders
**Stakeholder group**
**Why we engage**
**How we engage**
**Outcomes of engagement**
**Plans for 2025**
The dedication, skills, passion and support
of our people, at all levels, across the
Charity enable us to achieve our purpose
to build a healthier nation. They are the
beating heart of Nufeld Health.
We aim to provide outstanding levels
of healthcare and wellbeing services to
anyone who uses or touches our services
– our patients and members. It’s only by
giving a voice to the people who use our
services that we can continually improve
and develop.
We’re committed to being part of our
local communities, becoming more
accessible to people living with lower
resources, addressing health inequalities
and supporting unmet health needs. This
is central to our purpose to build a
healthier nation.
Regular CEO video and weekly email on areas of focus
for the organisation
Leadership and business briefngs
Peakon employee survey
Extranet and Viva Engage internal newsfeed
Healthy Work hub
Freedom to Speak Up Guardians
WeCARE values recognition scheme
Workday HR system.
Face-to-face through our people, at our hospitals,
medical centres, and ftness and wellbeing centres
Feedback from benefciaries
Customer satisfaction surveys
Patient forums
Our contact centre
Online booking systems
Our social media channels, digital, video, and our website
Leaders’ site visits.
Ofering free rehabilitation programmes, across all 110 of
our ftness and wellbeing centres
Delivering free community outreach initiatives, including
exercise sessions, health education and health checks
Delivering services in the local communities, such
as our Merton Libraries partnership and our free
blood pressure checks project.
The launch of our Employee Forum to ensure we’re the
best place to work in health and wellbeing in the UK
Networks supporting our Muslim, LGBTQIA+, black, and
disabled colleagues, and dedicated Neurodiversity and
Social Mobility networks
Gender and ethnicity pay gap reports
Proactive cost-of-living support and pay increases,
including paying above the Statutory Living Wage to all
eligible employees.
Increased membership in our fitness and wellbeing
centres
Increased hospital episodes
A greater understanding of our services that enables us
to develop and improve based on beneficiary feedback
Increased numbers of visits to our social media channels
year-on-year.
Delivered a social value of £126 million
(2023 – £100 million)
Supported 99,707 people through our social impact
activity, with 41,219 living with lower resources.
To deliver on our new strategic ambition
3 – to be the best place to work in health
and wellbeing in the UK – by investing in
training and development, providing
health and fnancial benefts and looking
for new opportunities, eg our electric
vehicle salary sacrifce scheme
Continue to build an environment that
advances equity, diversity and inclusion.
Enhance and develop technology to
meet the needs of our benefciaries
Invest in our facilities to ensure we ofer
the best possible customer experience.
Continue to extend our reach to more
people living with lower resources, in
underserved communities
Evolve our free rehabilitation
programme to cater for those with
long-term conditions
Pilot our free cancer activity programme.
**OUR PEOPLE**
**PATIENTS AND**
**MEMBERS**
**COMMUNITIES**|**35**
Our impact and success wouldn’t be possible without the support and perspective of our stakeholders, and their insights contribute significantly to our development. Indeed, as we aim
to deliver ever-more sustainable healthcare, we choose only to work alongside like-minded organisations who seek to learn and grow together.
Engaging with our stakeholders
**Stakeholder group**
**Why we engage**
**How we engage**
**Outcomes of engagement**
**Plans for 2025**
The dedication, skills, passion and support
of our people, at all levels, across the
Charity enable us to achieve our purpose
to build a healthier nation. They are the
beating heart of Nufeld Health.
We aim to provide outstanding levels
of healthcare and wellbeing services to
anyone who uses or touches our services
– our patients and members. It’s only by
giving a voice to the people who use our
services that we can continually improve
and develop.
We’re committed to being part of our
local communities, becoming more
accessible to people living with lower
resources, addressing health inequalities
and supporting unmet health needs. This
is central to our purpose to build a
healthier nation.
Regular CEO video and weekly email on areas of focus
for the organisation
Leadership and business briefngs
Peakon employee survey
Extranet and Viva Engage internal newsfeed
Healthy Work hub
Freedom to Speak Up Guardians
WeCARE values recognition scheme
Workday HR system.
Face-to-face through our people, at our hospitals,
medical centres, and ftness and wellbeing centres
Feedback from benefciaries
Customer satisfaction surveys
Patient forums
Our contact centre
Online booking systems
Our social media channels, digital, video, and our website
Leaders’ site visits.
Ofering free rehabilitation programmes, across all 110 of
our ftness and wellbeing centres
Delivering free community outreach initiatives, including
exercise sessions, health education and health checks
Delivering services in the local communities, such
as our Merton Libraries partnership and our free
blood pressure checks project.
The launch of our Employee Forum to ensure we’re the
best place to work in health and wellbeing in the UK
Networks supporting our Muslim, LGBTQIA+, black, and
disabled colleagues, and dedicated Neurodiversity and
Social Mobility networks
Gender and ethnicity pay gap reports
Proactive cost-of-living support and pay increases,
including paying above the Statutory Living Wage to all
eligible employees.
Increased membership in our fitness and wellbeing
centres
Increased hospital episodes
A greater understanding of our services that enables us
to develop and improve based on beneficiary feedback
Increased numbers of visits to our social media channels
year-on-year.
Delivered a social value of £126 million
(2023 – £100 million)
Supported 99,707 people through our social impact
activity, with 41,219 living with lower resources.
To deliver on our new strategic ambition
3 – to be the best place to work in health
and wellbeing in the UK – by investing in
training and development, providing
health and fnancial benefts and looking
for new opportunities, eg our electric
vehicle salary sacrifce scheme
Continue to build an environment that
advances equity, diversity and inclusion.
Enhance and develop technology to
meet the needs of our benefciaries
Invest in our facilities to ensure we ofer
the best possible customer experience.
Continue to extend our reach to more
people living with lower resources, in
underserved communities
Evolve our free rehabilitation
programme to cater for those with
long-term conditions
Pilot our free cancer activity programme.
**OUR PEOPLE**
**PATIENTS AND**
**MEMBERS**
**COMMUNITIES**|**35**
Our impact and success wouldn’t be possible without the support and perspective of our stakeholders, and their insights contribute significantly to our development. Indeed, as we aim
to deliver ever-more sustainable healthcare, we choose only to work alongside like-minded organisations who seek to learn and grow together.
Engaging with our stakeholders
**Stakeholder group**
**Why we engage**
**How we engage**
**Outcomes of engagement**
**Plans for 2025**
The dedication, skills, passion and support
of our people, at all levels, across the
Charity enable us to achieve our purpose
to build a healthier nation. They are the
beating heart of Nufeld Health.
We aim to provide outstanding levels
of healthcare and wellbeing services to
anyone who uses or touches our services
– our patients and members. It’s only by
giving a voice to the people who use our
services that we can continually improve
and develop.
We’re committed to being part of our
local communities, becoming more
accessible to people living with lower
resources, addressing health inequalities
and supporting unmet health needs. This
is central to our purpose to build a
healthier nation.
Regular CEO video and weekly email on areas of focus
for the organisation
Leadership and business briefngs
Peakon employee survey
Extranet and Viva Engage internal newsfeed
Healthy Work hub
Freedom to Speak Up Guardians
WeCARE values recognition scheme
Workday HR system.
Face-to-face through our people, at our hospitals,
medical centres, and ftness and wellbeing centres
Feedback from benefciaries
Customer satisfaction surveys
Patient forums
Our contact centre
Online booking systems
Our social media channels, digital, video, and our website
Leaders’ site visits.
Ofering free rehabilitation programmes, across all 110 of
our ftness and wellbeing centres
Delivering free community outreach initiatives, including
exercise sessions, health education and health checks
Delivering services in the local communities, such
as our Merton Libraries partnership and our free
blood pressure checks project.
The launch of our Employee Forum to ensure we’re the
best place to work in health and wellbeing in the UK
Networks supporting our Muslim, LGBTQIA+, black, and
disabled colleagues, and dedicated Neurodiversity and
Social Mobility networks
Gender and ethnicity pay gap reports
Proactive cost-of-living support and pay increases,
including paying above the Statutory Living Wage to all
eligible employees.
Increased membership in our fitness and wellbeing
centres
Increased hospital episodes
A greater understanding of our services that enables us
to develop and improve based on beneficiary feedback
Increased numbers of visits to our social media channels
year-on-year.
Delivered a social value of £126 million
(2023 – £100 million)
Supported 99,707 people through our social impact
activity, with 41,219 living with lower resources.
To deliver on our new strategic ambition
3 – to be the best place to work in health
and wellbeing in the UK – by investing in
training and development, providing
health and fnancial benefts and looking
for new opportunities, eg our electric
vehicle salary sacrifce scheme
Continue to build an environment that
advances equity, diversity and inclusion.
Enhance and develop technology to
meet the needs of our benefciaries
Invest in our facilities to ensure we ofer
the best possible customer experience.
Continue to extend our reach to more
people living with lower resources, in
underserved communities
Evolve our free rehabilitation
programme to cater for those with
long-term conditions
Pilot our free cancer activity programme.
**OUR PEOPLE**
**PATIENTS AND**
**MEMBERS**
**COMMUNITIES**|
|---|---|---|---|
|**Stakeholder group**
**Why we engage**
**How we engage**
**Outcomes of engagement**
**Plans for 2025**||||
|The dedication, skills, passion and support
of our people, at all levels, across the
Charity enable us to achieve our purpose
to build a healthier nation. They are the
beating heart of Nufeld Health.
**OUR PEOPLE**|Regular CEO video and weekly email on areas of focus
for the organisation
Leadership and business briefngs
Peakon employee survey
Extranet and Viva Engage internal newsfeed
Healthy Work hub
Freedom to Speak Up Guardians
WeCARE values recognition scheme
Workday HR system.|The launch of our Employee Forum to ensure we’re the
best place to work in health and wellbeing in the UK
Networks supporting our Muslim, LGBTQIA+, black, and
disabled colleagues, and dedicated Neurodiversity and
Social Mobility networks
Gender and ethnicity pay gap reports
Proactive cost-of-living support and pay increases,
including paying above the Statutory Living Wage to all
eligible employees.|To deliver on our new strategic ambition
3 – to be the best place to work in health
and wellbeing in the UK – by investing in
training and development, providing
health and fnancial benefts and looking
for new opportunities, eg our electric
vehicle salary sacrifce scheme
Continue to build an environment that
advances equity, diversity and inclusion.|
|||||
|We aim to provide outstanding levels
of healthcare and wellbeing services to
anyone who uses or touches our services
– our patients and members. It’s only by
giving a voice to the people who use our
services that we can continually improve
and develop.
**PATIENTS AND**
**MEMBERS**|Face-to-face through our people, at our hospitals,
medical centres, and ftness and wellbeing centres
Feedback from benefciaries
Customer satisfaction surveys
Patient forums
Our contact centre
Online booking systems
Our social media channels, digital, video, and our website
Leaders’ site visits.|Increased membership in our fitness and wellbeing
centres
Increased hospital episodes
A greater understanding of our services that enables us
to develop and improve based on beneficiary feedback
Increased numbers of visits to our social media channels
year-on-year.|Enhance and develop technology to
meet the needs of our benefciaries
Invest in our facilities to ensure we ofer
the best possible customer experience.|
|||||
|We’re committed to being part of our
local communities, becoming more
accessible to people living with lower
resources, addressing health inequalities
and supporting unmet health needs. This
is central to our purpose to build a
healthier nation.
**COMMUNITIES**|Ofering free rehabilitation programmes, across all 110 of
our ftness and wellbeing centres
Delivering free community outreach initiatives, including
exercise sessions, health education and health checks
Delivering services in the local communities, such
as our Merton Libraries partnership and our free
blood pressure checks project.|Delivered a social value of £126 million
(2023 – £100 million)
Supported 99,707 people through our social impact
activity, with 41,219 living with lower resources.|Continue to extend our reach to more
people living with lower resources, in
underserved communities
Evolve our free rehabilitation
programme to cater for those with
long-term conditions
Pilot our free cancer activity programme.|
Nuffield Health Annual Report 2024
Stakeholder engagement
**36**
|**Stakeholder group**
**Why we engage**
**How we engage**
**Outcomes of engagement**
**Plans for 2025**|**Stakeholder group**
**Why we engage**
**How we engage**
**Outcomes of engagement**
**Plans for 2025**|**Stakeholder group**
**Why we engage**
**How we engage**
**Outcomes of engagement**
**Plans for 2025**|**Stakeholder group**
**Why we engage**
**How we engage**
**Outcomes of engagement**
**Plans for 2025**|
|---|---|---|---|
|We pride ourselves on working with the
best healthcare partners and consultants,
including the NHS, private medical insurers
(PMIs) and research experts. They are
aligned to our purpose to build a healthier
nation, and as a charity, our ethos is to
share research, experiences and resources
for the common good.
**HEALTHCARE**
**PARTNERS**|Provision of high quality services to our partners
and consultants
Liaise directly with local NHS trusts to deliver services and
support aligned to their needs
Regular meetings with PMIs to ensure we are providing
high quality outcomes for their customers
Local and national level communications with consultants,
including surveys, newsletters and face-to-face meetings
and quarterly sustainability forums.|Continue to work with local NHS trusts to encourage
referrals and develop ways to ease pressure on their
services, and help to bring down waiting lists
An increase in private medical insurance activity and
demand for self-pay services
Better communication with our consultants, resulting in
stronger relationships.|Continue to strengthen our relationship
with the NHS and use our capacity to
help address long waiting lists
Continue to work with our consultant
population to embed greener surgery
environmental plans across our hospitals
Support more NHS staf to return to
work after attending our free Joint Pain
Programme through our partnership.|
|||||
|We work with suppliers and partners who
share our vision and values, who can
support one or more of our strategic
ambitions, improve or add value to
our benefciary experience and align to
our environmental sustainability goals.
We build collaborative relationships with
educational institutions, charities and
regulators.
**SUPPLIERS AND**
**PARTNERS**|Ensure our supplier code of conduct is adhered to
Regular communication including our sustainability
newsletter
Monthly, quarterly or biannual review of progress against
performance and agreed KPIs
Collaborate with research partners to develop future
programmes and models of care in the community
Publish joint research and present at key conferences.|Reassurance that our supplier and partner selections
align with our goal of driving a positive impact on society
and the environment
Industry-leading research positions us as a thought leader
and trusted partner within the healthcare sector
Strengthens the case for evidence-based healthcare
To evaluate, improve and develop our services.|Continued engagement with our suppliers
to ensure alignment with our social
impact and sustainability goals including
the creation of a dedicated web page
Publish results from our STAMINA
research programme in partnership with
Shefeld Hallam University
Advancing work to develop new pathways
across multiple long-term conditions.|
|||||
|We engage with policymakers to help
shape a policy environment that enables
us to have the greatest impact on the
nation’s health. We have a unique role to
play in supporting the NHS, tackling health
inequalities, and improving access to care.
By infuencing policy, we can ensure that
national decisions take into account the
full value of what we ofer.
**GOVERNMENT**|Meetings with ministers, parliamentarians, and civil servants
Access through industry bodies including IHPN and
ukactive
Responding to key government and parliamentary calls
for evidence and consultation responses
Briefings that cover insights from our programmes and
academic research
Host visits to our sites delivering our transformative
programmes.|Built a strong and trusted relationship with the
Department of Health and Social Care
Established good links with Government ministers,
including through our partnership to deliver the Joint Pain
Programme to NHS staff
Secured at a senior level, the recognition that Nuffield
Health plays a meaningful role in improving the
nation’s health.|Infuence the government’s evolving
health and work agenda, ensuring our
programmes and insights help shape
national policy
Position Nufeld Health as a natural ally
to the NHS
Continue to raise our profle as a leader
in movement-based care, supporting the
Government’s prevention agenda.|
Nuffield Health Annual Report 2024
Section 172 statement
**37**
## Section 172 statement
Companies are required to include a statement in their Strategic Report on how directors have complied with their duty to have regard to the matters in section 172 (a) – (f) of the Companies Act 2006 (the Act). In accordance with the Charities SORP Information Sheet 3: The Companies (Miscellaneous Reporting) Regulations 2018 and UK Company Charities, the duty of the Trustees, as directors of a charitable company under subsection 172 of the Act is to act in a way he or she considers, in good faith, would be most likely to achieve its charitable purpose and in doing so have regard (among other matters) to:
- (a) the likely consequences of any decision in the long term
- (b) the interests of the company’s employees
- (c) the need to foster the company’s business relationships with suppliers, customers and others
- (d) the impact of the company’s operations on the community and the environment
- (e) the desirability of the company maintaining a reputation for high standards of business conduct
- (f) the need to act fairly between members of the company.
We the Trustees listen to and engage effectively with our wide variety of stakeholders on whom the future success of Nuffield Health depends, including employees, members, patients and suppliers, to ensure responsible decisions are sustainable in the long term and do not disproportionately affect any single stakeholder group. The examples show decisions taken by the Board in 2024, and how stakeholder views and feedback, as well as other section 172 considerations, were taken into account.
All decisions are made in the interests of the Charity’s stakeholders, in line with our values:
**Connected Aspirational Responsive Ethical**
## **Key Board decisions in 2024**
To approve the sale of Cancer Centre London (CCL) and Parkside Scanning Services LLP (PSS) to Icon Group, forming part of a broader oncology partnership to strengthen the Charity’s cancer care model. **Action taken** The Board requested and received numerous updates on the
The Board requested and received numerous updates on the partnership with Icon Group aimed at improving the provision of oncology services. Following extensive negotiations, recommendations were made by the Executive Committee to dispose of CCL and PSS as part of the Charity’s longer-term strategy for the provision of oncology services. The Board agreed with the proposal and approved the sale documentation and the funds received from the sale were reinvested in charitable initiatives.
## **Impact of the decision**
The transaction strengthened the Charity’s strategic alignment with Icon Group, with the partnership intending to expand the Charity’s oncology service offering, and provide patients increased access to high-quality oncology services provided in partnership with ICON across multiple Nuffield Health sites. The partnership structure is intended to provide the Charity with operational flexibility while maintaining financial sustainability through substantially lower investment requirements.
**S172 factors considered**
**Stakeholder groups affected**
**OUR PEOPLE PATIENTS AND MEMBERS HEALTHCARE PARTNERS**
Nuffield Health Annual Report 2024
Section 172 statement
**38**
To continue our pathway towards carbon net zero, the decision was made to change the delivery system of nitrous oxide, a potent medical anaesthetic gas, significantly reducing leakage into the atmosphere.
## **Action taken**
In 2024 the Board recognised the need to continue to make significant progress on the Charity’s carbon reduction targets including the agreeing to the proposal to change the way nitrous oxide anaesthetic gas is delivered to our theatres at all 36 hospitals. Consideration was given to the risks and opportunities of this operational change.
## **Impact of the decision**
The piped delivery system, from an external storeroom, through a piping system, into theatres at all sites was changed to nitrous oxide canisters on trollies, stored securely in theatres. We expect to see up to an 80% reduction in the usage of the gas, resulting in a decrease in carbon dioxide equivalent emitted. The Board continues to drive forward on further actions to reduce carbon emissions across the Charity.
To proceed with a Managed Equipment Services agreement with GE Healthcare to replace and modernise diagnostic imaging equipment across the Charity’s estate.
## **Action taken**
The Board recognised the need to invest in assets across the estate to ensure best in class provision of clinical services. After an extensive tender process, a preferred supplier was identified and the Board reviewed, provided feedback, and approved the commercial and legal terms of the agreement and received assurance through independent external reviews.
## **Impact of the decision**
The long-term agreement will enable the Charity to modernise a critical revenue generating suite of clinical equipment with greater flexibility, reduced cost, and operational efficiency. The model supports long-term sustainability and improved outcomes for patients and clinical teams.
**S172 factors considered**
**Stakeholder groups affected**
**OUR PEOPLE PATIENTS AND MEMBERS COMMUNITIES SUPPLIERS AND PARTNERS**
**S172 factors considered Stakeholder groups affected**
**OUR PEOPLE PATIENTS AND MEMBERS HEALTHCARE PARTNERS SUPPLIERS AND PARTNERS**
Nuffield Health Annual Report 2024
Trustees’ report
**----- Start of picture text -----**
39
**----- End of picture text -----**
Inside this section
Chair’s Trustees’ statement Our Board of Trustees
**40**
Our Board of Trustees **41** Our Executive Committee **42**
Structure, governance and management
**43**
## **Committee reports**
– Board Quality and Safety Committee
**45**
– Executive Remuneration and Succession Committee
**45**
– Finance and Investment Committee **45** – Board Audit and Risk Committee **45** – Trustees’ Nominations Committee **46** – Trustees’ Remuneration Committee **46** Trustees’ Trustees’ review of our objectives **47** Trustees’ responsibilities for the **47** financial statements report
Nuffield Health Annual Report 2024
Chair’s statement
**40**
## Chair’s Trustees’ statement
With Steve Gray’s retirement in June 2024 and Alex Perry not taking up his post until September, I moved into the role of Executive Chair during the intervening period. This was undoubtedly challenging, but it gave me the opportunity to view the organisation in a different way, and meet more of the teams that deliver our services and social impact programmes. I’m grateful to Patrick Figgis for taking on the mantle of Chair during this time, allowing me to focus on the day-to-day operations of the Charity as we went through a time of transition.
The role of the Board of Trustees is one of stewardship, and ensuring that a sound governance and risk managementoperating model is in place that allows the Board and the leadership team to act quickly and with clarity of thought and speed of action.
To confirm our governance structure was aligned with best practice for comparable companies and charities, we instigated a comprehensive review, taking into account the appointment of a new Chief Executive Officer, and changes to both the Board of Trustees and Executive Committee, combined with the new political landscape, which will affect healthcare provision and the NHS. We have started to implement findings of the review and will make further changes in 2025.
Trustee Steve Maslin will step down from the Board in July 2025, after eight years’ dedicated service. As Chair of the Board Audit and Risk Committee (BARC), he has provided clear and principled leadership, while consistently acting in the best interests of the Charity. I will miss his wise counsel. Following Steve’s departure, Lee Rochford, who joined the Board last year, will take on the role of Chair of BARC.
Visiting the team at Parkside Hospital.
**“ The role of the Board of Trustees is one of stewardship, and ensuring that a sound governance and risk managementoperating model is in place that allows the Board and leadership team to act with clarity of thought and speed of action.”**
Junaid Bajwa will also leave the Board in July 2025, after three years’ service, during which time he successfully chaired the Board Quality and Safety Committee (BQSC), ensuring that these matters were always at the forefront of our discussions.
To both Steve and Junaid I express my sincere thanks for their hard work and commitment during an extremely challenging time for Nuffield Health, and the healthcare industry as a whole. I’ve valued their experience, support and advice, and I wish them both all the very best for the future.
The quality of our people has always been the hallmark of Nuffield Health and my appreciation goes to everyone, in every corner of the Charity, for their unwavering commitment to our purpose to build a healthier nation. As we move into 2025, I look forward to working with Alex as he embeds our five strategic ambitions into our daily activity, and develops his newly formed Executive Committee.
In accordance with section 487 of the Companies Act 2006, the auditors, Deloitte LLP, are deemed to be reappointed for the next financial year.
Our Board of Trustees approved the Trustee’s Report on 26 June 2025, and I commend it to our members, reflecting our ongoing commitment to transparency, accountability, fairness, and the pursuit of excellence in all that we do.
Dr Natalie-Jane Macdonald MBE, Chair
Nuffield Health Annual Report 2024
Board of Trustees
**41**
## Our Board of Trustees
At the date the Annual Report and financial statements were approved, the following Trustees were in place:
**----- Start of picture text -----**
Q
**----- End of picture text -----**
**----- Start of picture text -----**
A P P O I N T E D F E B 2 0 1 7
**----- End of picture text -----**
**----- Start of picture text -----**
A P P O I N T E D S E P 2 02 1
**----- End of picture text -----**
**----- Start of picture text -----**
F R N
**----- End of picture text -----**
## **Dr Natalie-Jane Macdonald MBE**
## **Junaid Bajwa**
Chair, Board of Trustees
Chair of the Board Quality and Safety Committee
**----- Start of picture text -----**
Q A N F
A P P O I N T E D O C T 2 02 2 A P P O I N T E D O C T 2 02 1
**----- End of picture text -----**
## **Mark Stansfeld**
## **Elizabeth Robb OBE**
**----- Start of picture text -----**
A R N
**----- End of picture text -----**
## **Patrick Figgis**
Chair of the Executive Remuneration and Succession Committee, Chair of the Trustees’ Nominations Committee
**----- Start of picture text -----**
Q R N
**----- End of picture text -----**
## **Tracey Killen**
**----- Start of picture text -----**
A R
**----- End of picture text -----**
## **Steve Maslin**
Chair of the Board Audit and Risk Committee
**----- Start of picture text -----**
A
**----- End of picture text -----**
## **Karen Whitworth**
**----- Start of picture text -----**
F
**----- End of picture text -----**
## **Lee Rochford**
Chair of the Finance and Investment Committee
## **Board changes in 2024**
Neil Sachdev resigned in July 2024
**Click here to read more about our Trustees**
**----- Start of picture text -----**
Diversity of the Board
**----- End of picture text -----**
G E N D E R D I V E R S I T Y Male Female
T E N U R E
0-2 years 2-5 years 6+ years E T H N I C I T Y
COMMITTEES KEY: **Q** Board Quality and Safety **A** Board Audit and Risk **R** Executive Remuneration and Succession **N** Trustees’ Nominations **F** Finance and Investment
White Asian
Nuffield Health Annual Report 2024
Executive Committee
**42**
## Our Executive Committee
At the date the Annual Report and financial statements were approved, the following executives were in place:
## **Executive Committee changes in 2024**
Steve Gray stepped down as Chief Executive Officer in June James Murray resigned as Chief Customer & Strategy Officer in July
**Alex Perry Matthew Lynn** Chief Executive Officer Chief Finance Officer
## G E N D E R D I V E R S I T Y
**----- Start of picture text -----**
Male
Female
**----- End of picture text -----**
## **David Beresford**
Interim Chief Operations Officer - Hospitals
**Arthur Stephen** Chief Medical Officer
## **Dan Cyprus**
Commercial and Operations Development Director
**Alison McCourt CBE ARRC** Chief Clinical and Quality Officer
## **Kathryn Pritchard**
Chief People Officer
## **Iben Thomson**
Chief Legal and Governance Officer
## **Gurpreet Gujral**
Chief Operations Officer - Fitness and Wellbeing
**Jacqs Harper** Chief Digital Information Officer
## **Chris Gowland**
Chief Commercial Officer
Caroline Smith resigned as Chief Operating Officer – Quality & Operations in October
Amanda Lambert resigned as Chief Operating Officer – Central Services in November
Mary O’Reilly resigned as Chief Communication Officer in November
Alex Perry appointed Chief Executive Officer in September
David Beresford appointed Interim Chief Operations Officer - Hospitals in August
Arthur Stephen appointed Chief Medical officer in September
Iben Thomson appointed to the Executive Committee in October Jacqs Harper appointed Chief Digital Information Officer in October
Alison McCourt appointed Chief Clinical and Quality Officer in October.
Dan Cyprus appointed Commercial and Operations Development Director in October.
## **Executive Committee appointments in 2025**
Kathryn Pritchard, Chief People Officer, March 2025
Chris Gowland, Chief Commercial Officer, April 2025
Gurpreet Gujral, Chief Operations Officer, April 2025.
**Click here to read more about our Executives**
Nuffield Health Annual Report 2024
Structure, governance and management
**43**
## Structure, governance and management
Nuffield Health is a registered charity, incorporated under the Companies Acts 2006, being a company limited by guarantee without share capital. Its regulatory document is the Articles of Association. A Board of Trustees governs the Charity.
The Trustees are also Directors of the company and collectively constitute the Board, which is responsible for:
## • setting strategy
- ensuring that the necessary financial, human and physical assets are available to meet the strategic aims
- monitoring performance
- overseeing risk management
- setting the Charity’s values
- ensuring that public benefit and adherence to its charitable purpose sits at the heart of everything it does
- .
- • supporting and advising the Executive Committee
## **Trustees**
The Nominations Committee recommends candidates for appointment as Trustees. The Trustees serve for a period of three years, appointed at the Annual General Meeting (AGM) by a vote of the Charity Members. They are eligible to stand for re-election but are usually limited to serving a total aggregate of nine years. For more information on our Trustees’ areas of responsibility, see page 41.
## **Structure of the Board**
**----- Start of picture text -----**
B OA R D O F T R U S T E E S
Dr Natalie-Jane Macdonald
Chair
Steve Elizabeth Tracey Lee Karen Patrick Mark Dr Junaid
Maslin Robb OBE Killen Rochford Whitworth Figgis Stansfeld Bajwa
Board Quality and Board Audit and Executive Trustees’ Finance and Trustees’
Safety Committee Risk Committee Remuneration Nominations Investment Remuneration
and Succession Committee Committee Committee
Committee
E X E C U T I V E T E A M
Alex Perry
CEO
Alison McCourt Arthur Matthew Kathryn Jacqs Iben David Gurpreet Chris
Dan Cyprus
CBE ARRC Stephen Lynn Pritchard Harper Thomson Beresford Gujral Gowland
Chief Clinical Chief Chief Chief Chief Digital Chief Legal Interim Chief Chief Chief Commercial
and
and Quality Medical Finance People Information and Operations Operations Commercial
Operations
Officer Officer Officer Officer Officer Governance Officer Officer Officer
Development
Officer - Hospitals - F & W Director
**----- End of picture text -----**
## **Charity Members**
As a registered charity, and a company limited by guarantee without share capital, Nuffield Health does not have shareholders. Instead, it has Charity Members who act as nominal guarantors, with liability limited to £1 in the event that the company should ever be wound up. Charity Members have a constitutional role fundamental to Nuffield Health’s governance and accountability.
Being a Charity Member is an unpaid position, and gives no entitlement to receive any profits or assets from Nuffield Health. Charity Members are entitled to vote at the AGM, where accounts are approved and Trustees are elected, and they are kept informed about the Charity’s progress throughout the year. Current membership includes former employees and Trustees, consultants, academics and supporters of the Charity and its objectives. A number of Charity Members are on the Trustees Remuneration Committee.
## **Committees**
The Trustees serve on one or more of the Board Committees and may attend any other Board Committee meeting if they wish. The Board delegates specific responsibilities to the Committees, which are shown on pages 45-46, and they provide counsel, expertise and support to the Executive Committee. The performance of the Committees is regularly evaluated to support continual improvements in the governance of the Charity.
Nuffield Health Annual Report 2024
Structure, governance and management
**44**
|**2024 Board attendance**||||Executive||
|---|---|---|---|---|---|
||||Board Quality|Remuneration|Finance and|
||Board of|Board Audit and|and Safety|and Succession|Investment|
||Trustees|Risk Committee|Committee|Committee|Committee|
|Number of meetings in 2024|14|8|4|7|6|
|**Numbers attended**||||||
|Dr Natalie-Jane Macdonald (Chair)|14|3|–|6|6|
|Steve Maslin|12|8|–|7|–|
|Patrick Figgis|12|8|–|7|–|
|Dr Junaid Bajwa|13|–|4|–|–|
|Mark Stansfeld|11|–|–|–|5|
|Elizabeth Robb OBE|14|8|4|–|–|
|Tracey Killen|11|–|3|6|–|
|Lee Rochford|13|7|–|–|6|
|Karen Whitworth|13|8|–|–|–|
|Neil Sachdev MBE||||||
|(served until July 2024, attending 8/8 Board of Trustees meetings)|8|–|–|–|2|
## **Board of Trustees**
Supporting this, the governance structures of the organisation ensure that decisions made at all levels align with our obligations as a charity. In light of the ongoing economic environment, we have been particularly mindful of our financial commitments and ensuring long-term sustainability to continue providing public benefit long into the future.
In 2024, the Board of Trustees met 14 times, including three extra-ordinary board meetings with a comprehensive schedule of work focused on:
- guiding the Charity’s continuing focus on its charitable objectives and ensuring public benefit
- the long-term strategy of Nuffield Health
In 2024, we continued our focus on high quality care and outcomes. Supported by the Board Quality and Safety Committee (BQSC), the Board of Trustees assessed ongoing improvement plans to enhance processes, management and culture.
- reviewing new opportunities to further extend the Charity’s public benefit
- continuous improvements in quality, outcomes and patient safety
- enhancing the Charity’s governance and assurance
- guiding the Charity’s response to external factors.
The Trustees are all experienced Non-Executive Directors, and they are regularly updated on relevant legal and regulatory matters pertaining to the Charity and its activities. The Charity has a comprehensive induction programme for new Trustees, providing meaningful insights into the Charity’s objectives, and the requirements relating to public benefit, operations and governance. We provide
In 2024, Nuffield Health continued to work under its clear strategic framework following a comprehensive review in 2021. Our strategy will ensure continued success and enable the Charity to deliver on its purpose to build a healthier nation.
an ongoing programme of training – for example, in charity law, cyber training and safeguarding – as well as online mandatory training. For important events since the end of the financial year, see note 35 on page 82.
## **Engaging with our stakeholders**
Our Board of Trustees believes that, throughout the year, it acted in a way that is most likely to promote the success of the Charity for the benefit of all stakeholders and in accordance with our purpose and values (see Section 172 statement on page 37).
The Board of Trustees has identified that our stakeholders are as described on pages 35-36 of this report. The table shows how we engaged with our stakeholders and the outcomes of these interactions during 2024. Regular reports are submitted to the Board of Trustees in respect of each stakeholder group, so that it is well informed about progress and any areas of concern. The Trustees take into account the interests of our stakeholders when making decisions or recommending actions to the Executive Committee.
The Board of Trustees has ensured that the Charity has in place appropriate policies that foster an environment of inclusion for our people. The Charity embraces the Equality Act and ensures that all applicants and employees (for example those with disabilities) are treated fairly and in line with the Charity’s values. This applies when individuals are applying for roles and during their employment, including training, promotions and supporting their career development. In the event of an employee becoming disabled, every effort is made and reasonable adjustments are considered with a view to ensuring that their employment continues and their training and development is unaffected.
## **Board review of compliance with the Modern**
## **Slavery Act 2015**
In accordance with our values and commitment to acting ethically and with integrity in all our relationships, the prevention, detection and reporting of modern slavery and human trafficking is the responsibility of our employees,
our suppliers and any associated organisations. Based on our 2024 review of supply chain due diligence, we remain satisfied that our key suppliers and associates have appropriate anti-slavery policies in place.
## **Qualifying third-party indemnity provisions**
During the financial year, qualifying third-party indemnity provisions (as defined by section 234 of the Companies Act 2006) were in force for the benefit of the Trustees of the Charity. These provisions were in place throughout the year and remain in force at the date of this report.
The indemnity is in respect of liabilities incurred by the Trustees in connection with the performance of their duties, to the extent permitted by law. The Charity also maintains directors’ and officers’ liability insurance which gives appropriate cover for legal actions brought against its Trustees.
## **Reserve policy**
The Trustees scrutinise the financial sustainability of the Charity through regular reviews of cash forecasts and budgets, and do not set a reserve target. We aim to use the majority of surplus cash to invest in operational assets and infrastructure that improve the quality of, or increase, the Charity’s activities for public benefit. It is therefore expected that free reserves will not be created at this stage. Further information on the Group’s funds, including the revaluation surplus is disclosed in the movement in funds section on page 10 of the Chief Finance Officer statement.
## Trustee responsibility for good governance was a
continuing theme of the Charity Commission during the year, and the Board remains mindful of its responsibilities. The Charity took significant steps to further strengthen the governance and assurance processes around both financial sustainability and the clinical aspects of the Charity’s work.
In addition to financial results, the Trustees monitor a range of KPIs to assess success. These include the amount of people we reach, the social value we deliver when considering our wider impact on society, our gender pay gap and reduction in carbon emissions. See page 13.
Nuffield Health Annual Report 2024
Structure, governance and management
**45**
## Committee reports
## **Board Quality and Safety Committee (BQSC)**
## Chair: Dr Junaid Bajwa
Committee members
Elizabeth Robb MBE Tracey Killen
## **Main activities of 2024**
The Board Quality and Safety Committee (BQSC) provides internal quality control assurance by monitoring and reviewing the effective operation of clinical governance throughout the Charity, considering clinical risk, and health and safety matters, maintaining statutory and regulatory oversight and driving a sound quality culture, in line with the Charity’s core values and behaviours.
During the year, the Committee has driven a more in-depth view and oversight across all elements of Quality including health and safety and property; this included strengthening the consideration of risk across both Board Audit & Risk Committee and BQSC.
The Committee continued to drive the Freedom to Speak up and Safety Culture agenda including the appointment of a non-executive to act as the Employee Engagement Designated Governor.
To continue to embed the Patient Safety Incident Response Framework our Patient Safety Partner was invited to become a permanent attendee of the meetings to provide the patient perspective.
## **Finance and Investment Committee (FINCOM)**
## Chair: Lee Rochford
## Committee members
Dr Natalie-Jane Macdonald Mark Stansfeld Neil Sachdev (served until July 2024)
## **Main activities of 2024**
The Finance and Investment Committee Forum (FINCOM) provides the Board of Trustees with assurance on key areas of financial commitments, including financing arrangements, financial performance updates and requests or developments on any substantial investments.
## **Financial reporting**
The Committee reviewed regular updates on how the Charity was progressing against forecast in terms of financial performance such as EBITDA and headroom with a focus on longer-term financial sustainability. It considered any substantial investments including longer-term commitments with suppliers and refinancing arrangements. The Committee challenged papers ensuring they had robust calculations and considered longer-term strategies.
At each meeting, the Committee received reports from management on each investment request. It conducted focused reviews in the following areas:
- Financing arrangements
- Property revaluation reports
- Significant business investments
- Post investment reviews of past investments.
The Committee reviewed the 2024 investment strategy and financial sustainability, ensuring the longer-term planning of any requested investment was fully considered.
## **Board Audit and Risk Committee (BARC)**
## Chair: Steve Maslin
Committee members Patrick Figgis Karen Whitworth Elizabeth Robb MBE
## **Main activities of 2024**
The Board Audit and Risk Committee (BARC) provides the Board of Trustees with assurance on key areas of financial reporting, audit, financial policy, risk and counter-fraud.
The Committee reviewed the draft Annual report and accounts and recommended approval to the Board. It considered key audit and accounting judgements, including impairment, adjusting items and going concern. The Committee challenged financial modelling and mitigation strategies and was satisfied appropriate rigour had been applied. It also reviewed and approved the Annual report.
At each meeting, the Committee received reports from management on Principal Risks, internal control, counter fraud and whistleblowing. It conducted focused reviews in the following areas: cyber security; financial sustainability; project governance and control environment; and asset risk and business continuity.
The Committee approved the 2024 Internal Audit Plan and reviewed progress on key activity, including controls, onboarding, business continuity and Freedom to Speak Up. It supported development of the internal audit model and reviewed risk appetite levels and assurance mapping aligned to Principal Risks, alongside regular meetings with external auditors.
## **Trustees’ Nominations Committee**
## Chair: Patrick Figgis
## Committee members
Dr Natalie-Jane Macdonald Tracey Killen Mark Stansfeld
## **Main activities of 2024**
The purpose of the Committee is to consider Trustee recommendations for appointment to membership of the Charity. Only two Charity Members may be appointed as Trustees.
With the retirements of Neil Sachdev in 2024, and Steve Maslin and Dr Junaid Bajwa as Trustees in July 2025, the Committee will be responsible for reviewing replacement candidates and making recommendations to the Board. In 2024, the Committee were responsible for the process of recruiting new CEO, Alex Perry.
The Committee appoints external recruitment consultants to help ensure the Charity has a diverse and high-quality range of potential candidates to choose from.
Nuffield Health Annual Report 2024
Structure, governance and management
**46**
## **Executive Remuneration and Succession Committee (ERSC)**
## Chair: Patrick Figgis
## Committee members
Dr Natalie-Jane Macdonald Steve Maslin Tracey Killen
## **Main activities of 2024**
The Committee undertook its annual review of executive remuneration to ensure total packages—comprising base salary, pension contributions, performance-based bonuses, and organisation-wide benefits—remained competitive while aligning with the charity’s not-for-profit status.Pay ranges were benchmarked by an external authority.
The performance of the Executive Committee was reviewed in depth, with attention paid not only to objective delivery but also to cultural and behavioural contributions. Both individual and collective team performance were considered. Following this assessment, the Committee awarded bonuses for FY2023 to the Chief Executive Officer and Executive Committee. However, the distribution was set below the scheme’s maximum to enable a fairer and more consistent allocation across the wider senior management population.
In respect to FY2024’s performance, the Committee assessed that whilst progress had been made in the year, this performance did not support the payment of performance related bonuses to the Chief Executive Officer and the Executive Committee in FY2025 and aligned to the non-payment of bonuses to senior management.
The Committee also reviewed future reward strategy, to shape appropriate short- and long-term incentive plans. As a result, the Committee agreed new bonus and longterm incentive plans for executives and senior management.
Succession planning remained a key focus, with significantprogress made during the year. A new Chief Executive Officer was appointed, along with key additions to the Executive Committee, ensuring strong leadership capacity for the Charity’s future.
## **Trustees’ Remuneration Committee**
## Chair: Dame Denise Holt
## Committee members
George Fergusson (retired in 2025) Guy McCracken
## **Main activities of 2024**
The Committee is made up of Charity Members and meets annually to review Trustee performance and discuss Trustees’ remuneration and whether it is commensurate with the level of duties and responsibilities imposed by the nature and activities of the Charity in line with Charity Commission guidance. The level of remuneration and any adjustment is benchmarked thoroughly in accordance to the Articles of Association of the Charity against a number of factors, including similar external roles. Details of the fees paid to the Trustees are shown within the financial statements under note 10 on page 68.
In 2024 the Committee agreed the Trustees remuneration be fixed for a three-year period. An annual review will continue to assess the economic context and ensure continued alignment with the Committee’s terms of reference, with discretion to adjust if necessary.
Nuffield Health Annual Report 2024
Structure, governance and management
**47**
- Trustees’ review of our objectives and responsibilities for the financial statements
## **Review of our objectives**
In 2024, the Trustees reviewed the Charity’s objectives, its activities, and the degree to which its services are made accessible to the public. This is all part of our charitable purpose, which we articulate simply as to build a healthier nation.
This review examined the Charity’s achievements, and the outcomes of its activities over the previous 12 months, together with the benefits delivered to the users of our Charity’s services. The Trustees’ review also ensures that the Charity remains focused on, and has due regard to, providing public benefit.
The Trustees continue to give careful consideration to the Charity Commission’s guidance on public benefit – in particular, for fee-charging charities. The Trustees considered the level of access and affordability of all the Charity’s services, across its sites, to each section of the population, particularly people living with lower resources.
We have developed specific initiatives to widen access for diverse communities and to expand our reach to those who could not normally afford our services. By the end of 2024, over 99,700 people had benefited from our free social impact programmes. Our Joint Pain Programme was delivered in all of our 110 fitness and wellbeing centres, while our virtual Long-COVID Programme continued to support those not within commuting distance of our centres.
We are working collaboratively with other organisations, such as the Faculty of Sports and Exercise Medicine, to remove barriers to exercise and to encourage more people living with long-term conditions to use movement to improve their health and wellbeing, through our free rehabilitation programmes.
Nuffield Health has policies in place to clarify, internally and
externally, how we deliver benefits to the public in order to fulfil our charitable objectives. These include:
- limiting revenues from ancillary activities to no more than 10% of the total turnover of the Charity
- establishing guidelines to judge ancillary or fundraising
- activities, ensuring they are directly related to, and necessary for, carrying out the Charity’s purpose
- a requirement that no activities are detrimental or harmful.
The Trustees’ responsibility to deliver our charitable purpose is only possible if the Charity has sufficient cash and loan facilities to continue in operational existence. Cash flow forecasts are prepared regularly. Following their review, the Trustees have a reasonable expectation that the Charity has adequate resources to continue to operate for the foreseeable future (being at least 12 months from the date of approval of these financial statements). This takes into consideration risks contained in the forecasts and, for this reason, the Trustees continue to adopt the going concern basis in preparing the financial statements. Further detail on going concern is disclosed on page 10 of the Strategic Report.
The Trustees have concluded that the objectives of the Charity remain focused on public benefit. In addition, the Trustees are confident that plans scheduled for 2025 will further enhance the accessibility of the Charity’s activities to people living on lower resources. They are also satisfied that the activities of the Charity are overwhelmingly carried out to fulfil its charitable objectives, that no activities are inconsistent with its objectives, and that the Charity meets the requirements of the policies described.
## **Responsibilities for the financial statements**
For the purposes of company law, our Trustees are also Directors of Nuffield Health. They are responsible for preparing the Strategic Report, the Trustees’ Report and the financial statements. Company law requires the Trustees to prepare financial statements for each financial year, in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law), including FRS 102, ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland’.
Under company law, Trustees must not approve the financial statements unless satisfied they give a true and fair view of the state of affairs of the Charity and its subsidiaries, and of the incoming resources and application of resources, including income and expenditure for that period.
In preparing these financial statements, the Trustees are required to:
- select suitable accounting policies and apply them consistently
- observe the methods and principles in the Charity’s Statement of Recommended Practice (FRS 102)
- make reasonable and prudent judgements and accounting estimates
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements
- prepare the financial statements on the going concern basis, unless it is inappropriate to presume that the Charity will continue in business.
The Trustees are responsible for keeping adequate records that are sufficient to show and explain the transactions of the Charity and its subsidiaries, and disclose the financial position of all entities, with reasonable accuracy at any time. They must ensure the financial statements comply with the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005, the Charities Accounts (Scotland) Regulations 2006 (as amended) and the provision of the Charity’s Articles of Association.
The Trustees are responsible for safeguarding the assets of the Charity, and for taking reasonable steps for the prevention and detection of fraud and other irregularities. The Trustees confirm that:
- so far as each Trustee is aware, there is no relevant audit information of which the Charity’s auditor is not aware
- all steps have been taken to make the Trustees aware of any relevant audit information and establish that the auditor is aware of that information.
The Trustees are responsible for the maintenance and integrity of the corporate and financial information included on the Charity’s website. UK legislation governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.
The Trustee’s report which includes the Director’s Report and Strategic Report has been approved by the Board of Trustees on 26 June 2025, and is signed on its behalf by
Dr Natalie-Jane Macdonald MBE, Chair
**Independent** Aa **uditor’s** reportReport
**----- Start of picture text -----**
48
**----- End of picture text -----**
Nuffield Health Annual Report 2024
- Independent auditor’s report
Nuffield Health Annual Report 2024
Independent auditor’s report
**49**
## Independent Auditor’s Report to the Charity Members and Trustees of Nuffield Health
## **Report on the audit of the financial statements**
- the Consolidated and Charity balance sheets;
- the Consolidated cash flow statement;
## **Opinion**
- the accounting policies; and
In our opinion the financial statements of Nuffield Health (the ‘charitable company’) and its subsidiaries (the ‘Group’):
- the related notes 1 to 35.
The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (United Kingdom Generally Accepted Accounting Practice).
- give a true and fair view of the state of the Group’s and the parent charitable company’s affairs as at 31 December 2024 and of the Group’s and parent charitable company’s incoming resources and application of resources, including its income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice, including Financial Reporting Standard 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland”; and
## **Basis for opinion**
We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the auditor’s responsibilities for the audit of the financial statements section of our report.
- have been prepared in accordance with the requirements of the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and regulations 6 and 8 of the Charities Accounts (Scotland) Regulations 2006.
We are independent of the Group and of the parent charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the Financial Reporting Council’s (the ‘FRC’s’) Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.
We have audited the financial statements which comprise:
- the Consolidated income statement;
- the Consolidated and Charity statement of financial activities;
## **Conclusions relating to going concern**
In auditing the financial statements, we have concluded that the Trustees’ use of the going concern basis of accounting in the preparation of the financial statements is appropriate.
Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Group’s and parent charitable company’s ability to continue as a going concern for a period of at least 12 months from when the financial statements are authorised for issue.
Our responsibilities and the responsibilities of the Trustees with respect to going concern are described in the relevant sections of this report.
## **Other information**
The other information comprises the information included in the Annual report, other than the financial statements and our auditor’s report thereon. The Trustees are responsible for the other information contained within the Annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.
Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.
We have nothing to report in this regard.
## **Responsibilities of Trustees**
As explained more fully in the Trustees’ responsibilities statement, the Trustees (who are also the directors of the charitable company for the purpose of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the Trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.
In preparing the financial statements, the Trustees are responsible for assessing the Group’s and the parent charitable company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Trustees either intend to liquidate the Group or the parent charitable company or to cease operations, or have no realistic alternative but to do so.
## **Auditor’s responsibilities for the audit of the financial statements**
We have been appointed as auditor under section 44(1) (c) of the Charities and Trustee Investment (Scotland) Act 2005 and the Companies Act 2006 and report in accordance with those Acts and relevant regulations made or having effect thereunder.
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.
A further description of our responsibilities for the audit of the financial statements is located on the FRC’s website
Nuffield Health Annual Report 2024
Independent auditor’s report
**50**
at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor’s report.
## **Extent to which the audit was considered capable of detecting irregularities, including fraud**
Irregularities, including fraud, are instances of noncompliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below.
We considered the nature of the Group’s industry and its control environment, and reviewed the Group’s documentation of their policies and procedures relating to fraud and compliance with laws and regulations. We also enquired of management and the trustees about their own identification and assessment of the risks of irregularities, including those that are specific to the Group’s business sector.
We obtained an understanding of the legal and regulatory frameworks that the Group operates in, and identified the key laws and regulations that:
- had a direct effect on the determination of material amounts and disclosures in the financial statements. These included UK Charities Act, UK Companies Act, pensions legislation and tax legislation; and
• do not have a direct effect on the financial statements but compliance with which may be fundamental to the Group’s ability to operate or to avoid a material penalty. These included the Group and charitable company’s operating licence, the Charity Commission for England and Wales (Charity Commission) regulations, Office of the Scottish Charity Regulator (OSCR) regulations, Care Quality Commission regulations, Health and Social Care Act 2008 (Regulations 9-20), Health and Safety Executive (HSE), Professional Standards Authority (PSA), Local Authority/Food Standards Agency, Healthcare Improvement Scotland (HIS), Healthcare Inspectorate Wales (HIW), Medicines and Healthcare products
Regulatory Agency (MHRA), Human Fertilisation and Embryology Authority (HFEA), General Pharmaceutical Council (GPhC) and Office for Standards in Education, Children’s Services and Skills (Ofsted).
We discussed among the audit engagement team and relevant internal specialists such as pensions, real estate, valuations and IT regarding the opportunities and incentives that may exist within the organisation for fraud and how and where fraud might occur in the financial statements.
As a result of performing the above, we identified the greatest potential for fraud in the determination of whether an expenditure is capital in nature, in particular for additions to assets under construction and software fixed assets. Our procedures performed to address this included testing the capitalised expenditure on a sample basis to assess whether the costs met the relevant accounting requirements to be recognised as capital in nature.
- In common with all audits under ISAs (UK), we are also required to perform specific procedures to respond to the risk of management override. In addressing the risk of fraud through management override of controls, we tested the appropriateness of journal entries and other adjustments; assessed whether the judgements made in making accounting estimates are indicative of a potential bias; and evaluated the business rationale of any significant transactions that are unusual or outside the normal course of business.
- In addition to the above, our procedures to respond to the risks identified included the following:
- reviewing financial statement disclosures by testing to supporting documentation to assess compliance with provisions of relevant laws and regulations described as having a direct effect on the financial statements;
- performing analytical procedures to identify any unusual or unexpected relationships that may indicate risks of material misstatement due to fraud;
- enquiring of management and in-house legal counsel concerning actual and potential litigation and claims,
and instances of non-compliance with laws and regulations; and
- reading minutes of meetings of those charged with governance and reviewing internal audit reports.
## **Report on other legal and regulatory requirements**
## **Opinions on other matters prescribed by the Companies Act 2006**
In our opinion, based on the work undertaken in the course of the audit:
- the information given in the Trustees’ report (Directors’ report), which includes the Strategic Report prepared for the purposes of company law for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the Strategic Report and Trustees’ report (Directors’ report) have been prepared in accordance with applicable legal requirements.
In the light of the knowledge and understanding of the Group and parent charitable company and their environment obtained in the course of the audit, we have not identified any material misstatements in the strategic report or the directors’ report included within the trustees’ report.
## **Matters on which we are required to report by**
## **exception**
Under the Companies Act 2006 and the Charities Accounts (Scotland) Regulations 2006 we are required to report in respect of the following matters if, in our opinion:
- adequate and proper accounting records have not been kept by the parent charitable company, or returns adequate for our audit have not been received from branches not visited by us; or
- the parent charitable company financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of trustees’ remuneration specified
## by law are not made; or
- we have not received all the information and explanations we require for our audit.
- We have nothing to report in respect of these matters.
## **Use of our report**
This report is made solely to the charitable company’s members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006 and to the charitable company’s Trustees, as a body, in accordance with section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005 and regulation 10 of the Charities Accounts (Scotland) Regulations 2006 (as amended). Our audit work has been undertaken so that we might state to the charitable company’s members and trustees those matters we are required to state to them in an auditor’s report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company, the charitable company’s members as a body and the charitable company’s Trustees as a body for our audit work, for this report, or for the opinions we have formed.
## Helen Burridge
(Senior statutory Auditor) For and on behalf of Deloitte LLP Statutory Auditor London, UK
## 26 June 2025
Deloitte LLP is eligible for appointment as auditor for the Charity by virtue of its eligibility for appointment as audit of a company under section 1212 of the Companies Act 2006.
Nuffield Health Annual Report 2024
Financial statements **51**
Inside this section
# Financial statements
Consolidated income statement
Consolidated and Charity statement of financial activities
Consolidated and Charity balance sheets
Consolidated cash flow statement Accounting policies Notes to the financial statements
**52**
**52**
**53**
**54 54 61**
Nuffield Health Annual Report 2024
Financial statements
**52**
## Consolidated income statement
## for the year ended 31 December 2024
||||||2024||2023||
|---|---|---|---|---|---|---|---|---|
||||Note||£m||£m||
||||||||||
|Turnover – unrestricted|||2||1,450.4||1,356.5||
|Turnover – restricted|||2||2.7||1.6||
|Cost of services|||||(1,259.4)||(1,174.3)||
|Gross surplus|||||193.7||183.8||
|Support costs|||||(208.4)||(201.5)||
||Operating surplus/(deficit) before adjusting items||||0.5||(0.8)||
||Adjusting items||5||(15.2)||(16.9)||
|Total operating (deficit) before interest and tax|||||(14.7)||(17.7)||
||Adjusted for:||||||||
||Depreciation and amortisation||13, 14||91.4||79.2||
||Adjusting items||5||15.2||16.9||
||Adjusted earnings before interest, tax, depreciation and amortisation||||91.9||78.4||
||Net interest payable and similar costs||7||(21.7)||(46.3)||
||(Deficit) before taxation||||(36.4)||(64.0)||
||Tax on surplus/(deficit)||12||–||–||
||(Deficit) after tax for the financial year||||(36.4)||(64.0)||
||(Deficit)/surplusattributable to:||||||||
||Charity||||(36.5)||(64.1)||
||Non-controlling interests||33||0.1||0.1||
## All amounts derive from continuing activities.
The Consolidated income statement includes all gains and losses other than those arising from actuarial gains or losses on defined benefit retirement schemes and other post-retirement benefits and changes in the fair value of land and buildings. These items are presented in the Consolidated and Charity statement of financial activities on the right.
- The accounting policies and notes on pages 54 82 form part of these financial statements.
## Consolidated and Charity statement of financial activities
for the year ended 31 December 2024
|for the year ended 31 December 2024||
|---|---|
|Note|Group total funds*
Charity total funds*|
||2024
£m
2023
£m
2024
£m
2023
£m|
|Income and endowments from
Charitable activities
2
Other trading activities
2
Other income – restricted
2
Gain on disposal of tangible assets
2|1,418.8
1,333.0
1,418.8
1,333.0
31.6
23.5
–
–
2.7
1.6
2.7
1.6
–
–
1.6
2.2|
|Total income and endowments|1,453.1
1,358.1
1,423.1
1,336.8|
|Expenditure on charitable activities
Other expenditure before adjusting items
3
Adjusting items
5
Interest payable and similar costs
7
Other expenditure
Other trading activities|(1,422.2)
(1,332.7)
(1,422.2)
(1,332.7)
(15.2)
(16.9)
(23.1)
(16.9)
(21.7)
(46.3)
(29.2)
(36.7)
(30.4)
(26.2)
–
–|
|Total expenditure|(1,489.5)
(1,422.1)
(1,474.5)
(1,386.3)|
|Net expenditure
Before adjusting items
Adjusting items
5|(21.2)
(47.1)
(28.3)
(32.6)
(15.2)
(16.9)
(23.1)
(16.9)|
|Net expenditure|(36.4)
(64.0)
(51.4)
(49.5)|
|Other movement in funds
Actuarial gain/(loss) on defined benefit retirement scheme
8
Gain on revaluation of land and buildings
14|15.0
(0.9)
8.6
(1.2)
4.4
1,250.5
4.4
1,115.5|
|Net movement in funds|(17.0)
1,185.6
(38.4)
1,064.8|
|Fund balances at 1 January|1,081.2
(104.4)
932.5
(132.3)|
|Fund balances at 31 December|1,064.2
1,081.2
894.1
932.5|
|Net movement in funds attributable to non-controlling interest
33|0.1
0.1
–
–|
* Total funds for the Group and Charity include restricted funds of £0.8 million (2023 – £0.8 million) and permanent endowments of £0.1 million (2023 – £0.1 million).
All amounts derive from continuing activities. Other trading activities derive from the activities of Mythbreaker Ltd, Cancer Centre London LLP and Parkside IHL Scanning Services LLP.
- The accounting policies and notes on pages 54 82 form part of these financial statements.
Nuffield Health Annual Report 2024
Financial statements
**53**
## Consolidated and Charity balance sheets
for the year ended 31 December 2024
|Note|Group
Charity|
|---|---|
||2024
£m
2023
£m
2024
£m
2023
£m|
|Fixed assets
Intangible assets
13
Tangible assets
14
Post-retirement defined benefit assets
8
Investments
15|77.3
86.8
78.0
87.0
1,611.5
1,659.6
1,611.5
1,659.6
2.2
2.8
35.0
23.2
0.2
0.2
36.1
36.1|
||1,691.2
1,749.4
1,760.6
1,805.9|
|Current assets
Stock
16
Debtors
17
Cash at bank
30|16.5
18.1
16.4
16.9
123.5
128.9
125.7
130.1
10.3
12.0
4.7
6.7|
||150.3
159.0
146.8
153.7|
|Creditors: amounts falling due within one year
18
Net current liabilities|(223.1)
(240.6)
(269.8)
(282.6)
(72.8)
(81.6)
(123.0)
(128.9)|
|Total assets less current liabilities
Creditors: amounts falling due after more than one year
19
Provisions for liabilities
22|1,618.4
1,667.8
1,637.6
1,677.0
(459.1)
(462.7)
(664.7)
(657.1)
(73.9)
(83.0)
(73.9)
(83.0)|
|Net assets excluding post-retirement liabilities
Post-retirement defined benefit liabilities
8|1,085.4
1,122.1
899.0
936.9
(21.2)
(40.9)
(4.9)
(4.4)|
|Net assets|1,064.2
1,081.2
894.1
932.5|
|Income funds
Restricted funds surplus
1
Unrestricted funds:
General fund (deficit)
25
Post-retirementreserve (deficit)/surplus
25
Revaluation reserve surplus
25|0.8
0.8
0.8
0.8
(155.0)
(132.7)
(240.4)
(202.7)
(19.0)
(38.1)
30.1
18.8
1,236.6
1,250.5
1,103.5
1,115.5|
|Total unrestricted funds surplus|1,062.6
1,079.7
893.2
931.6|
|Total income funds surplus
Permanent endowment
1, 23|1,063.4
1,080.5
894.0
932.4
0.1
0.1
0.1
0.1|
|Funds surplus attributable to the Charity|1,063.5
1,080.6
894.1
932.5|
|Non-controlling interest
33|0.7
0.6
–
–|
|Group Funds surplus
1|1,064.2
1,081.2
894.1
932.5|
- The accounting policies and notes on pages 54 82 form part of these financial statements.
Approved and issued by the Board of Trustees on 26 June 2025.
## Dr Natalie-Jane Macdonald Alex Perry Chair Chief Executive Officer
Company number 00576970. Charity number in England and Wales 205533. Charity number in Scotland SCO41793.
Nuffield Health Annual Report 2024
Financial statements
**54**
## Consolidated cash flow statement
for the year ended 31 December 2024
|||||2024||2023|
|---|---|---|---|---|---|---|
|||Note||£m||£m|
||||||||
|Cash generated from operating activities|||||||
|Before adjusting items||26||86.3||59.7|
|Adjusting items||26||–||(4.7)|
|||26||86.3||55.0|
|Cash flows from investing activities||27||(42.2)||(53.6)|
|Cash flows from financing activities||28||(50.8)||(10.6)|
|Net decrease in cash and cash equivalents||||(6.7)||(9.2)|
|Cash and cash equivalents at 1 January||||(1.0)||8.2|
|Cash and cash equivalents at 31 December||30||(7.7)||(1.0)|
|Reconciliation of net cash flow to movement in net debt|||||||
|Decrease in cash and cash equivalents for the financial year||||(6.7)||(9.2)|
|Cash outflow/(inflow) from changes in debt||||15.9||(20.2)|
|Cash (inflow) from changes in finance leases||||1.7||(0.7)|
|Cash movement in net debt in the financial year||29||10.9||(30.1)|
|Non-cash movement in net debt in the financial year||29||(5.9)||(7.9)|
|Net debt at 1 January||29||(478.2)||(440.2)|
|Net debt at 31 December||29||(473.2)||(478.2)|
- The accounting policies and notes on pages 54 82 form part of these financial statements.
## Accounting policies
for the year ended 31 December 2024
## **1. Company information**
The ultimate controlling party of the Group is Nuffield Health (Company number 00576970, Charity number in England and Wales 205533, Charity number in Scotland SCO 41793) a company limited by guarantee without share capital incorporated in the United Kingdom and registered in England and Wales. These consolidated financial statements represent the largest and smallest group in which the results of Nuffield Health are consolidated. The registered office is Epsom Gateway, Ashley Avenue, Epsom, Surrey, KT18 5AL. In the event of the Charity being wound up, the liability in respect of the guarantee is limited to £1 per Charity Member. There were 65 Charity Members on 31 December 2024.
## **2. Basis of preparation**
The financial statements have been prepared in accordance with UK accounting standards, including FRS 102 and the Charities SORP (FRS 102) ‘Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland’ (FRS 102), and the Companies Act 2006. The financial statements have been prepared on the historical cost basis except as modified to include the fair value basis for certain fixed assets, certain financial instruments and post-retirement defined benefits. The accounting policies adopted are consistent with those applied in the previous financial year, unless otherwise stated. The revaluation model for land and buildings was prospectively adopted by the Group on 31 December 2023.
Nuffield Health is a public benefit entity as defined by FRS 102.
The financial statements are prepared in Sterling, which is the functional currency of the Charity and all subsidiary entities in the Group, and rounded to the nearest hundred thousand.
The Charity has taken advantage of the reduced disclosure provisions of FRS 102 ‘The Financial Reporting Standard applicable to the United Kingdom and Republic of Ireland’ (FRS 102) and not disclosed its cash flow statement.
## Upcoming changes to FRS 102
The Financial Reporting Council (FRC) has issued
amendments to FRS 102 as part of its 2024 periodic review, with the revised standards becoming effective for accounting periods beginning on or after 1 January 2026. These changes include significant updates to lease accounting and revenue recognition, aligning more closely with international standards. The Group is currently assessing the potential impact of these amendments and will appropriately implement the changes to the Standard in advance of the effective date.
## **3. Going concern**
The Trustees have assessed the Group’s ability to continue as a going concern for a period of 18 months from the date of approval of the financial statements, taking into account the repayment of the additional £30 million facility due in August 2026. This assessment period extends to the end of the following financial year (31 December 2026), which the Trustees consider to be a prudent and appropriate timeframe in line with good governance practices for assessing going concern.
## This evaluation follows the guidance on the Going Concern
Basis of Accounting and Related Reporting on Solvency and Liquidity Risks (2025), issued by the FRC.
It includes a comprehensive assessment of solvency and liquidity risks, explaining how these risks are identified, assessed, and managed.
## The forecast projections include the extension of the
additional credit facility of £30.0 million to August 2026. This facility, due to expire in December 2025, was recently extended to August 2026. It also considers sensitivities such as potential fluctuations in NHS activity and related revenue, variability in energy prices and their impact on
Nuffield Health Annual Report 2024
Financial statements
**55**
## Accounting policies continued
## for the year ended 31 December 2024
operational costs, changes in membership levels and associated revenue, and variations in self-pay activity and its financial implications, as well as the mitigating actions under the Group’s control. The financial forecasts indicate that the Charity will continue to operate within its facilities and all banking covenants for the foreseeable future. Further detail on going concern is disclosed in the financial year section on page 10 of the Strategic Report.
After evaluating the Group’s forecasts and associated risks, the Trustees are confident that the Charity and the Group have sufficient resources to continue operating for the foreseeable future, which is at least 18 months from the approval date of these financial statements. Consequently, they maintain the going concern basis in preparing the Annual Report and financial statements.
## **4. Basis of consolidation**
The Group financial statements consolidate the financial statements of the Charity and all its subsidiary undertakings drawn up to 31 December each year.
Subsidiaries are consolidated from the date of their acquisition, being the date the Group obtains control, and continue to be consolidated until the date control ceases. Control is achieved where the Group has the power to govern the undertaking’s financial and operating policies so as to benefit from its activities.
Acquisitions of subsidiaries and businesses are consolidated using the purchase method. On acquisition of an undertaking, the undertaking’s identifiable assets and liabilities that exist at the date of acquisition are recorded at their fair values reflecting their condition at that date. Any excess of the fair value of the consideration given over the fair value of the identifiable assets and liabilities acquired is recognised as goodwill.
Where a subsidiary has been disposed of during the year, the Consolidated income statement includes its results up to the date of disposal. Any gain or loss arising on disposal is recognised in the Consolidated statement of financial activities.
Where necessary, adjustments are made to the financial statements of subsidiaries to bring their accounting policies into line with those used by other members of the Group. All intra-Group transactions, balances, incomes and expenses are eliminated on consolidation.
Shares of subsidiary undertakings owned by non-Group companies are included within minority interest, except so far as there are obligations to the third parties that are likely to result in the purchase of those shares, in which case the discounted value of the expected purchase price is reported as a liability.
Non-controlling interests in subsidiaries are identified separately from the Group’s funds therein. Those interests of non-controlling shareholders that are present-ownership interests entitling their holders to a proportionate share of net assets upon liquidation may initially be measured at fair value or at the non-controlling interests’ proportionate share of the fair value of the acquiree’s identifiable net assets. The choice of measurement is made on an acquisition-by-acquisition basis. Other non-controlling interests are initially measured at fair value. Subsequent to acquisition, the carrying amount of non-controlling interests is the amount of those interests at initial recognition plus the non-controlling interests’ share of subsequent changes in funds.
## **5. Significant judgements and estimates**
The preparation of the financial statements requires the Trustees to make judgements and estimates and to select suitable accounting policies. The nature of the estimation means the actual outcomes could differ from those estimates. The following are items in the financial statements where significant judgements and estimates have been made.
## Critical judgements in applying the Group’s accounting policies
Judgements made by management include the presentation of adjusting items (accounting policy 10). Adjusting items are considered to fall outside the routine operations of the Group and are excluded from adjusted earnings before interest, tax, depreciation and amortisation. Adjusting items include accounting movements in relation to onerous lease provisions, impairment of assets and profit/loss on disposal of businesses.
Judgement has been applied in determining that Nero Propco LLP qualifies as a subsidiary of the Group and should be consolidated into these financial statements. Although the Charity does not hold a majority of the voting rights in Nero Propco LLP, it has been consolidated on the basis that the Group exercises control. As a result, a thirdparty loan has been brought onto the Group’s Balance Sheet. Further details are provided in Note 15.
Judgement was also applied in determining capitalisation and useful economic lives of assets developed through key change projects. Judgement is applied when determining whether costs in the early stages of a capital project are recoverable, the treatment of overheads and assessing the treatment on a project-by-project basis to appropriately reflect the asset type and build.
In addition judgements applied relating to the Trustees’ going concern assessment are detailed in the Strategic Report on page 10. This is considered a critical accounting judgement due to the level of uncertainty around future forecasts.
## Key sources of estimation uncertainty
## Fair value of land and buildings
The Group and Charity adopted the revaluation model for land and buildings on 31 December 2023. The fair value of buildings has been derived from market-based evidence by professional valuers in accordance with the RICS Valuation – Global Standards effective from 31 January 2022 and the Red Book UK National Supplement effective from 1 May
2024, with specific regard to VPGA 1- Valuation for inclusion in financial statements and VPGA 4 - Valuation of individual trade-related properties. The valuation is provided having regard to each hospital’s trading potential as a fully operational entity. The valuer’s approach to fair value is guided by their knowledge of market practice and with regard to the principles of a ‘Reasonably Efficient Operator’. The fair value of the property is calculated using a multiple of fair maintainable trade (FMT), drawing on current and forecast EBITDA generated by the site in full operation. To arrive at the fair value of the land and buildings, the net book value of equipment and any fixtures and fittings that could be removed from the site in the event of a sale is excluded from the calculation. The amount of the overall valuation allocated to land has been made with a greater reliance placed on comparable market transactions and taking into account additional special assumptions. The land values assessed are not realisable in isolation, being an apportionment only.
Special assumptions applied to each site’s valuation include: the assumption that each of the properties would be sold independently of the wider Nuffield Health business; that in the event of a sale each hospital would continue to access Nuffield Health’s existing central sterilisation services on similar terms; that current occupational licences in place do not give rise to any liabilities to Nuffield Health in the event of a sale; that the current charitable status of the sites is not expected to deter prospective purchasers or adversely affect market valuation; and no charitable benefits currently enjoyed by the sites would transfer under new ownership. There are further considerations applied to land specifically. The special assumptions included in the fair value of land include considerations such as access, existing infrastructure, demand for such sites and any planning permission already granted. The valuations assume the land would be cleared of all existing buildings and appropriate for development.
There is judgement in the multiple and the FMT used by the valuers and so the valuation outcome is sensitive to both.
The general assumptions included in arriving at an annual FMT figure to which the multiple is applied include revenue
Nuffield Health Annual Report 2024
Financial statements
**56**
## Accounting policies continued
for the year ended 31 December 2024
growth of 6% and cost increases of 6% to 8%. FMT is also subject to a wide range of factors including changes in the local market (new competition emerging for example), changes in national trends (insurer policy, NHS outsourcing etc) as well as macroeconomic factors, (interest rates, inflation etc). A sensitivity analysis was carried out showing that if FMT moved by 10% in either direction, the valuation would increase or decrease by £141.8 million.
The multiple assigned is a benchmark, which is adjusted based on a grading of the attributes of each site. The benchmark reflects the valuer’s view of the multiple expected on an average UK private hospital property in the middle of the quality spectrum based on their knowledge of the market. The grading system takes into account factors potential purchasers are likely to consider most significant when appraising a potential acquisition: asset quality, revenue mix, location and growth prospects.
## Impairments of tangible fixed assets, goodwill and computer software
Tangible fixed assets, computer software and goodwill are reviewed if events or changes of circumstances indicate that the carrying amount may not be recoverable. For this purpose, individual Consumer Fitness and Wellbeing sites and hospitals are considered to be separate incomegenerating units. The carrying amount of tangible assets and computer software, and the impairments recognised, can be found in notes 13 and 14.
The impairment tests are based on value in use for both hospitals and wellbeing sites, with the exception of St Bartholomew’s Hospital, which also considers fair value less costs to sell due to the availability of more reliable marketbased data.
The value in use calculations use cash flow models derived from the budget and exclude significant future investments that will enhance the income generating unit’s performance. The value in use method is subject to assumptions on the
rate used to discount expected future cash flows and the short- and long-term growth rates used in the calculation. Key estimates are the short- and long-term growth rates of leasehold hospitals and wellbeing sites, as well as short-term cost inflation. A long-term EBITDA growth rate of 2% was applied; refer to note 14 for the impairment recognised in the year.
For Fitness and Wellbeing centres a sensitivity analysis was undertaken to evaluate the impact of changes in revenue growth assumptions on the impairment provision. The current total provision is £11.7 million, with a net in-year impairment charge of £2.9 million. If revenue growth were to increase by 1% compared to budget in years 2 to 4 and remain at 2% thereafter, the total provision would reduce to £7.6 million, resulting in a release of £1.2 million. Conversely, if revenue growth were to decrease by 1% compared to budget over the same period, followed by 2% long-term growth, the total provision would increase to £16.4 million, resulting in an in-year impairment charge of £7.6 million.
At the year end, the carrying value of St Bartholomew’s Hospital total fixed assets was £58.3 million (2023 – £63.4 million). Indicators of impairment existed at the Balance sheet date. An impairment assessment was carried out using the higher of fair value less costs to sell and value in use, as described above, and an impairment charge of £32.6 million (2023 – £2.3 million) was subsequently recognised reducing the carrying value of St Bartholomew’s Hospital to £25.7 million at the end of December 2024.
A sensitivity analysis of some of the principal assumptions used to measure the impairment charge for St Bartholomew’s Hospital for the year ended 31 December 2024 was carried out. An increase in FMT EBITDA at maturity by 10% would reduce the impairment charge by £3 million to a fair value of £28.7 million. A decrease in FMT EBITDA at maturity by 10% would increase the impairment charge by £3 million to a fair value of £22.7 million.
An increase in multiple applied to the FMT EBITDA by 10% would reduce the impairment charge by £5 million to a fair value of £30.7 million. A decrease in multiple applied to the FMT EBITDA by 10% would increase the impairment charge by £5 million to £20.7 million.
## Fair value of third-party loan
The Group recognises a financial liability arising from a third-party loan, held by Nero Propco LLP, a subsidiary entity. This liability is considered to be a non-basic financial instrument and is measured at fair value at each reporting date. The significant assumptions involved in calculating the fair value adjustment to this loan includes long-term RPI inflation and a market-based discount rate. These values are subject to uncertainty, and as a result, changes to these estimates could have a significant impact on the value of the loan liability. It is recognised that the long-term RPI inflation forecast and market-based discount rate adopted are likely to change in the future; as the long-term RPI inflation rate increases, as does the value of the loan liability. As the discount rate increases, the value of the loan liability decreases. To address the uncertainty arising in the valuation technique, these assumptions were sensitised as part of the valuation. A range of long-term RPI inflation rates were considered, between 2.5% and 3.3% (2023 – 2.1% and 3.4%) and a range of discount rates were considered, between 7.65% and 8.45% (2023 – 6.7% and 7.3%). This sensitivity analysis resulted in loan liability valuations ranging from £163.1 million to £198.9 million (2023 – £173.3 million to £222.3 million). The fair value of the loan recognised within liabilities on the balance sheet is £179.4 million as at 31 December 2024.
Defined benefit pensions and other post-retirement benefits In order to calculate the obligation under the defined benefit pension plans and post-retirement medical benefits, estimates are made of the future costs using actuarial valuations. Due to the complexity of the valuation and the long-term nature of these plans, such estimates are subject to uncertainty. The most significant assumptions are the rate used to discount the obligations (based on the AA corporate bond yield curve that reflects the duration of the liabilities) and mortality rates. These assumptions and the carrying amounts of the plan’s assets and obligations, along with the sensitivity impact of changing these assumptions, are set out in note 8.
In 2016 the Charity entered into an asset-backed funding (ABF) arrangement with the Nuffield Health Pension and Life Assurance Scheme (the Scheme). It was concluded that the Scheme is a separate reporting entity to the Charity.
Therefore the Charity’s post-retirement defined benefit scheme is less than the Group’s by £49.1 million (2023 – £56.9 million) and the Charity has a liability for ABF of the same amount. These are measured at their fair value using a valuation method with the payments and risk free discount rate being the major assumptions. Given these assumptions are subject to variation over time, it is possible that the fair value of the ABF liability recognised by the Charity and the asset recognised by the Scheme could vary significantly in the future. Detailed sensitivities are disclosed in note 8.
## Onerous leases
The onerous lease assessments carried out periodically are dependent on estimates of future cash flows including potential recovery profile scenarios. There is significant judgement in estimating these cash flows as it requires assessment of cost inflation, market growth and competitor influences. The latest actual results and budget are used to establish the anticipated long-term profitability of the sites.
A key estimate is the long-term growth rate of wellbeing sites, as well as short-term cost inflation. A long-term EBITDA growth rate of 2% has been applied. There is also significant judgement in estimating the unavoidable costs which has been forecast to grow at 2% per annum. The discount rate applied in the present value calculation is also a key assumption and has a material impact on the valuation of the provision. Refer to note 22 for the onerous lease provision recognised in the year. Changes to the growth rate and the outcome of future pricing initiatives could have a significant impact on the onerous lease provision recorded.
These future cash flows are sensitive both to the model assumptions used and to market conditions. A sensitivity analysis of some of the principal assumptions used to measure the onerous lease provision at 31 December 2024 is set out below.
A range of model scenarios was assessed, each aligned with the Group’s five-year business plan. These scenarios incorporated variations in key revenue and cost assumptions.
In a scenario where budgeted revenue growth increases 1% from budget for years 2 to 4, and by 2% thereafter, the resulting provision would be £51.7 million, compared to the
Nuffield Health Annual Report 2024
Financial statements
**57**
## Accounting policies continued
for the year ended 31 December 2024
current provision of £59.6 million. Conversely, a 1% decrease in short-term revenue growth followed by 2% long-term growth would increase the provision to £69.7 million.
## **6. Funds**
Unrestricted general funds are expendable at the discretion of the Trustees in furtherance of the objects of the Charity. The liability for post-retirement defined benefits is reported separately in the Post-retirement reserve.
Accumulated gains and losses relating to the revaluation of assets held under the revaluation model are held separately in the Revaluation reserve.
Restricted funds are subject to specific conditions imposed by the donors, and are within the objects of the Charity. These funds are transferred to unrestricted when the specific requirements of the donation are satisfied.
Permanent endowments are capital funds where the Trustees have no power to convert the capital into income. Only the income may be expended.
## **7. Income and turnover**
Income from charitable activities comprises the value of services and goods supplied by the Group after deducting discounts and excluding value added tax (VAT). These are:
- Income from the hospital and wellbeing clinical activities that are recognised when the treatment or goods are provided
- Wellbeing membership income that is recognised evenly over the membership period. Joining fees, which are non-refundable, are recognised when received
- Secondary income, including those from food and beverages
- and personal training, are recognised when delivered
- Income from management contracts for wellbeing services to employees, are accounted on an accruals basis over the period that the service was provided.
Turnover is income from charitable and other trading activities plus donations and other grant income.
Donations are accounted for when receipt is probable, there is evidence of entitlement and it can be measured reliably.
Interest income is recognised on a time basis, taking into consideration the principal outstanding and contractual interest rates.
## **8. Expenditure**
Expenditure is classified using the headings in Charities SORP (FRS 102). The direct costs of providing services to patients and others are categorised as charitable activities. Support costs are the Group’s central office costs and as such are indirect costs incurred in supporting the charitable activities. Governance costs comprise the expenditure associated with the strategic management of the Group and compliance with constitutional and statutory requirements.
Interest payable, other than retirement benefit finance costs, is accrued using the effective interest method.
## **9. Grants and reliefs**
The Charity has taken advantage of various forms of government assistance during the current and prior year. The Charity applies the accruals method in accordance with paragraph 24.4 of FRS 102 as reliefs are claimed as compensation for expenses or losses already incurred, for the purpose of giving immediate financial support to the Charity, with no future related costs. Grants are accounted for when receipt is probable, there is evidence of entitlement and it can be measured reliably.
## Government Grants
The Charity receives grant funding from local authorities in relation to childcare places at Nuffield day nurseries. The Charity also receives nurse placement and training grants from Health Education England.
The grants received were classed as restricted and fully utilised within the year.
## Other reliefs
Business rates relief is treated as an absent cost and the Consolidated income statement charge is reduced for the period of the relief within sites where rates relief was applicable.
## **10. Adjusting items**
Adjusting items are significant one-off items resulting from an event outside the Group’s operating activities or accounting movements. These would include, but are not exclusive to, onerous lease provisions, profit/loss on disposal of business and impairment of assets. These are reflected separately in the financial statements, to provide a meaningful reflection of how the Group is managed and measured on a day-today basis, but due to their nature, may recur. This achieves consistency and comparability between reporting periods.
## **11. Termination benefits**
Payments or other benefits arising from the termination of a person’s employment are recognised as a liability and expensed when there is a detailed formal plan for the termination and there is no realistic possibility of the plan being withdrawn.
## **12. Financial derivatives**
The Group enters into financial derivatives to manage its exposure to fluctuating interest rates but does not enter into speculative derivative contracts. Amounts payable or receivable in respect of interest rate derivatives are
recognised as adjustments to interest payable over the period of the contracts.
Derivative contracts are initially measured at fair value on the date the contract is entered into and are subsequently measured at fair value through the Consolidated income statement and the Consolidated and Charity statement of financial activities. Derivatives are carried as assets when the fair value is positive and as liabilities when the fair value is negative. The movement in the fair value of the interest rate derivatives is charged or credited to interest payable within the Consolidated and Charity statement of financial activities and the Consolidated income statement.
The fair value of the interest rate swaps is calculated using a valuation technique that takes into consideration observable interest rates for the period of the contracts.
## **13. Foreign currency**
## Group entities
The Group has no subsidiaries that have a different functional currency from the presentational currency.
## Transactions and balances
Foreign currency transactions are translated into the functional currency using the exchange rate prevailing at the date of the transactions. Exchange gains and losses resulting from the settlement of such transactions and from translation at the closing rate of monetary assets and liabilities denominated in foreign currencies are recognised in the Consolidated income statement and the Consolidated and Charity statement of financial activities.
## **14. Intangible fixed assets and amortisation**
## Goodwill
Goodwill is measured at cost less accumulated
amortisation and any accumulated impairment losses.
Positive goodwill is written off on a straight-line basis over its expected useful life, of between five and 20 years.
Nuffield Health Annual Report 2024
Financial statements
**58**
## Accounting policies continued
for the year ended 31 December 2024
If there is an indication that there is a significant change in amortisation rate, the amortisation is revised prospectively to reflect the new expectations.
The Charity’s goodwill includes the value of investments in certain subsidiaries in which the trade and assets have been transferred to the Charity.
## Computer software
Computer software that is not an integral part of its related hardware is treated as an intangible fixed asset and is recognised only when it is probable that future benefits will flow to the Group and the cost can be measured reliably. It is measured at cost less accumulated amortisation and any impairment losses. Cost includes internal project development costs.
Software development costs are recognised as an intangible asset when all the following conditions are met:
- It is technically and financially feasible to complete the development
- The intention is to complete the development and use the software
- It can be used when completed
- The costs can be measured reliably
- It is probable there will be future economic benefits to the Group.
Computer software is amortised on a straight-line basis over five years.
Intangible assets in the course of construction consist of costs that meet the criteria for recognition as an asset, as set out above, but are not yet in use. These items are transferred to their relevant asset category when they are brought into use; amortisation commences from this point.
## **15. Tangible fixed assets and depreciation**
Land and buildings, which includes property under finance lease, are held under the revaluation model and are measured at fair value. The Group and the Charity adopted the revaluation model for land and buildings on 31 December 2023. Subsequent full revaluation will be made at least every three years with desktop reassessment, if deemed material, in the interim.
The fair value of buildings has been derived from marketbased evidence by professional valuers and is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The reported fair value for land and buildings is based on the overall property valuation, less the net book value of equipment that could be removed from the site in the event of a sale. Under the cost model, fixtures and fittings are included within land and buildings for the revalued sites. Therefore, the valuation includes the trading potential of the property. Land values have been allocated by having regard to prevailing evidence of land transactions in each of the locations, to which a premium is applied to reflect the planning permission for hospital use. A set of special assumptions has also been applied to the land valuation approach, as disclosed in policy 5. An element of judgement exists in such valuation processes; this is discussed further in policy 5.
At the time of the revaluation, the carrying amount of the asset is increased to the revalued amount by adjusting the gross cost.
Revaluation gains and losses are recognised in the Statement of Financial Activities and added to reserves in a separate Revaluation reserve. An annual transfer is made from the Revaluation reserve to retained earnings equivalent to the excess depreciation in respect of the revalued assets.
Leasehold assets and equipment are held under the cost model and are measured at cost less accumulated depreciation and any accumulated impairment losses.
The cost of new buildings, major extensions and
refurbishments includes internal project development costs; all other development costs are written off in the year of expenditure.
Tangible fixed assets are transferred from assets in the course of construction at practical completion of the project.
No depreciation is charged while assets are in the course of construction; depreciation on assets in the course of construction commences at practical completion.
Depreciation on tangible fixed assets, other than land which is not depreciated, is calculated on a straight-line basis to write down the cost over their expected useful economic lives.
The applicable periods are:
|Land and buildings|Between 50 and 60 years or the|
|---|---|
||remaining useful life if less than|
||50 years|
|Leasehold properties|Over the period of the lease or|
||remaining useful life|
|Furniture and equipment|Between 3 and 15 years|
|Motor vehicles|Between 4 and 5 years|
## **16. Estimation of useful lives and residual values of fixed assets**
Intangible and tangible fixed assets are amortised or depreciated over their useful lives after taking into consideration their expected residual value. The useful lives and residual values are set at the time the assets are acquired. The lives are based on historical evidence of similar assets as well as anticipating the impact of future events that may affect their lives.
The estimated useful lives of the intangible fixed assets are set out in accounting policy 14 and those for tangible fixed assets in accounting policy 15.
## **17. Impairment of intangible and tangible fixed assets**
At each reporting date, intangible and tangible fixed assets are reviewed to determine whether there is any indication that those assets have suffered an impairment loss. If there is an indication of a possible impairment, the recoverable amount of the affected income-generating unit or asset is estimated and compared with its carrying amount. An impairment loss is expensed immediately.
Impairments of tangible fixed assets and intangible fixed
assets other than goodwill are reversed when a change in economic conditions or the expected use of an asset increases the recoverable amount of an impaired asset above its impaired carrying value. Impairment reversals are recognised in the Consolidated income statement and Consolidated and Charity statement of financial activities to the extent that they increase the carrying amount of the asset up to the amount that it would have been had the original impairment not occurred.
## **18. Purchase and disposal of properties**
The purchase or disposal of a property is accounted for in the year in which an unconditional and irrevocable contract is exchanged.
## **19. Investments**
Investments in subsidiaries are stated at cost, less provision for impairment within the Charity’s financial statements.
Other investments are stated at market value at the Balance sheet date. Changes in market values are accounted for as net gains/(losses) on investments within the Consolidated statement of financial activities.
## **20. Business combinations**
The acquisition of subsidiaries and businesses is accounted for using the purchase method. The consideration for each
Nuffield Health Annual Report 2024
Financial statements
**59**
## Accounting policies continued
for the year ended 31 December 2024
acquisition is measured at the aggregate of fair values of assets given, liabilities incurred or assumed, and instruments issued by the Group in exchange for control of the acquiree. Acquisition-related costs are recognised as part of the cost of investment.
Where the consideration for an acquisition includes any asset or liability resulting from a contingent arrangement, this is measured at its discounted fair value on the date of acquisition. Subsequent changes in fair values are adjusted through the Consolidated income statement in interest payable and similar income. Changes in the fair value of contingent consideration classified as equity are not recognised.
If the initial accounting for a business combination is incomplete by the end of the reporting period in which the combination occurs, the Group reports provisional amounts for the items for which the accounting is incomplete. Those provisional amounts are adjusted during the measurement period, or additional assets or liabilities are recognised, to reflect new information obtained about facts and circumstances that existed as at the date of the acquisition that, if known, would have affected the amounts recognised as at that date. The measurement period is the period from the date of acquisition to the date the Group obtains complete information about facts and circumstances that existed as at the acquisition date and is a maximum of one year.
## **21. Accounting for subsidiaries**
A subsidiary is an entity controlled by the Group. Control is achieved where the Group has power over an investee; exposure, or rights, to variable returns from its involvement with the investee; and the ability to use its power over the investee to affect the amount of the returns.
## **22. Non-controlling interests**
Non-controlling interests in the net assets of consolidated subsidiaries are identified separately from the Group’s funds therein, either at fair value or at the non-controlling interest’s share of the net assets of the subsidiary, on a case-by-case basis. The total comprehensive income of a subsidiary is apportioned between the Group and the non-controlling interest, even if it results in a deficit balance for the non-controlling interest. Where the Group’s interest in a controlled entity increases, the non-controlling interests’ share of net assets, excluding any allocation of goodwill, is transferred to Group funds. Any difference between the cost of the additional interest and the existing carrying value of the non-controlling interests’ share of net assets is recorded in the Consolidated income statement.
Where the Group’s interest in a controlled entity decreases, but the Group retains control, the share of net assets disposed, excluding any allocation of goodwill, is transferred to the non-controlling interests. Any difference between the proceeds of the disposal and the existing carrying value of the net assets or liabilities transferred to the non-controlling interests is recorded in the Consolidated income statement.
## **23. Stocks**
Stocks are stated at the lower of net realisable value and cost, where cost is weighted average cost.
Consignment stock is not included in the Balance sheet when the supplier retains the risk and reward of ownership. The risk and reward transfers to the Group when the asset is used or as the result of a contractual agreement.
## **24. Cash and cash equivalents**
Cash and cash equivalents include cash in hand, short-term deposits maturing within three months and bank overdrafts.
## **25. Provisions for liabilities**
Provisions are recognised when the Group has a present legal or constructive obligation as a result of a past event, it is probable that an outflow of economic benefits will be required to settle the obligation and a reliable estimate of the obligation can be made. Provisions are measured at the Trustees’ best estimate of the expenditure required to settle the obligation at the Balance sheet date. If such an obligation cannot be reliably estimated, no provision is recognised and the item is disclosed as a contingent liability where material.
Where the effect is material, the provision is determined by discounting the expected future cash flows and the unwinding of the discount is recognised as an interest cost in the Consolidated income statement and Consolidated Statement of financial activities.
A provision for the present value of future property reinstatement costs is recognised where there is an obligation to return the leased property to its original condition at the end of an operating lease. Where a leased property is no longer expected to be fully occupied, or where the costs exceed the future expected benefits, an onerous lease provision will be recognised for that portion of the lease in excess to the Group’s requirements and not fully recovered through alternative use, or through value in use.
Provisions for dilapidations are recognised when it is
probable that an obligation exists and the amount can be measured reliably, or from the date on which these conditions are first met.
## **26. Defined benefit pension schemes and other post-retirement benefits**
The Group operates two defined benefit pension schemes, both of which require contributions to be made to separately administered funds. Both the Nuffield Health Pension and Life Assurance Scheme and the Aspen Healthcare Limited Staff Pension Fund are closed to new entrants. The costs of providing benefits in the schemes are determined separately for each plan as outlined in note 8.
Scheme assets are measured at fair values. Scheme liabilities are measured annually on an actuarial basis using the projected unit credit method and are discounted at appropriate high-quality corporate bond rates of equivalent currency and term of the Scheme liabilities. The net surplus or deficit is presented separately from other net assets on the Balance sheet. A net surplus is recognised only to the extent that it is recoverable by the Group.
The current service cost and costs from settlements and curtailments are charged against operating surplus.
The net interest on the net defined benefit liability is determined by multiplying the net defined benefit liability by the discount rate as determined at the start of the reporting period and taking account of any changes in the net defined benefit liability during the period as a result of contributions and benefit payments. The discount rate is based on the yield curve of high-quality corporate bonds.
Actuarial gains and losses and returns on plan assets, excluding amounts included in net interest on the net defined benefit liability, are reported as recognised gains and losses in the Consolidated Statement of financial activities.
## **27. Defined contribution pension schemes**
Contributions to defined contribution schemes are charged to the Consolidated income statement and Consolidated statement of financial activities in the period in which they become payable.
## **28. Leased assets**
Leases are classified as finance leases whenever the terms of the lease transfer substantially all the risks and rewards of ownership to the Group. All other leases are classified as operating leases.
Where the Group enters into a sale and leaseback
transaction, and the sale and leaseback transaction results in a finance lease, the excess of sale proceeds over the carrying amounts is deferred and amortised over the lease term. If the
Nuffield Health Annual Report 2024
Financial statements
**60**
## Accounting policies continued
for the year ended 31 December 2024
sale and leaseback transaction results in an operating lease, the excess of sale proceeds over the carrying amount is recognised in the Consolidated income statement and Consolidated and Charity statement of financial activities.
Assets held under finance leases and hire purchase contracts are recognised initially at the lower of the fair value of the asset or the present value of the minimum payments at the inception of the contract.
The corresponding liability to the lessor is included in the Balance sheet as a finance lease obligation. Lease payments are apportioned between the reduction in lease obligation and interest using the effective interest method so as to achieve a constant rate of interest on the remaining portion of the lease obligation.
The assets held under finance leases and hire purchase agreements are included in tangible fixed assets and depreciated and assessed for impairment losses in the same way as owned assets.
Rentals paid under operating leases are charged to the Consolidated income statement and the Consolidated statement of financial activities on a straight-line basis over the lease term, unless the rental payments are structured to increase in line with expected general inflation or adjusted to the open market value, in which case the Group rent expense equals the amounts owed to the lessor.
The benefits of lease incentives are recognised as a reduction to the rental expense over the lease term on a straight-line basis.
Rentals receivable from operating leases are accounted for on a straight-line basis over the lease term.
## **29. Taxation**
The Charity is exempt from UK corporate taxation on its income and gains falling within Part 11 of the Corporation Tax Act 2010 or section 256 of the Taxation of Chargeable Gains Act 1992 to the extent that the income and gains are applied for charitable purposes. No corporation tax charges arose for the Charity during the year (2023 – £Nil). The non-charitable subsidiaries are subject to corporation tax. Due to the subsidiaries’ policy to donate any taxable profits to the Nuffield Health Charity by way of Gift Aid, no liabilities arose (2023 – £Nil).
VAT is recovered on the basis of an agreed partial
exemption special method with HMRC. Due to the high level of VAT-exempt sales, mainly through healthcare provision and sporting memberships provided by the Charity, there is a high level of irrecoverable VAT within the organisation. Any irrecoverable VAT is charged to the Consolidated and Charity statement of financial activities and Consolidated income statement as part of the operating expenditure to which it relates when it is incurred (subject to a VAT Group annual adjustment), or is allocated as part of the capital expenditure to which it relates.
The Charity also benefits from business rates relief up to 100% in relation to the properties that it occupies for charitable purposes.
## **30. Financial instruments**
Debt instruments (other than those wholly repayable or receivable within one year), including loans and other accounts receivable and payable, are initially measured at the present value of the future cash flows and subsequently at amortised cost using the effective interest method. Debt instruments that are payable or receivable within one year, typically trade creditors or debtors, are measured, initially and subsequently, at the undiscounted amount of the cash or other consideration expected to be paid or received.
Financial assets that are measured at cost and amortised cost are assessed at the end of each reporting period for evidence of impairment. An impairment loss is recognised in the Consolidated income statement and Consolidated and Charity statement of financial activities.
For financial assets measured at amortised cost, the impairment loss is measured as the difference between an asset’s carrying amount and the present value of estimated cash flows discounted at the asset’s original effective interest rate. If a financial asset has a variable interest rate, the discount rate for measuring any impairment loss is the current effective interest rate determined under the contract.
For financial assets measured at cost less impairment, the impairment loss is measured as the difference between an asset’s carrying amount and best estimate, which is an approximation of the amount that the Group would receive for the asset if it were to be sold at the Balance sheet date.
The financial liability arising from the asset-backed funding agreement with the pension fund is stated at its fair value. A valuation technique is used as there is no readily ascertainable market price. The valuation method incorporates a risk-free discount rate to reflect the timing of the payments, an option pricing element to value the contingent payments and solvency likelihood to take into consideration the different payment scenarios. Any gains or losses arising on remeasurement are recognised in the Consolidated and Charity statement of financial activities.
The financial liability arising from the third-party loan is held on the Group’s Balance sheet at fair value. A valuation technique is used as, due to the specific terms of the loan, there is no readily ascertainable market price. The valuation method estimates the loan’s RPI indexed cash flows, using published forecast data and estimates an appropriate discount rate by combining a risk-free rate and a suitable margin based on the valuation of the properties that secure this loan. Any gains or losses arising on remeasurement are recognised in the Consolidated income statement and the Group statement of financial activities and disclosed in Interest costs.
Nuffield Health Annual Report 2024
Financial statements
**61**
## Notes to the financial statements
for the year ended 31 December 2024
## **1. Fund analysis**
|**1. Fund analysis**||
|---|---|
|
**Group**|2024
2023|
||Permanent
£m
Restricted
£m
Unrestricted
£m
Total
£m
Permanent
£m
Restricted
£m
Unrestricted
£m
Total
£m|
|Total income
Donations and legacies including
government grants
Other sources of income|–
2.7
–
2.7
–
1.6
–
1.6
–
–
1450.4
1,450.4
–
–
1,356.5
1,356.5|
|Total incoming resources
Total expenditure|–
2.7
1,450.4
1,453.1
–
1.6
1,356.5
1,358.1
–
–
(1,489.5)
(1,489.5)
–
–
(1,422.1)
(1,422.1)|
|Net income/(expenditure)
Other movement in funds
Transfer between funds|–
2.7
(39.1)
(36.4)
–
1.6
(65.6)
(64.0)
–
–
19.4
19.4
–
–
1,249.6
1,249.6
–
(2.7)
2.7
–
–
(1.6)
1.6
–|
|Net movement in funds
Fund balance at 1 January|–
–
(17.0)
(17.0)
–
–
1,185.6
1,185.6
0.1
0.8
1,080.3
1,081.2
0.1
0.8
(105.3)
(104.4)|
|Fund balance at 31 December|0.1
0.8
1,063.3
1,064.2
0.1
0.8
1,080.3
1,081.2|
Included within group unrestricted funds balance is a non-controlling interests surplus of £0.7 million (2023 – £0.6 million).
|||
|---|---|
|**Charity**|2024
2023|
||Permanent
£m
Restricted
£m
Unrestricted
£m
Total
£m
Permanent
£m
Restricted
£m
Unrestricted
£m
Total
£m|
|Total income
Donations and legacies including
government grants
Other sources of income|–
2.7
–
2.7
–
1.6
–
1.6
–
–
1,420.4
1,420.4
–
–
1,335.2
1,335.2|
|Total incoming resources
Total expenditure|–
2.7
1,420.4
1,423.1
–
1.6
1,335.2
1,336.8
–
–
(1,474.5)
(1,474.5)
–
–
(1,386.3)
(1,386.3)|
|Net income/(expenditure)
Other movement in funds
Transfer between funds|–
2.7
(54.1)
(51.4)
–
1.6
(51.1)
(49.5)
–
–
13.0
13.0
–
–
1,114.3
1,114.3
–
(2.7)
2.7
–
–
(1.6)
1.6
–|
|Net movement in funds
Fund balance at 1 January|–
–
(38.4)
(38.4)
–
–
1,064.8
1,064.8
0.1
0.8
931.6
932.5
0.1
0.8
(133.2)
(132.3)|
|Fund balance at 31 December|0.1
0.8
893.2
894.1
0.1
0.8
931.6
932.5|
During the year, £2.7 million of grant income was received (2023 – £1.6 million). Further detail is provided in note 2, Turnover and income analysis.
Nuffield Health Annual Report 2024
Financial statements
**62**
## Notes to the financial statements continued
for the year ended 31 December 2024
## **2. Turnover and income analysis**
|||||||2024||2023|
|---|---|---|---|---|---|---|---|---|
|**Group**||Note||||£m||£m|
||||||||||
|Hospitals||||||1,030.4||967.4|
|Wellbeing services||||||388.4||365.6|
|Net income from charitable activities||||||1,418.8||1,333.0|
|Other grant income – restricted||||||2.7||1.6|
|Other trading income||||||31.6||23.5|
|Turnover||||||1,453.1||1,358.1|
|Total income before adjusting items||||||1,453.1||1,358.1|
|Adjusting items|||||||||
|Gain on disposal ofbusiness|||5|||8.5||–|
|Total income||||||1,461.6||1,358.1|
|||||||2024||2023|
|**Charity**||Note||||£m||£m|
||||||||||
|Hospitals||||||1,030.4||967.4|
|Wellbeing services||||||388.4||365.6|
|Net income from charitable activities||||||1,418.8||1,333.0|
|Other grant income – restricted||||||2.7||1.6|
|Turnover||||||1,421.5||1,334.6|
|Gain on disposal of tangible assets||||||1.6||2.2|
|Total income||||||1,423.1||1,336.8|
During the year, £2.7 million of grant income was received (2023 – £1.6 million). £1.9 million was received from the Local Authority in relation to day nurseries (2023 – £0.8 million), £0.8 million from Health Education England in relation to nurse training placements (2023 – £0.5 million). 2023 also included a £0.3 million grant for lift works from Barts Health NHS Trust. These sums were transferred between restricted and unrestricted funds as they were fully utilised in 2024. All sums were fully utilised in the year they were received.
Other trading income includes the income from Mythbreaker Ltd, Cancer Centre London LLP and Parkside IHL Scanning Services LLP. Gain on disposal of tangible assets in the Charity includes a deferred gain on sale and lease back of the tangible assets to Nero Propco LLP which is eliminated in the Group.
## **3. Expenditure on charitable activities**
||Direct activities
Support costs
Total|
|---|---|
|**Charity**
Note|2024
£m
2023
£m
2024
£m
2023
£m
2024
£m
2023
£m|
|Normal
Staff and related costs
Partnership fees
Consumable and supply costs
Depreciation and amortisation
Other costs|482.6
441.3
100.1
93.3
582.7
534.6
250.9
238.7
–
–
250.9
238.7
172.9
159.7
–
–
172.9
159.7
65.5
46.8
25.6
30.5
91.1
77.3
241.7
250.2
82.9
72.2
324.6
322.4|
|Expenditure on charitable activities before adjusting items|1,213.6
1,136.7
208.6
196.0
1,422.2
1,332.7|
|Adjusting items
Reorganisation and transformation costs
5
Impairment of fixed assets
5
Gain on disposal of business
5
Onerous lease provision
5|–
–
–
4.7
–
4.7
34.9
2.5
–
–
34.9
2.5
(0.6)
–
–
–
(0.6)
–
(11.2)
9.7
–
–
(11.2)
9.7|
|Total adjusting items|23.1
12.2
–
4.7
23.1
16.9|
|Expenditure on charitable activities|1,236.7
1,148.9
208.6
200.7
1,445.3
1,349.6|
Within expenditure on charitable activities there were £0.8 million (2023 – £0.9 million) of research and development costs; £0.4 million (2023 – £0.4 million) in staff and related costs and £0.4 million (2023 – £0.5 million) relating to non-staff costs.
|||2024||2023|
|---|---|---|---|---|
|**Charity**||£m||£m|
||||||
|Hospitals||1,059.4||948.6|
|Wellbeing services||385.9||401.0|
|||1,445.3||1,349.6|
The above segmental reporting shows direct costs allocated to each relevant area plus support costs allocated to hospitals and wellbeing services based upon the 2024 revenue derived from each of these segments.
Nuffield Health Annual Report 2024
Financial statements
**63**
## Notes to the financial statements continued
for the year ended 31 December 2024
## **4. Governance costs**
|**4. Governance costs**|||||
|---|---|---|---|---|
|||2024||2023|
|**Group**||£m||£m|
||||||
|Staff and related costs||7.0||5.4|
|Other costs||1.8||2.0|
|||8.8||7.4|
Governance costs are included within support costs in note 3.
## **5. Adjusting items**
Adjusting items include, but are not limited to, accounting movements in relation to onerous lease provisions, profit/loss on disposal of business, impairment of assets and reorganisation and transformation costs, which are reflected separately in the financial statements, to provide a meaningful reflection of how the Group is managed and measured on a day-today basis. This achieves consistency and comparability between reporting periods. Adjusting items fall outside the routine operations of the Group but due to their nature, may recur. Other adjusting items are significant one-off items resulting from an event outside the Group’s operating activities. These are disclosed separately to improve the understanding of the Group’s underlying financial performance.
The total adjusting items charge/(income) of £15.2 million for Group (2023 – £16.9 million) and £23.1 million for the Charity (2023 – £16.9 million) is analysed and categorised in the Income statement as follows:
||Group
Charity|
|---|---|
||2024
£m
2023
£m
2024
£m
2023
£m|
|Impairment of tangible and intangible assets
Movement in onerous lease provision
(Gain) on disposal of business
Reorganisation and transformation costs|34.9
2.5
34.9
2.5
(11.2)
9.7
(11.2)
9.7
(8.5)
–
(0.6)
–
–
4.7
–
4.7|
|Total adjusting items|15.2
16.9
23.1
16.9|
Impairment of tangible and intangible assets During the year the Group recognised a total impairment charge of £34.9 million (2023 – £2.5 million).
In fitness and wellbeing sites, an impairment charge of £5.2 million and a total impairment reversal of £2.3 million (2023 – £2.2 million charge) was recorded, following the onerous lease assessment and associated impairment reviews at year end.
The Hospitals impairment review resulted in an impairment charge for St. Bartholomew’s Hospital of £32.6 million (2023 – £2.3 million) and a £0.9 million impairment reversal (2023 – £2.7 million charge) in relation to Woking hospital.
The impairment charge also includes a £0.3 million relating to the NEPR project.
## Onerous lease provision
The onerous lease provision represents the minimum unavoidable lease cost loss expected to be incurred, after considering the net costs to fulfil the lease. The net costs to fulfil the lease have been determined as the expected cash flows at each site over the remainder of the lease and the net present value of rent.
The provision is calculated on a site-by-site basis and discounted as appropriate. An additional provision of £15.1 million and a reversal of £26.3 million (2023 – charge of £27 million and a reversal of £17.3 million) result in a net gain to the Income statement of £11.2 million (2023 – £9.7 million charge) and are reflected within adjusting items in the Income statement and Consolidated and Charity statement of financial activities and in note 5.
## Gain on disposal of business
Aspen Healthcare Limited, a group company have disposed of Cancer Centre London LLP (CCL), a wholly owned subsidiary on 30 November 2024.
|**Group**|2024|
|---|---|
||£m
£m|
|Consideration
Tangible assets
Stock
Trade debtors
Other debtors
Prepayments
Cash & cash equivalents
Accruals & other creditors
Trade creditors|11.6|
||(1.2)
–|
||(0.6)
–|
||(1.5)
–|
||(0.4)
–|
||(0.5)
–|
||(0.5)
–|
||1.8
–|
||0.6
–|
|CCL net assets|(2.3)|
|CCL goodwill
Legal fees|(0.6)|
||(0.2)|
|Profit on disposal|8.5|
The £0.6 million gain on disposal of business, recognised in the Charity, reflects an intercompany write-off arising from the disposal of CCL.
## Reorganisation and transformation costs
In the previous year, the Group was completing its transformation programme aimed at improving the way the Charity provides holistic healthcare to customers and to standardise activities through improved systems.
Changes arising from the improved systems resulted in the redeployment or redundancy of certain teams across the organisation; additional costs in 2023 amounted to £4.7 million.
No other adjusting items over £1.0 million were identified in the year.
Nuffield Health Annual Report 2024
Financial statements
**64**
## Notes to the financial statements continued
for the year ended 31 December 2024
## **6. Operating deficit**
This is stated after charging or (crediting):
|This is stated after charging or (crediting):|||||||
|---|---|---|---|---|---|---|
|||||2024||2023|
|||Note||£m||£m|
||||||||
|Amounts payable to auditor:|||||||
|Audit fees payable||||1.1||1.1|
|Depreciation on tangible assets:|||||||
|On owned assets||||70.1||46.7|
|On assets held under finance leases and hire purchase contracts||||1.5||11.2|
|Losson disposal of tangible assets||||0.5||0.5|
|Amortisation of intangible assets||13||19.8||21.3|
|Research and development expenditure||||0.8||0.9|
|Hire of plant and machinery (including operating lease charges)||||19.5||17.6|
|Property operating lease rentals||||84.7||73.9|
|Rental income from operating leases||||(0.8)||(0.9)|
|Third-partyindemnity insurance||||4.5||2.5|
|Adjusting item – reorganisation and transformation costs||5||–||4.7|
|Adjusting item – impairment of intangible and tangible assets||5||34.9||2.5|
|Adjusting item – onerous lease provision||5||(11.2)||9.7|
|Adjusting item – gain on disposal of business||5||(8.5)||–|
Fees payable by the Charity for the audit of the Annual report and financial statements of the Charity inclusive of irrecoverable VAT amounted to £998,880 (2023 – £951,360) and its subsidiaries amounted to £81,120 (2023 – £125,880). Fees payable for other services amounted to £19,200 (2023 – £22,084) mainly relating to tax advisory services. Fees paid to Deloitte LLP for non-audit services to the Charity itself are not disclosed in these financial statements because the Charity’s consolidated financial statements are required to disclose such fees on a consolidated basis. In the prior year, the audit fees payable were disclosed exclusive of irrecoverable VAT and therefore the comparative figure has been amended to be inclusive of irrecoverable VAT.
## **7. Net interest payable and similar income**
|**7. Net interest payable and similar income**||
|---|---|
||Group
Charity|
||2024
£m
2023
£m
2024
£m
2023
£m|
|Interest receivable|0.5
0.7
0.2
0.4
(23.9)
(20.9)
(23.9)
(20.9)
(0.6)
(0.1)
(5.7)
(8.2)
–
–
(4.0)
(4.0)
(2.9)
(4.4)
(3.6)
(5.1)
(2.3)
(2.4)
(2.3)
(2.4)|
|Interest payable||
|Bank loans and overdraft||
|Financechargesin respect of finance leases||
|Financechargesin respect of pension liability forasset-backedfunding||
|Other interest payable||
|Costs in connection with loan facilities||
|Measured at amortised cost|(29.7)
(27.8)
(39.5)
(40.6)
(6.0)
(9.1)
–
–
(1.9)
(2.0)
0.7
0.9|
|Third-partyloan||
|Retirement benefit finance(costs)/income||
|Measured at fair value through the Consolidated Income statement
and Consolidated and Charity statement of financial activities
Fair value movement|(7.9)
(11.1)
0.7
0.9
15.4
(8.1)
9.4
2.6|
|Interest payable and movement in fair values|(22.2)
(47.0)
(29.4)
(37.1)|
|Net interest payable and similarincome/(costs)|(21.7)
(46.3)
(29.2)
(36.7)|
The Group fair value movement includes £13.7 million gain (2023 – £9.3 million loss) on the year end value of the thirdparty loan and a fair value gain on interest rate derivatives of £1.7 million (2023 – £1.2 million). The Charity fair value movement includes £7.7 million (2023 – £1.4 million) gain on the asset-backed funding arrangement, and a fair value gain on interest rate derivatives of £1.7 million (2023 – £1.2 million).
Indemnity insurance for the Trustees and officers amounted to £94,400 (2023 – £98,000).
Nuffield Health Annual Report 2024
Financial statements
**65**
## Notes to the financial statements continued
for the year ended 31 December 2024
## **8. Defined benefit pensions and other post-retirement benefits**
The Group operates two separately administered defined benefit pension schemes: the Nuffield Health Pension and Life Assurance Scheme and the Aspen Healthcare Limited Staff Pension Fund. In addition, the Group operates one unfunded defined benefit pension scheme in respect of two members, which has no assets.
Nuffield Health’s funded defined benefit pension scheme and the defined benefit pension scheme acquired during 2021 as part of the Aspen acquisition, is closed to future benefit accrual and new entrants. As a result of the closure of the Aspen scheme, under the projected unit method, the current service cost will increase as the members of the scheme approach retirement.
In addition, the Group operates one unfunded defined benefit pension scheme in respect of two members, which has no assets. The assets of the funded scheme are administered by trustees in funds independent from the assets of the Group. The Group also provides postretirement healthcare benefits to some of its employees. This healthcare arrangement is also closed to new entrants.
## Nuffield Health Pension and Life Assurance Scheme
Nuffield Health’s funded defined benefit pension scheme is closed to future benefit accrual and new entrants. The assets of the funded scheme are administered by trustees in funds independent from the assets of the Group. The Group also provides post-retirement healthcare benefits to some of its employees. These benefit schemes are also closed to new entrants.
Nuffield Health is the sponsoring employer of the defined benefit pension schemes and the post-retirement healthcare benefits and has legal responsibility for the plans. There is no contractual arrangement or policy for charging the net defined benefit costs to individual Group entities and therefore the Charity has recognised the entire net benefit cost and the relevant net defined benefit liability in its individual financial statements.
The most recent formal actuarial valuation of the Nuffield Health Pension and Life Assurance Scheme (the Scheme), a defined benefit pension scheme, was carried out as at 31 March 2024. This valuation was carried out by the Scheme actuary, Adam Stanley of XPS Pensions Limited. The principal assumptions made by the actuary are set out in the Scheme’s statement of funding principles dated 26 September 2024, which were agreed by the Trustee of the Scheme and Nuffield Health as part of the 31 March 2024 valuation, which was completed on 11 September 2024.
## Aspen Healthcare Limited Staff Pension Fund
The most recent formal actuarial valuations of the Aspen plan assets and the present value of the defined benefit obligation were carried out at 31 December 2022 by Duncan Ross, Fellow of the Institute of Actuaries, on behalf of Hughes Price Walker Limited. The present value of the defined benefit obligation, the related current service cost and past service cost were measured using the projected unit credit method.
The level of employer contributions in relation to Aspen in the year totalled £Nil (2023 – £Nil).
## Asset-backed funding
The employer and the Trustee of the Scheme entered into an asset-backed funding arrangement (ABF) in March 2016 by which the freehold of the Nuffield Health Oxford Hospital (The Manor) was transferred to a Scottish Limited Partnership, with both parties being limited partners. This gives the Scheme a secured asset should the Charity become insolvent. It was agreed that the employer’s contribution in relation to the ABF would be £4.0 million per year.
These contributions were allowed for in the recovery plans agreed by the Trustee and Nuffield Health as part of the 2018, 2021 and 2024 actuarial valuations – the current recovery plan aims to remove the deficit by 31 March 2030. Following the reduction in the liability in recent years, a revised recovery plan was agreed dated 11 September 2024. This revised recovery plan included £Nil contributions for two months in 2024 with a £1 million payment before 31 March 2025, £5 million per year from 1 April 2025 to 31 March 2027 and £6.1 million from 1 April 2027 to March 2030.
The defined accrued benefits method is used to value the liabilities of the defined benefit pension scheme.
Scheme assets are stated at their market values at the respective Balance sheet dates.
As at 31 March 2024, the present value of the Scheme’s assets was sufficient to cover 98% of the actuarial value of the benefits that had accrued to the members after allowing for assumed future increases to deferred pensions and pensions currently in payment.
The level of employer contributions in the year totalled £6.8 million (2023 – £7.9 million).
Nuffield Health Annual Report 2024
Financial statements
**66**
## Notes to the financial statements continued
for the year ended 31 December 2024
## **8. Defined benefit pensions and other post-retirement benefits** continued
The main assumptions are as follows:
|The main assumptions are as follows:||
|---|---|
||2024
2023|
||Nuffield
Health
defined
benefit
% pa
Aspen
defined
benefit
% pa
Nuffield
Health
defined
benefit
% pa
Aspen
defined
benefit
% pa|
|Rate of increase in medical inflation
Rate of increase for pensions in payment pre 1 August 2005 service
Rate of increase for pensions in payment post 31 July 2005 service
Rate of increase for deferred pensions
Discount rate (yield curve basis)
Inflation rate (CPI)|4.7
–
4.6
–|
||3.5
2.8
3.4
2.8|
||2.1
2.1
2.1
2.0|
||2.7
2.9
2.6
2.7|
||5.5
5.3
4.8
4.4
2.7
2.9
2.6
2.7|
The amounts charged to the Consolidated income statement and Group statement of financial activities were as follows:
||NuffieldHealthdefined
benefit pension funds
Retirement healthcare
Aspen defined
benefit pension funds
Total|
|---|---|
||2024
£m
2023
£m
2024
£m
2023
£m
2024
£m
2023
£m
2024
£m
2023
£m|
|Operating surplus|1.2
1.1
–
–
0.2
–
1.4
1.1
(13.7)
(14.1)
–
–
(0.5)
(0.6)
(14.2)
(14.7)
15.4
16.1
0.1
0.1
0.4
0.5
15.9
16.7|
|Administrative costs||
|Net interest (receivable)/payable||
|Interest on schemes’ assets||
|Interest on schemes’ liabilities||
|Total charged to finance
expenses|1.7
2.0
0.1
0.1
(0.1)
(0.1)
1.7
2.0|
|Total charged to net income|2.9
3.1
0.1
0.1
0.1
(0.1)
3.1
3.1|
The post-retirement mortality assumptions used to value the benefit obligation at 31 December 2024 and 31 December 2023 are based on the S3PA base tables. Assumed life expectancies on retirement at age 65 are:
The total Group actuarial gains on defined benefit retirement schemes and retirement healthcare are as follows:
||2024
2023|
|---|---|
||Nuffield
Health
Years
Aspen
Years
Nuffield
Health
Years
Aspen
Years|
|Retiring today
Males
Females|20.6
20.8
21.4
20.9
23.4
23.3
23.7
23.4|
|Retiring in 20 years’ time
Males
Females|21.8
21.7
23.0
21.9
24.8
24.4
25.1
24.5|
||2024
2023|
|---|---|
||Nuffield
Health
£m
Aspen
£m
Nuffield
Health
£m
Aspen
£m|
|Actual return on schemes’ assets
Less interest on schemes’ assets|(5.0)
(0.8)
19.2
0.7
(13.7)
(0.5)
(14.1)
(0.6)|
||(18.7)
(1.3)
5.1
0.1|
|Actuarial movements on obligations excluding interest costs|34.2
0.8
(6.3)
0.2|
|Net actuarial gain/(loss) on defined benefit retirement schemes|15.5
(0.5)
(1.2)
0.3|
The Charity’s post-retirement defined benefit scheme liability is less than the Group’s by £49.1 million (2023 – £56.9 million) and the Charity has a liability for the asset backed funding (ABF) of the same amount.
Nuffield Health Annual Report 2024
Financial statements
**67**
## Notes to the financial statements continued
for the year ended 31 December 2024
## **8. Defined benefit pensions and other post-retirement benefits** continued
The amounts recognised in the Group Balance sheet are as follows:
|Growth assets
Matching assets including
liability hedge
Other assets|Defined benefit pension funds
Retirement healthcare
Aspen defined
benefit pension funds
Total|
|---|---|
||2024
£m
2023
£m
2024
£m
2023
£m
2024
£m
2023
£m
2024
£m
2023
£m|
||142.9
147.6
–
–
–
0.4
142.9
148.0
127.3
139.9
–
–
11.1
12.3
138.4
152.2
7.5
6.4
–
–
–
–
7.5
6.4|
||277.7
293.9
–
–
11.1
12.7
288.8
306.6|
|Present value of funded
obligations|(293.9)
(330.4)
–
–
(8.9)
(9.9)
(302.8)
(340.3)|
||(16.2)
(36.5)
–
–
2.2
2.8
(14.0)
(33.7)|
|Present value of unfunded
obligations|(1.7)
(1.9)
(3.3)
(2.5)
–
–
(5.0)
(4.4)|
|Net (liabilities)/assets|(17.9)
(38.4)
(3.3)
(2.5)
2.2
2.8
(19.0)
(38.1)|
Changes in the present value of the defined benefit obligation are as follows:
||Defined benefit pension funds
Retirement healthcare
Aspen defined benefit
pension funds
Total|
|---|---|
||2024
£m
2023
£m
2024
£m
2023
£m
2024
£m
2023
£m
2024
£m
2023
£m|
|Opening defined benefit
obligations
Benefits paid
Interest cost
Actuarial gains/(losses)|(332.3)
(326.2)
(2.5)
(2.9)
(9.9)
(10.2)
(344.7)
(339.3)
16.8
16.5
0.4
0.3
0.6
0.6
17.8
17.4
(15.4)
(16.1)
(0.1)
(0.1)
(0.4)
(0.5)
(15.9)
(16.7)
35.3
(6.5)
(1.1)
0.2
0.8
0.2
35.0
(6.1)|
|Closing defined benefit
obligations|(295.6)
(332.3)
(3.3)
(2.5)
(8.9)
(9.9)
(307.8)
(344.7)|
The cumulative actuarial losses recognised in the Statement of financial activities at 31 December 2024 were £77.5 million (2023 – £93.0 million) in relation to the Nuffield Health Pension and Life Assurance Scheme. These results are sensitive both to the actuarial assumptions used and to market conditions. A sensitivity analysis of some of the principal assumptions used to measure the Nuffield Health Pension and Life Assurance Scheme liabilities at 31 December 2024 is set out in the following table. The disclosures are likely to remain volatile in future years, particularly the figures shown in the balance sheet.
|||Liability value||Change in|
|---|---|---|---|---|
||at 31 December|||liability|
|||2024 after||relative to|
|||change||base value|
|||£m||£m|
||||||
|Discount rate up by 0.5% p.a.||279.4||(14.5)|
|Discount rate down by 0.5% p.a.||309.8||15.9|
|RPI inflation rate up by 0.5% p.a.||307.7||13.8|
|RPI inflation rate down by 0.5% p.a.||281.1||(12.8)|
|Mortality: minus 1 year age rating||305.1||11.2|
Changes in the fair value of the post-retirement funds’ assets are as follows:
||Defined benefit pension funds
Retirement healthcare
Aspen defined
benefit pension funds
Total|
|---|---|
||2024
£m
2023
£m
2024
£m
2023
£m
2024
£m
2023
£m
2024
£m
2023
£m|
|Open fair value of plan assets
Interest income
Actuarial(losses)/gains
Contributions paid
Scheme administrative costs
Benefits paid|293.9
284.4
–
–
12.7
12.6
306.6
297.0
13.7
14.1
–
–
0.5
0.6
14.2
14.7
(18.7)
5.1
–
–
(1.3)
0.1
(20.0)
5.2
6.8
7.9
0.4
0.3
–
–
7.2
8.2
(1.2)
(1.1)
–
–
(0.2)
–
(1.4)
(1.1)
(16.8)
(16.5)
(0.4)
(0.3)
(0.6)
(0.6)
(17.8)
(17.4)|
|Closing fair value of plan assets|277.7
293.9
–
–
11.1
12.7
288.8
306.6|
The Charity and Nuffield Health Pension and Life Assurance Scheme (the Scheme) entered into an asset backed funding arrangement in 2016 by which the Nuffield Health Oxford Hospital (The Manor) was sold to and leased back from Nuffield Health Scottish Limited Partnership.
The arrangement results in the Charity having irrevocable cash flow obligations to the Scheme and the Scheme’s assets increasing by the same amount. The cash flows are recorded at their fair value, which at the end of the financial year is £49.1 million (2023 – £56.9 million). As these obligations are due to other members of the Group, no liability has been recognised within the Consolidated financial statements.
At the end of 2024, the Charity’s net post-retirement defined benefit asset is £30.1 million (2023 – asset of £18.8 million) and the liability for asset backed funding due within one year is £2.2 million (2023 – £5.0 million) and due after one year is £46.9 million (2023 – £51.9 million).
Nuffield Health Annual Report 2024
Financial statements
**68**
## Notes to the financial statements continued
for the year ended 31 December 2024
## **8. Defined benefit pensions and other post-retirement benefits** continued
## Virgin Media Section 37 ruling
The Group is aware of the Virgin Media Section 37 case, which concerns the validity of certain historical amendments made to pension schemes under Section 37 of the Pensions Act 1995. In response, the Trustee’s legal advisors have undertaken an initial review to assess whether any amendments to the Group’s defined benefit schemes may be affected.
As part of this review, certain historical amendments within both the Aspen Scheme and the PLAS have been identified as potentially impacted by the ruling. However, no assessment has yet been made as to whether these amendments would have a positive or negative effect on the schemes. If it is subsequently determined that the amendments have a material impact, they will be formally reinstated as appropriate.
At this stage, the Trustees have not yet determined whether the impact is material and are continuing to monitor developments. Further reviews will be undertaken if considered appropriate, particularly in light of any future guidance issued by the Department for Work and Pensions (DWP).
## Contingent liability considerations and provisions
Due to the ongoing nature of the legal review, there remains some uncertainty over the potential financial impact of the Virgin Media Section 37 case to the PLAS and Aspen Schemes. If any amendments were found to be void and required reinstatement, this could result in a change in scheme liabilities, however, at present, it is not possible to reliably quantify any potential impact to the scheme. The Group has considered whether a provision or contingent liability under FRS 102 Section 21 (Provisions and Contingencies) is required. Based on the current assessment by the Trustees, no provision has been recognised and no contingent liability has been disclosed, as there is no known present obligation and the financial impact, if any, cannot be reliably estimated.
The Group continues to work closely with the Trustees and their legal advisors to monitor the situation and will provide further updates should any material implications arise.
## **9. Defined contribution pension schemes**
|||||2024||2023|
|---|---|---|---|---|---|---|
|||||£m||£m|
||||||||
|The amounts charged to the income and expenditure account and statement of financial activities||||23.9||20.0|
|Contributions owing to the pension schemes at 31 December||||3.0||2.7|
## **10. Trustee remuneration**
The Trustees are the same as Directors under company law. Remuneration was paid in relation to services provided as Trustees of the Charity, as per the Nuffield Health Articles of Association clauses 4.1 to 4.4.
|Trustees of the Charity, as per the NuffieldHealthArticles of Association clauses 4.1 to 4.4.|||||
|---|---|---|---|---|
|||2024||2023|
|||£||£|
||||||
|Emoluments paid to the Trustees:|||||
|Mr M W Bryant (retired July 2023)||–||25,000|
|Mr P Figgis||55,000||45,000|
|Mr D W Lister (retired July 2023)||–||20,000|
|MsN JMacdonald*||45,000||62,000|
|Mr S Maslin||42,000||41,000|
|Mr N Sachdev (resigned July 2024)||21,000||36,000|
|Dr J Bajwa||40,000||37,000|
|Mr M Stansfeld||35,000||35,000|
|T Killen||35,000||20,000|
|L Rochford||39,000||23,000|
|K Whitworth||35,000||12,000|
|E J Robb||39,000||37,000|
|||386,000||393,000|
*The emoluments paid during FY2023 include £6,000 in respect of services provided in prior years.
The highest paid Trustee, who was also a Director under company law in 2024, was Mr P Figgis with remuneration of £55,000 (2023 – Ms N Macdonald £62,000). Ms N Macdonald acted as Executive Chair of the Charity for three months during the year and therefore remuneration for this period was reflected as an employee. During this time, Mr P Figgis served as Chair of the Board of Trustees.
The total value of employer contributions towards defined contribution pension schemes in respect of the Trustees is £1,278 (2023 – £1,584) included within the £425,000 remuneration above. Travel and subsistence paid on behalf of or reimbursed to 7 Trustees was £13,623 (2023 – £12,020 to 9 Trustees) in the year.
The number of employees in defined contribution pension schemes at year end was 13,228 (2023 – 12,515).
Nuffield Health Annual Report 2024
Financial statements
**69**
## Notes to the financial statements continued
for the year ended 31 December 2024
## **11. Group employees**
|||2024||2023|
|---|---|---|---|---|
|||Number||Number|
||||||
|Average number of employees:|||||
|Hospital||9,808||9,160|
|Wellbeing||7,493||7,146|
|Support||2,060||1,909|
|Total||19,361||18,215|
The employees are classified into the categories where the related costs are finally charged.
||Note
2024
£m
2023
£m|
|---|---|
|Staff costs during the year:
Wages and salaries
Social security costs
Defined benefit scheme administrative costs
Defined contribution|475.0
438.8
44.8
40.7
8
1.4
1.1
9
23.9
20.0|
|Total employee costs
Agency costs|545.1
500.6
16.6
25.5|
|Total staff related costs|561.7
526.1|
|**Termination benefits**|Charged to Consolidated and
Charity statement of financial
activities and Consolidated
income statement
Accrued at year end|
||2024
£m
2023
£m
2024
£m
2023
£m|
|Staff costs during the year:
Individual redundancy and terminations
Associated with reorganisations|6.1
1.3
1.2
–
–
2.8
–
–|
||6.1
4.1
1.2
–|
The emoluments of the higher paid employees fell within the ranges indicated below. These emoluments include any s. bonuses payable, redundancy payments and settlement agreement payments but exclude pension contribution
|||2024||2023|
|---|---|---|---|---|
|||Number||Number|
||||||
|£60,000 to £69,999||346||252|
|£70,000 to £79,999||168||138|
|£80,000 to £89,999||117||86|
|£90,000 to £99,999||39||47|
|£100,000 to £109,999||28||27|
|£110,000 to £119,999||16||20|
|£120,000 to £129,999||8||14|
|£130,000 to £139,999||14||12|
|£140,000 to £149,999||8||6|
|£150,000 to £159,999||8||6|
|£160,000 to £169,999||5||11|
|£170,000 to £179,999||1||10|
|£180,000 to £189,999||4||13|
|£190,000 to £199,999||3||2|
|£200,000 to £209,999||4||5|
|£210,000 to £219,999||2||7|
|£220,000 to £229,999||1||2|
|£230,000 to £239,999||3||1|
|£240,000 to £249,999||–||2|
|£250,000 to £259,999||2||–|
|£260,000 to £269,999||–||1|
|£270,000 to £279,999||1||3|
|£280,000 to £289,999||1||1|
|£290,000 to £299,999||–||1|
|£310,000 to £319,999||1||–|
|£330,000 to £339,999||–||1|
|£340,000 to £349,999||–||1|
|£370,000 to £379,999||–||2|
|£460,000 to £469,999||1||–|
|£480,000 to £489,999||–||1|
|£540,000 to £549,999||–||1|
|£650,000 to £659,999||1||–|
|£970,000 to £979,999||-||1|
|£1,430,000 to £1,439,999||1||–|
Nuffield Health Annual Report 2024
Financial statements
**70**
## Notes to the financial statements continued
for the year ended 31 December 2024
## **11. Group employees** continued
The total emoluments and employee benefits for the Executive Committee, who are the key management personnel, in the year was £4.0 million (2023 – £3.4 million). The highest-paid individual in 2024 was the former Chief Executive Officer, Steve Gray (2023 – Steve Gray).
|Steve Gray (2023 – Steve Gray).|||||
|---|---|---|---|---|
|||2024||2023|
|||£m||£m|
||||||
|Employer contributions towards defined contribution pension schemes for higher-paid employees||5.1||4.3|
||||||
|||2024||2023|
|||Number||Number|
||||||
|Number of higher-paid employees to whom retirement benefits are accruing under the defined contribution|||||
|pension scheme||720||652|
## **12. Tax on deficit**
|**12. Tax on deficit**||
|---|---|
||Group
Charity|
||2024
£m
2023
£m
2024
£m
2023
£m|
|Current tax
United Kingdom corporation tax main rate of 25% (2023 – 23.5%)|–
–
–
–|
The parent company is a charity whose charitable activities are exempt from corporation tax.
The subsidiary companies have tax losses available to carry forward against future taxable profits or sufficient shareholder funds to Gift Aid taxable profits to the Charity. No deferred taxation asset has been recognised within the financial statements at 31 December 2024 (2023 – £Nil) in respect of these losses because they are unlikely to be recovered.
## **13. Intangible fixed assets**
||Group
Charity|
|---|---|
||Goodwill
£m
Assets in the
course of
construction
£m
Computer
software
£m
Total
£m
Goodwill
£m
Assets in the
course of
construction
£m
Computer
software
£m
Total
£m|
|Cost
At 1 January 2024
Additions
Transfers
Disposals|122.7
3.0
215.3
341.0
123.4
3.0
215.4
341.8
–
11.2
0.2
11.4
–
11.2
0.2
11.4
–
(5.9)
11.6
5.7
–
(5.9)
11.6
5.7
(0.9)
–
(0.2)
(1.1)
–
–
(0.2)
(0.2)|
|At 31 December 2024|121.8
8.3
226.9
357.0
123.4
8.3
227.0
358.7|
|Amortisation
At 1 January 2024
Charge for the year
Transfers
Impairment
Disposals|(99.4)
(2.3)
(152.5)
(254.2)
(100.3)
(2.3)
(152.2)
(254.8)
(7.8)
–
(12.0)
(19.8)
(7.8)
–
(12.0)
(19.8)
–
–
(5.9)
(5.9)
–
–
(5.9)
(5.9)
–
(0.2)
(0.1)
(0.3)
–
(0.2)
(0.1)
(0.3)
0.3
–
0.2
0.5
–
–
0.1
0.1|
|At 31 December 2024|(106.9)
(2.5)
(170.3)
(279.7)
(108.1)
(2.5)
(170.1)
(280.7)|
|Net book value at
31 December 2024|14.9
5.8
56.6
77.3
15.3
5.8
56.9
78.0|
|Net book value at
31 December 2023|23.3
0.7
62.8
86.8
23.1
0.7
63.2
87.0|
Goodwill is the difference between the consideration paid for the acquisitions and the fair value of the assets and liabilities attributed to the purchase.
Additions during the year included capitalised internal project development costs of £2.5 million (2023 – £3.0 million). The internal project development costs capitalised to date are £41.7 million (2023 – £39.2 million). Software development costs were recognised as an intangible asset as per the accounting policy 14 Intangible fixed assets and amortisation. During the year the Group recognised intangible fixed assets impairment charge in relation to NEPR project cost of £0.3 million (2023 – £Nil).
Transfers between tangible and intangible fixed asset categories net to £Nil across cost, amortisation and depreciation, with equal adjustments made in notes 13 and 14.
Nuffield Health Annual Report 2024
Financial statements
**71**
## Notes to the financial statements continued
for the year ended 31 December 2024
## **14. Tangible fixed assets**
|**14. Tangible fixed assets**||
|---|---|
|**Group**|Group|
||Assets in course
of construction
£m
Land and
buildings
£m
Leasehold
£m
Equipment
£m
Total
£m|
|Cost or valuation
At 1 January 2024
Additions at cost
Transfers
Disposals
Revaluation surplus|18.3
1,519.8
210.7
701.8
2,450.6
13.5
13.4
6.2
23.1
56.2
(27.3)
1.6
4.0
16.0
(5.7)
–
(0.8)
(8.7)
(8.6)
(18.1)
–
4.4
–
–
4.4|
|At 31 December 2024|4.5
1,538.4
212.2
732.3
2,487.4|
|Depreciation and impairment
At 1 January 2024
Charge for the year
Transfers
Disposals
Impairment|–
(126.1)
(91.1)
(573.8)
(791.0)
–
(26.3)
(10.8)
(34.5)
(71.6)
–
(1.5)
6.9
0.5
5.9
–
0.6
7.6
7.2
15.4
–
–
(34.6)
–
(34.6)|
|At 31 December 2024|–
(153.3)
(122.0)
(600.6)
(875.9)|
|Net book value at 31 December 2024|4.5
1,385.1
90.2
131.7
1,611.5|
|Net book value at 31 December 2023|18.3
1,393.7
119.6
128.0
1,659.6|
The Group has revalued its land and buildings on 31 December 2024. Following the revaluation, £1.7 million of buildings valuation surplus and £2.7 million of land valuation surplus was transferred to the revaluation reserve. An unwinding of the revaluation surplus in relation to land and buildings of £18.3 million was transferred to the general fund during the year. The revaluation surplus comprises of £1,160.5 million (2023 – £1,177,1 million) for buildings and £76.1 million (2023 – £73.4 million) for land. The fair value of buildings is £1,277.9 million (2023 – £1,289.2 million) and fair value of land is £107.2 million (2023 – £104.5 million).
Under the historic cost model, the net book value of buildings would be £117.4 million (2023 – £112.1 million) and the net book value of land would be £31.1 million (2023 – £31.1 million). The amount on which depreciation on buildings is being calculated is £1,302.6 million (2023 – £238.2 million). Under the current model, the depreciation of buildings is being calculated on the fair value (2023 – cost model) following the change in accounting policy at the end of the prior year. The net book value of equipment and motor vehicles held under finance leases and similar hire purchase contracts is £10.2 million (2023 – £4.2 million).
|**Charity**|Charity|
|---|---|
||Assets in course
of construction
£m
Land and
buildings
£m
Leasehold
£m
Equipment
£m
Total
£m|
|Cost or valuation
At 1 January 2024
Additions at cost
Transfers
Disposals
Revaluation surplus|18.3
1,517.5
210.7
701.8
2,448.3
13.5
13.4
6.1
22.2
55.2
(27.3)
1.6
4.0
16.0
(5.7)
–
(0.8)
(8.7)
(7.7)
(17.2)
–
4.4
–
–
4.4|
|At 31 December 2024|4.5
1,536.1
212.1
732.3
2,485.0|
|Depreciation and impairment
At 1 January 2024
Charge for the year
Transfers
Disposals
Impairment|–
(123.8)
(91.1)
(573.8)
(788.7)
–
(26.3)
(10.7)
(34.3)
(71.3)
–
(1.5)
6.9
0.5
5.9
–
0.6
7.2
7.4
15.2
–
–
(34.6)
–
(34.6)|
|At 31 December 2024|–
(151.0)
(122.3)
(600.2)
(873.5)|
|Net book value at 31 December 2024|4.5
1,385.1
89.8
132.1
1,611.5|
|Net book value at 31 December 2023|18.3
1,393.7
119.6
128.0
1,659.6|
The Charity has revalued its land and buildings on 31 December 2024. Following the revaluation, £1.7 million of buildings valuation surplus and £2.7 million of land valuation surplus was transferred to the revaluation reserve. An unwinding of the revaluation surplus in relation to land and buildings of £16.4 million was transferred to the general fund during the year. The revaluation surplus comprises of £1,027.4 million (2023 – £1,042.1 million) for buildings and £76.1 million (2023 – £73.4 million) for land. The fair value of buildings is £1,277.9 million (2023 – £1,289.2 million) and fair value of land is £107.2 million (2023 – £104.5 million).
Under the historic cost model, the net book value of buildings would be £250.5 million (2023 – £247.1 million) and the net book value of land would be £31.1 million (2023 – £31.1 million). The amount on which depreciation on buildings is being calculated is £1,302.6 million (2023 – £370.9 million). Under the current model, the depreciation of buildings is being calculated on the fair value (2023 – cost model) following the change in accounting policy at the end of the prior year. The fair value of buildings held under finance leases is £734.0 million (2023 – £715.2 million). Equipment and motor vehicles held under finance leases and similar hire purchase contracts is £10.2 million (2023 – £4.2 million).
Nuffield Health Annual Report 2024
Financial statements
**72**
## Notes to the financial statements continued
for the year ended 31 December 2024
## **14. Tangible fixed assets** continued
## Group and Charity
Following an assessment of the market value of Nuffield Health’s estate, the Group and Charity adopted the revaluation model for land and buildings on 31 December 2023. The fair value has been derived from the desk top valuation performed by professional valuers with accordance with RICS Valuation - Global Standards effective from 31 January 2022 and the Red Book UK . National Supplement effective from 1 May 2024 This approach follows a full physical valuation undertaken at the point the revaluation model was first applied.
The reported fair value for land and buildings is based on the overall property valuation, less the net book value of equipment that could be removed from the site in the event of a sale. Under the cost model, fixtures and fittings are included within land and buildings for the revalued sites. Therefore, the valuation includes the trading potential of the property.
Additions during the year included capitalised internal project development costs of £0.2 million (2023 – £0.2 million). The interest charges and internal project development costs capitalised to date are £10.5 million (2023 – £10.7 million) and £11.3 million (2023 – £11.1 million) respectively.
The Hospitals impairment review resulted in an impairment charge for St. Bartholomew’s Hospital of £32.6 million (2023 – £2.3), and a £0.9 million impairment reversal (2023 – £2.7 million charge) in relation to Woking hospital. Transfers between tangible and intangible fixed asset categories net to £Nil across cost, amortisation and depreciation, with equal adjustments made in notes 13 and 14.
## Charity
During 2022, the Charity sold the freeholds of 10 hospitals to Nero Propco LLP, another group company, under a sale and leaseback transaction as part of the Group’s refinancing arrangements. The Charity is leasing these 10 properties from Nero Propco LLP over a 50-year term with the option to purchase at the end of the term. This lease has been recognised as a finance lease and the properties remain in the land and buildings category within tangible fixed assets as the risks and rewards relating to these properties have remained with the Charity throughout the transaction. A surplus of £133.7 million was recognised which reflects the difference between funds received and the previous net book value. A corresponding liability had been recorded within Creditors to reflect the deferred gain. This is being amortised over 50 years within gain or loss on disposal of fixed assets.
## **15. Investments**
**----- Start of picture text -----**
UK listed Unlisted
investment investment Total
Group £m £m £m
Market value
At 1 January 2024 0.1 0.1 0.2
At 1 January and 31 December 2024 0.1 0.1 0.2
Subsidiary UK listed Unlisted
undertaking investment investment Total
Charity £m £m £m £m
Cost or market value
At 1 January 2024 56.0 0.1 0.1 56.2
At 1 January and 31 December 2024 56.0 0.1 0.1 56.2
Provision for impairment
– –
At 1 January 2024 (20.1) (20.1)
– –
At 1 January and 31 December 2024 (20.1) (20.1)
Net book value at 31 December 2024 35.9 0.1 0.1 36.1
Net book value at 31 December 2023 35.9 0.1 0.1 36.1
**----- End of picture text -----**
## The Group’s investments are held primarily to provide an investment return for the Charity.
The shares of a UK listed investment are valued at their market value at the Balance sheet date. The unlisted investments are valued at the lower of cost or management’s estimate of market value.
During the year the Group recognised a total impairment charge of £34.9 million (2023 – £2.5 million), including £0.3 million (2023 – £2.3 million) of intangible fixed assets impairment.
In fitness and wellbeing sites, an impairment charge of £5.2 million and a total impairment reversal of £2.3 million (2023 – £2.2 million charge) was recorded, following the onerous lease assessment and associated impairment reviews at year end.
Nuffield Health Annual Report 2024
Financial statements
**73**
## Notes to the financial statements continued
for the year ended 31 December 2024
## **15. Investments** continued
## Subsidiary undertakings
The subsidiary undertakings at 31 December 2024 are shown below:
||||Class of|Class of||||Portion held by|||
|---|---|---|---|---|---|---|---|---|---|---|
||Company||share capital|||Portion held by||the other Group|||
|Company name|Number||held|||parent company||companies||Nature of business|
||||||||||||
|Registered in England and Wales|||||||||||
|Archer Leisure Ltd|01685725||Ordinary|||||100%||Dormant|
|Ark Leisure Management Ltd|03735682||Ordinary|||||100%||Dormant|
|Aspen Healthcare Ltd|3471084||Ordinary|||100%||||Subsidiary holding company|
|Aspen Leasing Ltd|01913617||Ordinary|||||100%||Dormant|
|Bladerunner Ltd|04035973||Ordinary|||100%||||Dormant|
|Body and Mind Ltd|03712276||Ordinary|||||100%||Dormant|
|Cannons Adventures Ltd|02413844||Ordinary|||||100%||Dormant|
|Cannons Covent Garden Ltd|01594304||Ordinary|||100%||||Dormant|
|Cannons Group Ltd|00384113||Ordinary|||||100%||Subsidiary holding company|
|Cannons Health Clubs Ltd|03601050||Ordinary|||||100%||Dormant|
|Cannons Sports Clubs (U.K.) Ltd|01416792||Ordinary|||100%||||Dormant|
|Centre Court Tennis Ltd|02460253||Ordinary|||||100%||Dormant|
|Chichester (Leasing) Company Ltd|02578008||Ordinary|||||100%||Dormant|
|Chichester Independent Hospital Ltd|02542995||Ordinary|||100%||||Dormant|
|Corby Tennis Ltd|2606177||Ordinary|||||100%||Dormant|
|Greens Health & Fitness Ltd|6126413||Ordinary|||100%||||Dormant|
|Health Club Acquisitions Ltd|04166910||Ordinary|||||100%||Subsidiary holding company|
|Health Club Investments Group Ltd|04167080||Ordinary|||100%||||Subsidiary holding company|
|Health Club Investments Ltd|04167038||Ordinary|||||100%||Dormant|
|Healthscore Ltd|08609624||Ordinary|||100%||||Dormant|
|Highgate Hospital LLP|OC370636||Ordinary|||||100%||Dormant|
|Hillside Holdings Ltd|02320361||Ordinary|||||100%||Dormant|
|Hillside Hospital Ltd|02292605||Ordinary|||||100%||Dormant|
|Holly House Hospital Ltd*|01340973||Ordinary|||||100%||Dormant|
|Holly House Hospital Oncology LLP*|OC399769||Ordinary|||50%||50%||Dormant|
|Independent Surgery Centres Ltd|03004585||Ordinary|||100%||||Subsidiary holding company|
||||Class of|Class of||||Portion held by|||
|---|---|---|---|---|---|---|---|---|---|---|
||Company||share capital|||Portion held by||the other Group|||
|Company name|Number||held|||parent company||companies||Nature of business|
||||||||||||
|ISC Estates Ltd|03249073||Ordinary|||||100%||Dormant|
|ISC Leasing (Ipswich) Ltd|03298331||Ordinary|||||100%||Dormant|
|ISC Projects Ltd|03249064||Ordinary|||||100%||Property company|
|Jonathan Webb Ltd|04605061||Ordinary|||100%||||Dormant|
|MSCP Holdings Ltd|08206709||Ordinary|||100%||||Subsidiary holding company|
|MSCP Wellbeing Ltd|02730279||Ordinary|||||100%||Subsidiary holding company|
|Mythbreaker Ltd|05581441||Ordinary|||100%||||Provision of ancillary trading services|
|Nuffield Cosmetic Surgery Ltd*|02327543||Ordinary|||100%||||Dormant|
|Nuffield Health Care Ltd|01279419||Ordinary|||100%||||Dormant|
|Nuffield Health Day Nurseries Ltd|03489051||Ordinary|||100%||||Subsidiary holding company|
|Nuffield Health One Ltd|11171870||Ordinary|||100%||||Dormant|
|Nuffield Health Pension Trustees Ltd|10001741||Ordinary|||||100%||Pension Trustee company|
|Nuffield Health Wellbeing Ltd|02849324||Ordinary|||||100%||Subsidiary holding company|
|Nuffield Nursing Homes Trust|04639458||Ordinary|||100%||||Dormant|
|Nuffield Proactive Health Group Ltd|05322913||Ordinary|||100%||||Dormant|
|Nuffield Proactive Health Ltd|01568809||Ordinary|||||100%||Dormant|
|Nuffield Proactive Health Medical Ltd|04860867||Ordinary|||||100%||Dormant|
|Parkside Hospital Ltd*|01328198||Ordinary|||||100%||Dormant|
|Parkside IHL Scanning Services LLP|OC415560||Ordinary|||||52%||Provision of medical services|
|Pinnacle Leisure Group Ltd*|03242383||Ordinary|||||100%||Dormant|
|Precis (1748) Ltd|03770350||Ordinary|||||100%||Dormant|
|Sherburne (Leasing) Company Ltd|03297244||Ordinary|||||100%||Dormant|
|The Food Calculator Ltd*|05882911||Ordinary|||||100%||Dormant|
|Twickenham Leisure Ltd|01801282||Ordinary|||100%||||Dormant|
|Vale Health Partners Ltd|06023923||Ordinary|||100%||||Dormant|
|Vale Healthcare Ltd|04237264||Ordinary|||23%||77%||Dormant|
|Vardon Ltd|03571549||Ordinary|||||100%||Dormant|
|Wandsworth Leisure Ltd|01406593||Ordinary|||100%||||Dormant|
|Registered in Scotland|||||||||||
|Edinburgh Medical Services Ltd|SC360250||Ordinary|||||100%||Dormant|
|Nuffield Health (General Partner) Ltd|SC525658||Ordinary|||100%||||Managing partner of NHSLP|
|Nuffield Health Scottish Limited|||||||||||
|Partnership (NHSLP)|SL025621||Ordinary|||15%||85%||Property company|
|The Edinburgh Clinic Ltd*|SC413642||Ordinary|||||100%||Dormant|
* Entity filed for strike-off and dissolved subsequent to the year end date. Please refer to note 35 for more information.
Nuffield Health Annual Report 2024
Financial statements
**74**
## Notes to the financial statements continued
for the year ended 31 December 2024
## **15. Investments** continued
During 2022, the Charity became a member of Nero Propco LLP, a special-purpose entity. No capital was invested. The freeholds of 10 hospitals were sold to Nero Propco LLP in September 2022 under a sale and leaseback transaction, as part of the Group’s refinancing arrangements. The Charity is leasing these 10 properties from Nero Propco LLP over a 50-year term with the option to purchase at the end of the term. This lease has been recognised as a finance lease for the Charity in notes 18, 19 and 20. While the Charity does not own more than half of the voting power within Nero Propco LLP, it has been consolidated into the Group financial statements on the basis that control exists. Nero Propco LLP was incorporated to meet the needs of the Charity and its activities represent, in substance, a continuation of the Charity’s own. Furthermore, the Charity will obtain and retain the majority of the risks and rewards related to Nero Propco LLP and its assets.
The result of consolidating Nero Propco LLP is that a third-party loan is brought onto the Group’s balance sheet, as shown in notes 18, 19 and 20. Nero Propco LLP, company number OC443283, is registered in England and Wales at 1 Bartholomew Lane, London, EC2N 2AX.
On 30 November 2024, Aspen Healthcare Limited, a group company disposed of Cancer Centre London LLP (CCL), a wholly owned subsidiary, with an associated profit on disposal of £8.5 million reported within adjusted items.
All subsidiary undertakings are registered in England and Wales and their registered office is Epsom Gateway, Ashley Avenue, Epsom, Surrey KT18 5AL except four subsidiaries registered in Scotland. Nuffield Health (General Partner) Ltd and Nuffield Health Scottish Limited Partnership are registered at Nuffield Health Beaconsfield Road, Glasgow, Scotland, G12 0PJ. Edinburgh Medical Services Ltd and The Edinburgh Clinic Ltd are registered in Scotland at 40 Colinton Road, Edinburgh, EH10 5BT.
## Relationship with subsidiaries
The majority of subsidiaries are wholly owned by the Charity, and the Directors are generally members of the Executive Committee.
Activities carried out by subsidiaries are in the main noncharitable, including activities coming with acquisitions that have not been transferred to the Charity or businesses that are being developed with the aim of selling or entering into a partnership with another organisation.
The aim is for the subsidiaries to make a return to the Charity. Intercompany loans and trading are covered by written agreements.
## **16. Stock**
||Group
Charity|
|---|---|
||2024
£m
2023
£m
2024
£m
2023
£m|
|Raw materials and consumables|16.5
18.1
16.4
16.9|
There were no significant differences between the replacement cost and the values disclosed above.
Consignment stock not included in the Group Balance sheet is £19.6 million (2023 – £19.3 million). Consignment stock is stock owned by a supplier that is stored in our premises, which will be charged to the Group if drawn on or when the Group takes contractual liability for the stock.
The value of stock recognised as an expense during the year was £185 million (2023 – £163.7 million).
## **17. Debtors falling due within one year**
|**17. Debtors falling due within one year**||
|---|---|
||Group
Charity|
||2024
£m
2023
£m
2024
£m
2023
£m|
|Trade debtors
Amount owed by Group undertakings
Other debtors
Prepayments
Accrued income|72.9
71.4
72.7
70.0
–
–
2.9
3.0
13.5
6.8
12.9
6.7
24.6
36.3
24.8
36.1
12.5
14.4
12.4
14.3|
||123.5
128.9
125.7
130.1|
Interest is charged on loans to Group undertakings at various rates of interest between 2.7% and 2.9% above the base rate (2023 – 2.7% and 2.9% above the base rate). The loans are repayable on demand and are unsecured.
Nuffield Health Annual Report 2024
Financial statements
**75**
## Notes to the financial statements continued
for the year ended 31 December 2024
## **18. Creditors: amounts falling due within one year**
|**18. Creditors: amounts falling due within one year**||
|---|---|
|Note|Group
Charity|
||2024
£m
2023
£m
2024
£m
2023
£m|
|Trade creditors
Amounts owed to Group undertakings
Obligations under finance leases
Social security and other taxes
Other creditors
Pension contributions
Liability for asset-backed funding
8
Accruals
Deferred income
Deferred gain on sale and leaseback disposal
Third-party loan
Bank loan
Bank overdraft|46.6
59.3
46.6
58.3
–
–
54.3
39.8
3.1
0.4
4.6
1.9
12.5
13.1
12.4
13.0
18.6
13.5
16.8
14.5
3.0
2.7
3.0
2.6
–
–
2.2
5.0
95.9
112.3
93.2
109.2
16.0
14.4
16.0
12.6
–
–
2.7
2.7
9.4
1.9
–
–
–
10.0
–
10.0
18.0
13.0
18.0
13.0|
||223.1
240.6
269.8
282.6|
The Deferred gain on the sale and leaseback disposal is amortised over the lease period of 50 years. During the year, £2.7 million was credited to the Charity Statement of financial activities and recognised within Gain on disposal of tangible assets.
Included within Obligations under finance leases for the Charity is a finance lease for 10 properties held with Nero Propco LLP, a Group company. The lease payments are indexed linked, with the annual increase capped at 5%. The lease liability was measured at inception as the present value of the minimum lease payments and the finance charge is determined using the effective interest rate method. The additional charge incurred as a result of indexation is deemed contingent rent and expensed to the Consolidated and Charity statement of financial activities and Consolidated income statement.
Interest is charged on amounts owed to Group undertakings at various rates of interest between 2.7% and 2.9% above the base rate (2023 – 2.7% and 2.9% above the base rate). The loans are repayable on demand and are unsecured.
## **19. Creditors: amounts falling due after more than one year**
|Note|Group
Charity|
|---|---|
||2024
£m
2023
£m
2024
£m
2023
£m|
|Bank loan
Deferred expenses in connection with bank loan
Fair value of interest rate derivatives|266.0
270.0
266.0
270.0
(7.6)
(9.1)
(7.6)
(9.1)
1.1
3.2
1.1
3.2|
||259.5
264.1
259.5
264.1|
|Obligations under finance leases
Liability for asset-backed funding
8
Third-party loan
Deferred expenses in connection with loan
Deferred gain on sale and leaseback disposal
Other creditors|17.0
1.8
219.9
208.8
–
–
46.9
51.9
170.0
193.1
–
–
(0.9)
(0.9)
–
–
–
–
125.0
127.7
13.5
4.6
13.4
4.6|
||459.1
462.7
664.7
657.1|
In September 2022, Nero Propco LLP, a group company, took out an indexed linked third-party loan of £210.9 million in order to purchase the 10 freehold properties from the Charity. The loan is a non-basic financial instrument and so has been revalued to £179.4 million as at 31 December 2024. Further information is disclosed in policy 5 on page 55.
## Liability for asset backed funding
|Liability for asset backed funding|Charity|
|---|---|
||Risk free
discount
rate
%
2024
Forecast
payments
£m
Fair value
of liability
£m
Risk free
discount
rate
%
2023
Forecast
payments
£m
Fair value
of liability
£m|
|Amounts falling due within one year
Amounts falling due after one year|4.46%
4.8
2.2
4.73%
8.0
5.0
4.02% to
4.26%
59.3
46.9
3.25% to
4.01%
60.6
51.9|
||64.1
49.1
68.6
56.9|
|Cash contribution paid in year|(4.0)
(4.0)|
Deferred income represents amounts received in advance of providing wellbeing membership and hospital procedures services in future periods. The deferred income balance at year end is recognised as revenue in the following financial year.
Nuffield Health Annual Report 2024
Financial statements
**76**
## Notes to the financial statements continued
for the year ended 31 December 2024
## **20. Borrowings**
The future minimum payments on borrowings are unindexed and undiscounted minimum cash outflows on borrowings and are classified as follows:
|and are classified as follows:||
|---|---|
|Note|Group total funds
Charity total funds|
||2024
£m
2023
£m
2024
£m
2023
£m|
|Borrowings are repayable as follows:
Not later than one year:
Bank overdraft
Finance leases
Third-party loan|18.0
13.0
18.0
13.0
3.9
0.5
14.1
9.9
9.6
9.4
–
–|
|Later than one year and not later than five years:
Bank loans
Finance leases
Third-party loan|266.0
280.0
266.0
280.0
13.5
1.7
54.4
39.3
38.3
37.6
–
–|
|Later than five years:
Finance leases
Third-party loan|5.3
0.5
439.6
409.3
411.8
408.8
–
–|
||766.4
751.5
792.1
751.5|
The Charity holds a finance lease relating to 10 hospitals that were sold to Nero Propco LLP, a Group company, under a sale and leaseback transaction in 2022. The lease term is 50 years with the option to purchase at the end of the term. During the year, the Charity paid £10.0 million (2023 – £9.6 million) to Nero Propco LLP in relation to finance leases, with the balance of future minimum lease payments outstanding of £485.4 million (2023 – £478.6 million) at the year end.
Nero Propco LLP, holds an indexed-linked third-party loan, the original proceeds of which were used to purchase the 10 freehold properties from the Charity in 2022. The finance lease payments from the Charity allow Nero Propco LLP to service this debt.
The bank loans, overdraft and secured loan notes are secured by a fixed charge on some of the freehold properties of the Group and a floating charge on all the assets of the Charity. The terms of the bank loan and third-party loan are shown below:
|Description|Security|Security|Interest rate|Interest rate||Repayment date|
|---|---|---|---|---|---|---|
||||||||
|Bank loans and overdraft|Secured||Variable 3.15-3.30%+ SONIA|||23 September 2027|
|Bank loans – temporary facility|Secured||Variable 3.15-3.30%+ SONIA|||31 August 2026|
|Third-party loan|Secured||3.3092% + RPI indexation capped at 5%p.a.|||22 September 2072|
Please refer to note 35 for further details on the temporary bank loan facility.
## **21. Finance derivatives**
The financial derivatives in place during 2024 were:
|||||Fixed rate||Principal|
|---|---|---|---|---|---|---|
||Maturity|||%||£m|
||||||||
|Charity and Group|||||||
|At 1 January and 31 December 2024|||||||
|Interest rate swap – floating to fixed rate|Sep-25|||5.53%||67.5|
|Interest rate swap – floating to fixed rate|Sep-25|||5.57%||67.5|
The fair value of derivatives at 31 December 2024 was £1.1 million (2023 – £3.2 million). The derivatives are recognised in the Balance sheet at their fair value within creditors and the movement in the fair value is included in interest payable within the Consolidated statement of financial activities and the Consolidated income statement. The above table excludes the mark to market derivative on the asset-backed funding arrangement in the Charity and the fair value movement on the third-party loan, both of which are included in note 7.
Nuffield Health Annual Report 2024
Financial statements
**77**
## Notes to the financial statements continued
for the year ended 31 December 2024
## **22. Provisions for liabilities**
|**22. Provisions for liabilities**||||||||||
|---|---|---|---|---|---|---|---|---|---|
|||Property||Self||||||
|||related||insured||Other||Total||
|**Group**||£m||£m||£m||£m||
|||||||||||
|As at 1 January 2024||76.0||3.8||3.2||83.0||
|Additional provision||15.1||12.1||0.8||28.0||
|Unwinding of discount rate||3.0||–||–||3.0||
|Utilisation of provision||(8.2)||(0.8)||(0.3)||(9.3)||
|Reversal of provision||(26.3)||(0.8)||(3.7)||(30.8)||
|At 31 December 2024||59.6||14.3||–||73.9||
|||Property||Self||||||
|||related||insured||Other||Total||
|**Charity**||£m||£m||£m||£m||
|||||||||||
|As at 1 January 2024||76.0||3.8||3.2||83.0||
|Additional provision||15.1||12.1||0.8||28.0||
|Unwinding of discount rate||3.0||–||–||3.0||
|Utilisation of provision||(8.2)||(0.8)||(0.3)||(9.3)||
|Reversal of provision||(26.3)||(0.8)||(3.7)||(30.8)||
|At 31 December 2024||59.6||14.3||–||73.9||
The property-related provisions are estimated unavoidable costs relating to vacant properties and onerous leases. The costs of the vacant properties are certain. The provisions are discounted. Provisions are utilised based on the remaining lease of individual sites.
The onerous lease provision represents the minimum unavoidable lease cost loss expected to be incurred, after considering the net costs to fulfil the lease. The net costs to fulfil the lease have been determined as the expected cash flows at each site over the remainder of the lease and the net present value of rent.
The provision is calculated on a site-by-site basis and discounted as appropriate. An additional provision of £15.1 million and a reversal of £26.3 million (2023 charge of £27 million and a reversal of £17.3 million) result in a net charge to the Income statement of £11.2 million (2023 – £9.7 million) and are reflected within adjusting items in the Consolidated income statement, Consolidated and Charity statement of financial activities and in note 5.
The self-insured provision covers the estimated exposure to medical negligence and public liability claims. The maximum exposure is limited as insurance provided by a third-party will cover any claims once the cumulative claim value exceeds £1.0 million (2023 – £1.0 million). Where the provision exceeds the excess, an asset has been recognised in debtors for the amount receivable from the insurance provider. Provisions are utilised based on the outcome of claims, which could take a number of years.
Other provisions relate to Fitness & Wellbeing Public liability claims, and the self-pay promise where there are no time limits on the aftercare of eligible patients.
Other provisions can include contractual disputes which
are those identified by the group, including instances where legal claims have been instigated and are being defended by the Group. Claims are considered by the Board of Trustees and are defended robustly where the Board concludes that the Group is not liable. Provision is made for the most likely outcome of each individual case, based upon the information available to the Board.
## **23. Permanent endowments**
||||||||2024||2023|
|---|---|---|---|---|---|---|---|---|---|
||||||||£m||£m|
|||||||||||
|At|1|January and|31|December|2024||0.1||0.1|
The permanent endowment is held for the benefit of Nuffield Health Manor Hospital in Oxford.
Nuffield Health Annual Report 2024
Financial statements
**78**
## Notes to the financial statements continued
for the year ended 31 December 2024
## **24. Financial instruments**
|**24. Financial instruments**||
|---|---|
|Financial assets
Note|Group
Charity|
||2024
£m
2023
£m
2024
£m
2023
£m|
|Measured at fair value through the Consolidated Income statement
and of Consolidated and Charity statement of financial activities
15
Equity instruments measured at cost less impairment
15
Debt instruments measured at amortised cost|0.1
0.1
0.1
0.1
0.1
0.1
36.0
36.0
109.2
104.6
105.6
100.7|
|Financial liabilities
Measured at fair value through the Consolidated Income statement
and of Consolidated and Charity statement of financial activities
Measured at amortised cost|180.5
198.2
50.2
60.1
429.2
480.3
685.0
725.5|
facilities (2023 – £27.0 million). The repayment dates of debt are set out in note 20.
## Credit, liquidity and interest rate risk
## Credit risk
Credit risk arises from deposits and derivative financial instruments with banks and trade debtors. The credit risk relating to banks is managed centrally within the parameters set by the Board of Trustees which restricts the counterparty banks and the exposure to each bank. The risk from trade debtors is considered low as the majority of debtors are with NHS partners and key private medical insurance providers, with the values in the Balance sheet being presented after an allowance for doubtful debts.
The Group holds secured bank debt of £290.0 million, expiring in 2027, as well as a £30.0 million additional facility, expiring in August 2026. The facility was extended post year end, please refer to note 35 for further details. In addition, the Group performs regular cash flow forecasts to manage sufficient liquidity. The cash flow forecasts take into consideration the risks contained within the modelling and monitor progress of any mitigating actions to manage optimum liquidity for the Group.
## Liquidity risk
## Interest rate risk
Prudent liquidity risk management includes maintaining sufficient cash and committed credit facilities. The Group subjects its cash flow forecasts to stress tests to assess the risk of a major cash shortfall or breaches of covenants. Refer to the going concern policy for more information. While current forecasts do not indicate any significant reduction in the amount of cash generated by the Group, any severe shortfall would be addressed by tight control over capital spending and operating costs. At the end of 2024, there were £36.0 million of unutilised bank loan
The Group is exposed to fluctuations in the interest rate. The interest rate management policy is to optimise the balance between the fixed and floating interest rates in order to minimise the annual interest rate costs and reduce volatility. This is achieved by an element of fixed rate borrowing and modifying the interest rate exposure through the use of interest rate swaps; details of the latter are set out in note 21.
## **25. Analysis of net assets between funds**
|**25. Analysis of net assets between funds**||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|||||Post-||||||||
|||||retirement||Revaluation||||Total||
|||General||reserve||reserve||NCI||unrestricted||
|**Group**||£m||£m||£m||£m||£m||
|||||||||||||
|Fund balance||||||||||||
|At 1 January 2024||(132.7)||(38.1)||1,250.5||0.6||1,080.3||
|Net (expenditure)/income||(39.2)||–||–||0.1||(39.1)||
|Other movement in funds||–||15.0||4.4||–||19.4||
|Transfer between funds||16.9||4.1||(18.3)||–||2.7||
|At 31 December 2024||(155.0)||(19.0)||1,236.6||0.7||1,063.3||
|||||||||||||
|||||Post-||||||||
|||||retirement||Revaluation||||Total||
|||General||reserve||reserve||NCI||unrestricted||
|**Charity**||£m||£m||£m||£m||£m||
|||||||||||||
|Fund balance||||||||||||
|At 1 January 2024||(202.7)||18.8||1,115.5||–||931.6||
|Net (expenditure)||(54.1)||–||–||–||(54.1)||
|Other movement in funds||–||8.6||4.4||–||13.0||
|Transfer between funds||16.4||2.7||(16.4)||–||2.7||
|At 31 December 2024||(240.4)||30.1||1.103.5||–||893.2||
The Group and Charity’s assets and liabilities are unrestricted except for £0.1 million (2023 – £0.1 million) of investments that are a permanent endowment and restricted funds comprising cash of £0.8 million (2023 – £0.8 million).
Unrestricted funds amount to a surplus of £1,063.3 million for the Group (2023 – £1,080.3 million) and a £893.2 million surplus for the Charity (2023 – £931.6 million). Within these unrestricted surplus amounts are gains arising from the revaluation of land and buildings on 31 December 2024, amounting to £1,236.6 million for the Group (2023 – £1,250.5 million) and £1,103.5 million for the Charity (2023 – £1,115.5 million). Also within unrestricted funds is a General fund deficit of £155.0 million for the Group (2023 – £132.7 million deficit) and a deficit of £240.4 million for the Charity (2023 – £202.7 million deficit) and the Post-retirement reserve, which shows a deficit of £19.0 million for the Group (2023 – £38.1 million deficit) and a surplus of £30.1 million for the Charity (2023 – £18.8 million surplus). In addition within unrestricted funds there is a non-controlling interest surplus of £0.7 million for the Group (2023 – £0.6 million).
Nuffield Health Annual Report 2024
Financial statements
**79**
## Notes to the financial statements continued
for the year ended 31 December 2024
## **25. Analysis of net assets between funds** continued
During the year, £2.7 million (2023 – £1.6 million) of grant income was transferred between restricted and unrestricted funds as it was fully utilised in 2024 (2023 – fully utilised).
The restricted funds represent donations where the monies received have not yet been used for the purpose defined by the donor. Most of the restricted donations are those given to specific sites that have not yet been used to purchase tangible fixed assets at those locations.
Funds are transferred from restricted to unrestricted when the performance condition connected with that donation has been met or has been used to purchase an asset for general purpose use. As a result, the grant income classified as restricted income, was transferred in full to unrestricted income in 2024.
## **26. Reconciliation of operating deficit to cash flow from operating activities**
|||||2024||2023|
|---|---|---|---|---|---|---|
|||Note||£m||£m|
||||||||
|Total operating (deficit)||||(14.7)||(17.7)|
|Adjusting items in operating surplus||5||15.2||16.9|
|Non-cash elements of post-retirement benefits||||1.4||–|
|Depreciation and amortisation||||91.4||79.2|
|Earnings before interest, tax, depreciation, amortisation, adjusting items and non-cash elements of|||||||
|post-retirement benefits||||93.3||78.4|
|Loss on disposal of assets||||1.6||0.5|
|Decrease/(increase) in stocks||||1.0||(0.8)|
|Decrease/(increase) in debtors||||5.4||(10.0)|
|(Decrease)/increase in creditors||||(7.0)||4.3|
|(Decrease) in provisions||||(0.8)||(4.5)|
|Total cash flow from operations||||93.5||67.9|
|Post-retirement benefits – cash payments||||(7.2)||(8.2)|
|Cash generated from operating activities before adjusting items||||86.3||59.7|
|Adjusting cash outflow from operations|||||||
|Adjusting items in operating surplus||5||(15.2)||(16.9)|
|Impairment of tangible and intangible assets||||34.9||2.5|
|Non-cash profit on disposal on subsidiary||||(8.5)||–|
|(Decrease)/increase in provisions||||(11.2)||9.7|
|Total cash outflow from adjusting items||||–||(4.7)|
|Total cash inflow from operating activities||||86.3||55.0|
Nuffield Health Annual Report 2024
Financial statements
**80**
## Notes to the financial statements continued
for the year ended 31 December 2024
## **27. Cash flows from investing activities**
|**27. Cash flows from investing activities**|||||||
|---|---|---|---|---|---|---|
|||||2024||2023|
|||Note||£m||£m|
||||||||
|Purchase of tangible fixed assets and computer software||||(53.8)||(54.3)|
|Interest received||7||0.5||0.7|
|Disposal of subsidiary, net of cash disposed of||||11.1||–|
|||||(42.2)||(53.6)|
## **28. Cash flows from financing activities**
|||2024||2023|
|---|---|---|---|---|
|||£m||£m|
||||||
|Interest paid||(32.6)||(29.9)|
|Interest element of finance lease and hire purchase agreements||(0.6)||(0.1)|
|Repaymentof bank loan||(57.0)||–|
|Receipt from new bank loan||43.0||22.0|
|Repayment ofthird-partyloan||(1.9)||(1.8)|
|Repayment of finance lease and HP agreements||(1.7)||(0.8)|
|||(50.8)||(10.6)|
## **29. Analysis of net debt**
|**29. Analysis of net debt**||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|||||||||Non-cash||||
|||||At 1 Jan||Cash flow||changes||At 31 Dec||
|||Note||£m||£m||£m||£m||
|||||||||||||
|Cash at bank and in hand||30||12.0||(1.7)||–||10.3||
|Bank overdraft||18||(13.0)||(5.0)||–||(18.0)||
|Bank loans due within one year||||(10.0)||10.0||–||–||
|Bank loans due after more than one year||19||(270.0)||4.0||–||(266.0)||
|Third-party loans due within one year||18||(1.9)||1.9||(9.4)||(9.4)||
|Third-party loans due after more than one year||19||(193.1)||–||23.1||(170.0)||
|Finance leases due within one year||18||(0.4)||1.7||(4.4)||(3.1)||
|Finance leases due after more than one year||19||(1.8)||–||(15.2)||(17.0)||
|||||(478.2)||10.9||(5.9)||(473.2)||
For the purpose of the cash flow statement, cash and cash equivalents include the bank overdraft. The overdraft balance is recognised as a creditor on the Balance sheet in note 18. The most significant non-cash change relates to fair value on third-party loan of £13.7 million. See further information in note 7.
## **30. Cash and cash equivalents**
|Note
Group|Group
Charity|
|---|---|
||2024
£m
2023
£m
2024
£m
2023
£m|
|Cash at bank and in hand
Overdraft
18|10.3
12.0
4.7
6.7
(18.0)
(13.0)
(18.0)
(13.0)|
||(7.7)
(1.0)
(13.3)
(6.3)|
Nuffield Health Annual Report 2024
Financial statements
**81**
## Notes to the financial statements continued
for the year ended 31 December 2024
## **31. Capital commitments**
||Group
Charity|
|---|---|
||2024
£m
2023
£m
2024
£m
2023
£m|
|Contracts for future capital expenditure not provided in the financial statements –
property, plant and equipment|9.4
11.9
9.4
11.9|
Capital commitments consist of purchase orders placed for capital expenditure where the goods or services have not been delivered at the balance sheet date and commitments under lease agreements for capital expenditure relating to improving certain leasehold properties. Purchase orders for capital expenditure placed at 31 December 2024 totalled £2.7 million (2023 – £4.1 million) and are expected to be fulfilled during the following financial year. The capital commitments relating to leasehold properties totalled £7.8 million (2023 – £7.8 million). These commitments will be fulfilled by 30 September 2031 in line with the lease agreements. These commitments will be funded in the same way as all other capital expenditure for the Group, using cash generated from operations and the Group’s credit facilities as outlined in note 20.
## **32. Obligations under leases and hire purchase contracts**
|Note|Group
Charity|
|---|---|
||2024
£m
2023
£m
2024
£m
2023
£m|
|Future minimumlease paymentsunder non-cancellable operating leases:
Land and buildings
Less than one year
More than one and less than five years
After five years|77.8
80.9
77.8
79.3
290.6
300.1
290.6
293.2
1,092.0
1,157.4
1,092.0
1,105.2|
||1,460.4
1,538.4
1,460.4
1,477.7|
|Other
Less than one year
More than one and less than five years
After five years|8.0
14.5
8.0
14.5
5.1
13.0
5.1
13.0
–
0.1
–
0.1|
||13.1
27.6
13.1
27.6|
|Future minimum payments due under finance leases and hire
purchase agreements:
Less than one year
20
More than one and less than five years
20
After five years
20|9.8
0.5
20.0
9.9
30.4
1.7
71.3
39.3
29.5
0.5
463.8
409.3|
||69.7
2.7
555.1
458.5|
On 17 December 2024 Nuffield Health and GE HealthCare have signed a 20-year, £200 million partnership to bring AIenabled diagnostic imaging equipment to all hospitals. This will enable Nuffield Health to provide diagnostic imaging, such as MRI and CT scans and significantly advance Nuffield Health’s ability to diagnose patients, and our capacity to support more patients waiting for these much-needed services.
The 20-year term will ensure all our major diagnostic imaging equipment is upgraded at the end of its lifecycle, usually 10-12 years. In the first five years, GE HealthCare will replace all our equipment that requires it, so will support the investment requirements and be fully up to date. This year, every hospital with the exception of St Bartholomew’s will receive a new piece of equipment, and there will be 22 major fixed installations for MRI, mammography, vascular, CT, and X-ray going into our hospitals.
Nuffield Health Annual Report 2024
Financial statements
**82**
## Notes to the financial statements continued
for the year ended 31 December 2024
## **33. Non-controlling interest**
|**33. Non-controlling interest**||||||
|---|---|---|---|---|---|
|||||Total
£m||
|||||||
|As at 1 January 2024||||0.6||
|Share of gain for the period||||0.1||
|Non-controlling interest at 31 December2024||||0.7||
## **34. Related party transactions**
The Executive Committee and Trustees are considered key management personnel. Total remuneration of these individuals were £4.4 million (2023 – £3.8 million).
## **35. Events after the reporting period**
Aspen Healthcare Limited, a Group company, divested its interest in Parkside IHL Scanning Service LLP on 31 January 2025, a majority interest owned subsidiary to Icon Group PTY Ltd for a cash consideration of £0.6 million.
Management has initiated a project to strike off non-trading subsidiaries as part of an ongoing effort to streamline the corporate structure and eliminate redundant entities. As of 4 March 2025, the strike-off process has been formally completed for the following six entities: Holly House Hospital Limited, Holly House Hospital Oncology LLP, Parkside Hospital Limited, Pinnacle Leisure Group Limited, The Edinburgh Clinic Limited, and The Food Calculator Limited.
The Group opted to extend the £30 million additional facility arranged in May 2023 for a further eight months until 31 August 2026 under the extension options in the agreement. On 31 August 2026 it is repayable to the lenders, reducing the rolling credit facility from £320 million to £290 million under the original Lenders agreement dated September 2022. In addition, the imposed capital investment covenant will no longer apply once the facility has been repaid. An arrangement fee will be payable in regard to this extension.
Alloc8tor Limited provided software for the management of bank and agency staff to the Group. A director of Alloc8tor Limited is the spouse of Caroline Smith, Chief Operating Officer at Nuffield Health until 3 September 2024. The value of the contract in 2024 amounted to £675,719 (2023 – £320,670), with an outstanding balance in respect of services provided of £171,015 (2023 – £166,844) at the year end.
Nuffield Health also purchased system implementation support services from Caroline Smith operating under MS4H. Expenses incurred by the Group payable to MS4H amounted to £272,096 in 2024 (2023 – £262,656). An outstanding balance in respect of services provided by MS4H of £Nil (2023 – £62,525) was included within liabilities at year end.
The Charity holds a finance lease relating to 10 hospitals that were sold to Nero Propco LLP, a Group company, under a sale and leaseback transaction in 2022. Please refer to note 20 for further details.
The Charity has no other related party transactions in 2024 (2023 – none) other than with wholly owned undertakings, and is using the exemption allowed by FRS 102 to not disclose transactions with wholly owned undertakings.
Annual Report and Financial Statements 2024
## Contact and registered office details
Nuffield Health Registered Office:
Address: Nuffield Health, Epsom Gateway, Ashley Avenue, Epsom, Surrey KT18 5AL
Epsom Gateway, Ashley Avenue, Epsom, Surrey KT18 5AL. A registered Charity number 205533 (England and Wales), a Charity number SCO41793 (Scotland) and a company limited by guarantee. Registered in England. Company number 00576970.
Telephone: 0300 123 6200
All our hospitals in England, and those clinics delivering regulated activities, are registered with the Care Quality Commission. Our hospitals in Scotland are registered with Healthcare Improvement Scotland and our hospital and clinic in Cardiff are registered with Healthcare Inspectorate Wales.
Online: www.nufeldhealth.com facebook.com/nufeldhealth instagram.com/nufeld.health youtube.com/nufeldhealthtv - linkedin.com/company/nufeld health